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ABSTRACT 
Asthma is characterised by airway remodelling and an increase in airway resistance. A 
greater understanding of the mechanisms involved in airway inflammation and airway hyper-
responsiveness (AHR) may highlight therapeutic opportunities for asthma. This study initially aimed 
to optimise the preparation of precision cut lung slices (PCLS) in mouse and pig to investigate the 
influence of calcium (Ca2) homeostasis on airway smooth muscle (ASM) contraction as a prelude to 
human studies. The PCLS technique was then applied to a murine model of allergic airway disease to 
explore the inflammatory process and pathogenesis of airway hyper-reactivity in sensitised mice. 
Initial experiments using murine and porcine airways validated the PCLS model and 
demonstrated the significance of release and refilling of Ca2+ from internal stores to induce and 
maintain an airway contraction. Results also highlight interesting species differences in agonist 
sensitivity, with the porcine system sharing similar phannacology to human airways. 
Using a murine model of allergic airway disease, agonist induced contractile responses in 
peripheral airways were measured in vitro using the PCLS technique. BALB/c mice underwent initial 
sensitisation by intraperitoneal administration of ovalbumin, receiving a 3 day challenge with 
aerosolised OVAl % (vlv), for varying periods of up to 3 weeks for acute, mid-chronic and chronic 
sensitisation protocols. To investigate the influence of the inflammatory environment, naive murine 
lung slices were incubated with selected inflammatory mediators. OV A sensitisation led to 
progressive structural remodelling and AHR to methacholine (MCh) challenge. However, this hyper-
responsiveness was decreased 48 hours post lung removal. Of the inflammatory mediators selected for 
lung slice incubation, IL-33 significantly increased AHR to MCh. IL-33 is a proinflammatory 
cytokine with transcriptional repressor properties, playing a role in initiating the T H2 inflammatory 
response. In lung slices prepared from IL-33 receptor (ST2) KO mice IL-33 was unable to sensitise 
the contractile response. These d ~ t a a suggest the inflammatory environment promotes AHR and 
disassociates this airway sensitivity from structural remodelling. These data suggest a key role for IL-
33 in mediating AHR in this murine model. 
Investigation of the mechanisms involved in airway hyper-reactivity revealed mRNA 
expression of IL-33 and the IL-33 receptor (ST2) in soluble and membrane bound forms were 
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significantly increased in the mid-chronic and chronic ovalbumin sensitised murine lung tissue. 
Further quantitative analysis in human lung showed expression of IL-33 in epithelial and ASM cells. 
The human ST2 receptor (also known as IL-IRL-l) was expressed in mast cells. Together these 
results suggest IL-33 is a sensor of tissue damage; indirectly inducing AHR through further 
inflammatory cell activation to target ASM. This study demonstrates IL-33's role as an inflammatory 
marker of asthma and suggests a novel therapeutic intervention by targeting of the ST2 receptor. 
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1. CHAPTER ONE 
1.1 ASTHMA 
Chapter One: Introduction 
Asthma is classed as a chronic inflammatory disorder of the airways (Homer 
and Elias 2005) and is estimated to affect approximately 10% of the population 
during their life span (Fuhlbrigge, Adams et al. 2002). In some patients, chronic 
inflammation can lead to structural changes, referred to as airway remodelling; 
characterised by an increase in extracellular matrix deposition, an increase in airway 
wall thickness and an increase in smooth muscle mass (Elias, Zhu et al. 1999; Homer 
and Elias 2000; Vignola, Mirabella et al. 2003). Lung inflammation and remodelling 
contribute to the development of such characteristic asthmatic features as airway 
obstruction and airway hyper-responsiveness (AHR) (Pare, Bai et al. 1997; Bames 
1998; Busse, Banks-Schlegel et al. 2004). Asthma is a complex, heterogeneous 
disease caused by the interaction of multiple environmental factors with genetic 
factors with greater than 100 major and minor susceptibility genes implicated 
(Umetsu, McIntire et al. 2002; von Mutius 2009). Several different phenotypes 
including allergic asthma (most common) (Robinson, Hamid et al. 1992), exercise 
induced (Carlsen and Carlsen 2002) and occupational asthma (Lombardo and 
Balmes 2000) exist. Theories on the initiation of the inflammatory process in asthma 
suggest the origin of the disease usually occurs early in life and involves a complex 
interplay between genetic and environmental factors at critical times (Reed 2006). 
Our understanding of the inflammatory response in asthma has changed 
drastically in recent years with an emphasis on the link between the innate and 
adaptive human immune system (Turvey and Broide 2011). Investigation of the 
development and regulation of asthma has focused on the balance between T HI and 
12 
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T H2 cytokine induced pathways with a shift towards a T H2 profile (Bames 2008) 
being present in most patients. The epithelial cell produced cytokines, thymic 
stromallymphopoietin (TSLP), IL-25 and IL-33 may be the link between the innate 
and adaptive immune system to drive this T H2 response (Bulek, Swaidani et al. 
2011; Coffinan 2011; Paul and Zhu 2011; Zhu, Yamane et al. 2011; Barrett and 
Austen 2009). 
1.1.1 The innate response 
Innate immunity is present in all multi cellular organisms, while adaptive 
immunity evolved much later in jawed fish and all succeeding vertebrates (Pancer 
and Cooper 2006; RoltT 2007). Innate immune protection involves such 
hematopoietic cells as mast cells, dendritic cells, macrophages, neutrophils and 
eosinophils (Iwasaki and Medzhitov 2011; Turvey and Broide 2011; Barrett and 
Austen 2009). Skin and epithelial cells lining the respiratory and gastrointestinal 
tract contribute. The innate immune response involves a limited number of 
genetically predetermined germline encoded receptors (such as toll like receptors 
(TLR)) that recognise a variety of pathogen associated molecular patterns (PAMP); 
these are highly conserved structures expressed by large groups of microbes (Turvey 
and Broide 2011; Janewayand Medzhitov 2002). The receptors enable the innate 
defense system to discriminate pathogens and determine the appropriate cascade for 
adaptive responses (Turvey and Broide 2011). Host defense appears to be achieved 
through interface of innate and adaptive immunity; with contribution from the 
epithelial cell produced cytokines TSLP, IL-25 and IL-33 (Iwasaki and Medzhitov 
2011; Saenz, 2008; Barrett and Austen 2009). 
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TSLP is an IL-7 like cytokine (Sims, Williams et al. 2000). During allergic 
inflammation bronchial epithelial cells produce TSLP, which is fundamental for T H2 
differentiation. TSLP is highly expressed in the epithelium of patients with asthma 
(Soumelis, Reche et al. 2002). TSLP acts on dendritic cells (DC) through an OX40 
ligand (Arestides, He et al. 2002; Ito, Wang et al. 2005) leading to differentiation of 
naive CD4 + T cells to T H2 cells (Eisenbarth, Piggott et al. 2002; Soumelis, Reche et 
al. 2002; Ying, O'Connor et al. 2005); resulting in production of T H2 cytokines 
CrNF-a, IL-4, IL-5 and IL-13) and chemokines (CCLI7, CCL22, CXC18, CCL24) 
which attract neutrophils and eosinophils (Soumelis, Reche et al. 2002). A 
neutralising antibody for OX40L results in complete loss of ability to generate T H2 
differentiation (Ito, Wang et al. 2005). 
IL-25 (IL-17E) is a member of the IL-17 cytokine family (Hurst, Muchamuel 
et al. 2002). Of the family members, IL-25 is exceptional in promoting the T H2 
response (Dong 2008). IL-25 is produced by epithelial cells in response to allergens 
(Saenz, Taylor et al. 2008; Hammad, Chieppa et al. 2009), activated eosinophils, 
bone marrow derived mast cells and basophils after FceRI mediated activation 
(Barrett and Austen 2009) and also by TH2 cells (Fort, Cheung et al. 2001). 
Therefore IL-25 is produced in innate and adaptive immune responses. IL-25 
promotes the differentiation of murine T H2 cells via an IL-4 and SI A I6-dependent 
pathway (Angkasekwinai, Park et al. 2007). In mice exogenous administration (Fort, 
Cheung et al. 2001; Hurst, Muchamuel et al. 2002) of IL-25 or transgenic expression 
(Pan, French et al. 2001; Kim, Manoukian et al. 2002) induces asthma like features. 
Mouse models of OVA sensitisation have shown up regulation of the IL-25 
transcript in the lung and eosinophils, CD4+ T cells and IL-5 and IL-13 protein in 
the bronchoalveolar lavage (BAL); all of which are reduced by treatment with a 
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soluble IL-25 receptor prior to OV A challenge (Tamachi, Maezawa et al. 2006). 
Human TH2 central memory cells up regulate the IL-25 receptor on activation from 
TSLP stimulated DC, or from specific antigen; resulting in increased sensitivity to 
IL-25 and correlated with sustained expression of GATA3 (discussed below) (Wang, 
Angkasekwinai et al. 2007); suggesting that IL-25 may contribute to maintaining the 
inflammatory response. 
There has been a recent explosion of evidence from genome wide association 
studies and sensitised animal models to suggest that IL-33 plays a fundamental role 
in the allergic inflammatory response. Results Chapters Four and Five of this thesis 
aimed to investigate the role of IL-33 in the inflammatory response and airway 
hyper-responsiveness. Initially IL-33 was discovered in lymph node associated 
endothelial cells (Baekkevold, Roussigne et al. 2003), showing the ability to relocate 
to the nucleus. IL-33 is now known as an IL-I family member and has been named 
as the ligand for the ST2 receptor (Schmitz, Owyang et al. 2005). IL-33 mRNA 
expression has been found in epithelial cells, smooth muscle, fibroblasts, 
cardiomyocytes, keratinocytes, adipocytes and mucosal epithelial cells (Schmitz, 
Owyang et al. 2005; Moussion, Ortega et al. 2008; Wood, Wang et al. 2009); mainly 
in organs such as the skin, intestine, lung, brain and spinal cord (Hudson, Christophi 
et al. 2008; Moussion, Ortega et al. 2008). IL-33 protein expression in these tissues 
is predominantly localised to the nucleus (Baekkevold, Roussigne et al. 2003; 
Carriere, Roussel et al. 2007; Moussion, Ortega et al. 2008). In a similar fashion to 
IL-la and HMGBI which show both nuclear and extracellular activity, it is 
suggested that IL-33 may have a dual function as an 'alarmin', with the ability to 
signal tissue damage to local immune cells (Moussion, Ortega et al. 2008; Cayrol 
and Girard 2009; Haraldsen, Balogh et al. 2009), discussed further in 6.2. 
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There is now evidence to suggest that inflammatory cells recruited to the 
airways such as mast cells, eosinophils and basophils may act as antigen presenting 
cells (APC) to initiate or amplify the T H2 response (Kim, OeKruyff et al.). 
Mast cells express FcsRI (lgE receptor) and c-kit and are localised in tissue 
near mucosal surfaces and blood vessels. Mast cells degranulate in response to both 
i) innate immune signals such as Toll-like receptor agonists or the IL-33 cytokine 
(figure 1.1) (Silver, Margulis et al. 2010) and ii) adaptive signals such as cross 
linking of antigen-specific 19E bound to FceRI (figure 1.2) (prussin and Metcalfe 
2006). Mast cells produce histamine, synthesise leukotriene C4, 04, E4 and 
prostaglandin O2, chemokines and cytokines (IL-I, IL-3, IL-4, IL-5, IL-6, IL-8, IL-
10, IL-13, IL-16, TNF-a and transforming growth f a c t o r - ~ ~ ( T G F - ~ ) ) (Brightling, 
Bradding et al. 2002; Galli, Kalesnikoff et al. 2005; Barrett and Austen 2009). Mast 
cells can also act as APCs through IL-3, IL-4 and granulocyte macrophage-colony 
stimulating factor (GM-CSF) which increase mast cell expression of major 
histocompatibility complex (MHC) class 11 for T cell proliferation (Kim, OeKruyff 
et al. 2011; Frandji, Oskeritzian et al. 1993). Mast cells originate from circulating 
stem cell factor (SCF)-dependent committed progenitor cells (Ochi, Hirani et al. 
1999). Mast cell recruitment to the lung site of inflammation involves leukotriene B4 
(Weller, Collington et al. 2005), chemokines such as CCR3 (Ochi, Hirani et al. 
1999) and the integrins vascular cell adhesion molecule 1 (VCAM1), a 4 ~ 1 1 and a 4 ~ 7 7
(Abonia, Hallgren et al. 2006). Recruitment to the ASM bundle involves the 
CXCR3/CXCL 1 0 axis (Brightling, Arnmit et al. 2005). 
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Figure 1.1 The innate immune response in allergic airway disease. Allergens 
stimulate epithelial cells to secrete TSLP, 1L-25, 1L-33. TSLP activates innate like 
natural killer T cells (NKT) to secrete TH2 cytokines. 1L-25 induces TH2 cytokines 1L-
5 and 1L-13 from natural helper cells in the absence of T H2 cells and also stimulates 
NKT to produce 1L-13 which is linked with airway remodelling and airway hyper-
responsiveness. 1L-33 may influence mast cells, eosinophils, basophils, natural 
helper cells and NKT cells to secrete TH2 cytokines. Activated eosinophils release 
eosinophil derived neurotoxin (E N) which acts on dendritic cell (DC) toll like 
receptor 2 (FLR2) to mature DC. Mast cell derived TNF-(J. facilitates DC migration 
to the lymph node_ Activated mast cells and basophils produce TSLP which up 
regulates OX40L on DC; to stimulate induction ofTH2 cells by DC. SCF: stem cell 
factor; LTC4: leukotriene C; lin: linage_ Adapted from (Kim, DeKruyff et at. 2011; 
Saenz, Taylor et at. 2008). 
Basophils amplify immediate responses by releasing histamine containing 
granules and producing large quantities of IL-4. Basophils also show expression of 
MHC class II and co stimulatory molecules; therefore studies suggest the ability to 
act as an APC to drive the TH2 response (Kim, Prout et al. 2010). These circulating 
granulocytes also express the IgE receptor Fc€RI. 
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Eosinophils produce cysteine leukotrienes and T H2 cytokines (lL-4, IL-5, IL-
13 and TNF-a). Such THl cytokines as interferon-y, IL-1O and IL-2 are also 
produced (Akuthota, Wang et al. 2008). Eosinphils are suggested to function as 
APCs through GM-CSF induced expression of MHC class 11 and co stimulatory 
molecules. Recruitment of eosinophils to tissue sites of inflammation is mediated by 
adhesive interactions between circulating eosinophils and vascular endothelial cells 
(Sriramarao, von Andrian et al. 1994; Bochner 1997; Matsumoto, Sterbinsky et al. 
1997). After stimulation with IL-l, TNF and IL-4, epithelial cells acquire adhesive 
properties, involving E-selectin (Kyan-Aung, Haskard et al. 1991), P-selectin (Wein, 
Sterbinsky et al. 1995), intracellular adhesion molecule 1 (lCAM1) (Bochner, 
Luscinskas et al. 1991) and vascular cell adhesion molecule 1 (VCAMl) (Dobrina, 
Menegazzi et al. 1991). Interaction of eosinophils with these vascular adhesion 
molecules requires eosinophil cell surface receptors such as L-selectin (Knol, Tackey 
et al. 1994), PSGL-l (Symon, Walsh et al. 1994) and a4 (Walsh, Mermod et al. 
1991) and P2 integrins (Nakajima, Sano et al. 1994) e.g the a4pl integrin also 
known as very late antigen 4 (VLA4) (figure 1.2). 
Innate like natural killer T cells (NKn appear to amplify allergic responses 
in the presence of T H2 cells and also drive AHR in the absence of adaptive immune 
responses (Kim, DeKruyff et al. 2010; Akbari, Stock et al. 2003). NKT cells 
constitute a subset of lymphocytes with qualities of both T cells and NK cells. The 
iNKT cells express an invariant T cell receptor (TCR), which behaves like a pattern 
recognition receptor; recognising glycolipid antigens, instead of conventional 
peptide antigens. Stimulation of TCR on NKT cells leads to rapid production of such 
inflammatory cytokines as IL-4, IL-13 and IFN-V required later for the adaptive 
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response (Lloyd and Hessel 2011; Taniguchi, Harada et al. 2003; Taniguchi, Seino et 
al. 2003). 
The natural helper cell (also named nuocyte or multipotent progenitor cell), 
has been identified in fat-associated lymphoid clusters (Moro, Yamada et al.) and 
mesenteric lymph nodes from helminth infected mice (Neill, Wong et al. ; Saenz, 
Siracusa et al.). Natural helper cells respond to IL-25 and IL-33 and produce T H2 
cytokines in the innate response (Moro, Yamada et al. 2011; Neill, Wong et al. 2011; 
Saenz, Siracusa et al. 2011). These multipotent progenitor cells show expression of 
c-Kit, IL-7R, IL-33R and IL-17RB and MHC class 11 and co stimulatory molecules; 
with the advantage of differentiating into monocyte, macrophage, mast, eosinophils 
or basophils in the presence of stem cell factor (SCF) and IL-3 (Saenz, Siracusa et al. 
2011). Given that both IL-25 and IL-33 induce AHR without added stimulation, it is 
possible that natural helper cells contribute to this response in the absence of T H2 
cells (Kim, DeKruyff et al. 2011). 
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Figure 1.2 The A daptive response in airway inflammatory disease. Initial 
sensitisation involves activation and maturation of antigen presenting dendritic cells 
in response to thymic stromal lymphopoietin (FSLP), produced by epithelial, 
fibroblasts and mast cells. Mature dendritic cells induce differentiation of nafve 
CD4+ T cells to TH2 cells which produce IL-4, IL-5, IL-9, IL-13 and tumour necrosis 
factor (FNF). IL-4 promotes the differentiation and proliferation of T cells and 
switching of B cells from IgG to IgE production to target mast cells for 
degranulation. IL-5 plays a role in eosinophil differentiation, maturation and 
survival. IL-13 plays a role in AHR and mucus productiOn. IL-17 mediates 
neutrophil infiltration by inducing bronchial epithelial cells to produce CXC 
chemoldnes and G-CSF (a survival and proliferation factor). Epithelial cells also 
release stem cell factor (SCF), required for maintaining mucosal mast cells at the 
airway surface and CCL11 which recruits eosinophils via CCR3. Tregs negatively 
regulate the TH2 response through IL-10 and transforming growthfactor-fJ (FGF-fJ) . 
Adapted from (Levine and Wenzel 2011; Barnes 2008; Holgate and Polosa 2008). 
MHC class II: major histocompatibility complex class 11, VLA4: very late antigen 4, 
VCAM1: vascular cell adhesion molecule 1, TCR: T-cell receptor. 
1.1.2 The adaptive response 
In asthma, the induction of the adaptive immune response involves uptake of 
allergens by antigen presenting cells (APC) , such as DC (Iwasaki and Medzhitov 
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2004) located immediately above the basement membrane of the airway epithelium 
which have direct contact with invading allergens (Jahnsen, Moloney et al. 2001). 
DC originate from CD34+ bone marrow progenitor cells or CD 14+ monocytes and 
differentiate into immature DC (Finn and Bigby 2009). DC maturation is stimulated 
by necrotic cells, cytokines, activated T cells that express CD40 ligand and innate 
immune response ligands derived from microbes. These components lead to reduced 
endocytosis and up regulation ofT cell co-stimulatory molecule expression including 
CD80, CD86 and CD40 on APCs in addition to MCH class 11 expression and 
chemokines (CCLI7, CCL22) which attract T cells, eosinophils and basophils to the 
lungs (Lambrecht and Hammad 2009). During allergic airway inflammation DC 
levels are increased in the lung and regional lymph nodes (Lambrecht and Hammad 
2003) and peripheral blood (Matsuda, Suda et al. 2002). CD40 and CD86 expression 
is also increased on DC at the site of inflammation (Vermaelen and Pauwels 2003). 
Antigen bearing mature plasmacytoid DCs migrate away from the airway wall to 
regional lymph nodes (Huh, Strickland et al. 2003) then stimulate naIve T cells to 
produce a T H2 profile (Rissoan, Soumelis et al. 1999). 
TH2 cells then coordinate upregulated expression of a cluster of genes on 
human chromosome 5q31-33 which include genes encoding IL-4, IL-5, IL-9, IL-13 
and GM-CSF (Cousins, Lee et al. 2002; Bames 2008). IL-4 acts through ST AT6 to 
regulate GA TA3 ( GA TA 3 binding protein) (Bames 2008). An increased population 
of GA T A3 T cells is noted in asthmatic airways compared to normal airways 
(Nakamura, Ghaffar et al. 1999). Following phosphorylation and activation by 
mitogen activated protein kinase (MAPK) p38, GAT A3 translocates from the 
cytoplasm to the nucleus to activate gene transcription (Maneechotesuwan, Xin et al. 
2007), which mediates cytokine secretion (lL-4, IL-5, IL-13, IL-9) and also inhibits 
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the actions of T-bet (which acts to induce IL-12) via inhibition of STAT4 (Usui, 
Preiss et al. 2006). IL-9 attracts and drives mast cell differentiation (Kay 2006), IL-5 
drives eosinophil differentiation in the bone marrow and further maturation and 
survival (O'Byrne 2007). IL-4 promotes the differentiation and proliferation of T H2 
cells and drives 19E production by B cells (Avila 2007). Cross linking of FctRI by 
19E bound antigen triggers mast cell degranulation. IL-13 plays a role in airway 
hyper-reactivity and mucus hyper-production (Wills-Karp and Finkelman 2008). 
Polymorphisms in IL-4, the IL-4 receptor a chain (lL-4Ra) and IL-13 are 
consistently observed in human asthma (Ober and Hoftjan 2006). Polymorphisms in 
both IL-4 and IL-4Ra have been associated with severe asthma (Sandford, Chagani 
et al. 2000; Wenzel, Balzar et al. 2007) and with increased airway mast and 19E cells 
(Balzar, Strand et al. 2007). IL-3, IL-4, IL-5 and GM-CSF are involved with 
maturation of eosinophils and basophils (Hammad and Lambrecht 2008) (see figure 
1.2). Stimulated by the T H 17 cells, IL-17 is also suggested to play a role in 
neutrophilic inflammation and steroid resistance in a murine model of asthma 
(McKinley, Alcom et al. 2008). The recently discovered IL-33 appears to promote 
T H2 cell differentiation by translocating to the nucleus and regulating transcription 
through an effect on chromatin structure (Carriere, Roussel et al. 2007). In addition 
to TSLP, IL-25 and IL-33, the epithelium produces CCLII, CCLI7, CCL22. These 
chemokines act on the chemokine receptor CCR3 on eosinophils and CCR4 on T H2 
cells, to amplify the T H2 response (Holgate 2007; Schleimer, Kato et al. 2007). 
Treg (T regulation) cells provide inhibition by producing anti-inflammatory 
cytokines such as IL-IO and T G F - ~ ~ (Ostroukhova, Seguin-Devaux et al. 2004; 
Kearley, Barker et al. 2005) and by expressing inhibitory molecules such as 
cytotoxic T lymphocyte antigen4 (CTLA4) and also induce down regulation of MHC 
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class II and the co stimulatory molecules CD80 and CD86 by APC (Cederbom, Hall 
et al. 2000). Rather than produce IL-lO directly, Treg can induce nearby CD4+ T 
cells to express IL- lO (Kearley, Barker et al. 2005). For suppression of DC, Treg 
cells form lymphocyte function associated antigen 1 (LFA1 ) dependent aggregates 
with DC which results in down regulated DC co stimulatory molecules in response to 
CTLA4 (Onishi, Fehervari et al. 2008). 
T HI cell differentiation also plays a role in defence against infection. 
Through STATl and STAT4, T-bet induces production of IL-2 and interferon-y 
(IFN-y) (Barnes 2008). Notably T -bet is reduced in airways from asthmatic patients 
compared with non-asthmatic subjects (Finotto, Neurath et al. 2002). T-bet serves as 
an important regulator of GATA3. When phosphorylated T-bet can associate and 
inhibit GATA3 function by preventing it from binding to its target DNA sequences 
(Hwang, Szabo et al. 2005) (figure 1.3). 
IL-27 IL-12 
.. t 
STATl 1 STAT4 I.L 
IL-4 IL-33 
/ 
'-1 -sr.-AT-6-'1 ,,, 
,/ B t-I -- ( GATA3 ) 
+ 
Defence against 
infection 
T H1 type cytokines 
(IL-2, IFNy) 
Allergic Inflammation 
T H2 type cytoldnes 
(IL-4,IL-S,IL-9,IL-13) 
Figure 1.3 The TH1/ TH2 
balance in asthma (described in 
text, adapted from (Barnes 
2008)). 
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1.1.3 ASM cells and asthma pathogenesis 
ASM is a therapeutic target in asthma given its role in regulating airflow 
obstruction, however, accumulating research suggests ASM may contribute to the 
pathophysiology of asthma in the airways through changes in airway wall structure, 
abnormal resistance to relaxation and maintenance of airway inflammation. The 
prevalence of inflammation in bronchoscopic biopsies and post mortem studies of 
asthmatics showing bronchial eosinophilic infiltrates has prompted research into the 
mediators involved in inflammation and the structural implications on contraction 
from airway remodelling. 
Evidence for the immunomodulatory effects of ASM comes from studies 
showing that in vivo human ASM (HAS M) cells can release IL-I p, IL-5, IL-6, GM-
CSF, CCLII and RANTES (regulated upon activation normal T cells, which is a CC 
chemokine with chemo-attractant activity for eosinophils, memory T cells and 
monocytes) (Ammit, Lazaar et al. 2002; Grunstein, Hakonarson et al. 2002; Hirst, 
Hallsworth et al. 2002; Moore, Church et al. 2002; Halayko and Amrani 2003; Tran, 
Femandes et al. 2005; Rahman, Yamasaki et al. 2006; Bloemen, Verstraelen et al. 
2007). IL-I 0 administration on naive HASM induces up regulated mRNA expression 
and release of IL-5 protein (Grunstein, Hakonarson et al. 2001). TNF-a induces 
secretion of IL-6 and RANTES from ASM cells (Ammit, Lazaar et al. 2002). 
Cultured airway myocytes also release GM-CSF after IL-I p and TNF-a stimulation 
(Saunders, Mitchell et al. 1997). Both IL-13 and IL-4 (and in combination with IL-
I ~ ) ) induce CCLIl (eotaxin) release by ASM, mediated by IL-4R-a (Hirst, 
Hallsworth et al. 2002). Both IL-9 and IL-l7 A mediated CCL II release from ASM 
requires the ST A T3 pathway (Yamasaki, Saleh et al. ; Saleh, Shan et al. 2009). IL-5 
24 
Chapter One: Introduction 
also acts on ASM to induce IL-I ~ ~ and other IL-I members (Hakonarson, Maskeri et 
al. 1999; Hakonarson, Whelan et al. 2002; Whelan, Kim et al. 2004). High affInity 
(FCERI) and low affinity (FcERII, also known as C023) receptors are expressed on 
HASM (Oelespesse, Sarfati et al. 1992; Sarfati, Fournier et al. 1992; Bonnefoy, 
Lecoanet-Henchoz et al. 1997; Kinet 1999). Following IgE sensitisation, HASM 
cells release CCLl1 and IL-5. This release is inhibited by an anti-FcERI a.-chain 
antibody (Ab) targeting the IgE binding site (Hakonarson, Carter et al. 1999; 
Grunstein, Hakonarson et al. 2002; Gounni 2006). FCERI activated transient 
increases in intracellular Ca2+ in HASM cells have also been reported (Gounni, 
Wellemans et al. 2005). The increased contractility/ attenuated relaxation seen after 
activation of FCERII by IgE complexes and atopic asthmatic serum is also inhibited 
by an anti-C023 neutralising Ab (Hakonarson and Grunstein 1998). 
Inflammatory mediators may influence the contractile response in HASM. In 
cultured cells both IL-13 and IL-4 act through the IL-4 type 11 receptor, a dimer that 
consists of IL-4Ra. and IL-l3Ra. (Laporte, Moore et al. 2001). Both IL-4 and IL-13 
activate STAT6 and mitogen activated protein kinase (MAPK) signalling cascades in 
HASM (Peng, Matsuda et al. 2004). In animal models exogenous administration or 
over expression of IL-13 results in AHR, while inhibition of IL-13 decreases this 
AHR (Wills-Karp, Luyimbazi et al. 1998; Kuperman, Huang et al. 2002; Venkayya, 
Lam et al. 2002; Kibe, Inoue et al. 2003). 
ASM plays a role in the deposition of extracellular matrix proteins (Johnson et 
al., 2000), by releasing fibronectin and collagen. ASM also promotes inflammatory 
cell recruitment through expression of cell surface adhesion molecules (Black et al., 
2001). Vascular cell adhesion molecule 1 (VCAM1) and intracellular adhesion 
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molecule 1 (lCAM1) are expressed on cultured HASM and further induced after 
exposure to I L - l ~ , , TNF-a and IL-13 (Panettieri, Lazaar et al. 1995; Syed, Panettieri 
et al. 2005; Wang, Lin et al. 2005). This can potentially facilitate binding of T cells 
(Lazaar, Albelda et al. 1994) and eosinophils (Hughes, Arthur et al. 2000) to airway 
myocytes (Hershenson, Brown et al. 2008). IL-l ~ ~ and TNF -a stimulation of cultured 
HASM increases activity of cyc1ooxygenase-2 (COX-2) (Belvisi, Saunders et al. 
1997) which can lead to increased levels of proinflammatory prostanoids. Interferon 
~ ~ attenuates TNF-a induced RANTES expression by HASM (Tliba, Tliba et al. 
2003). The growth factor T G F - ~ ~ stimulates HASM hypertrophy (McKay, de Jongste 
et al. 1998). IL-4, IL-5, IL-13 induce expression of vascular endothelial growth 
factor (VEGF) in HAS M, HASM also express VEGF receptors (Wen, Liu et al. 
2003; Kazi, Lotfi et al. 2004). VEGF induces fibronectin expression, which has been 
suggested to promote ASM mitogenesis. 
In asthma changes due to inflammation and remodelling can be seen 
throughout the airway generations (Jeffrey 1998; Bousquet, Jeffery et al. 2000). An 
increase in ASM layer thickness is a consistent feature in histological sections from 
asthmatic airways (Black and Johnson 2002) particularly patients with fatal asthma 
(Ebina, Yaegashi et al. 1990; Kuwano, Bosken et al. 1993). Studies of force 
generation in asthmatic airways versus healthy controls produce conflicting results. 
However, the rare studies assessing isotonic shortening in general show increased 
shortening in asthmatic airways compared to controls (Bramley, Thomson et al. 
1994; Thomson, Bramley et al. 1996). 
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Figure 1.4 Histological staining in 
central airway walls from a) asthmatic 
and b) normal subjects. The asthmatic 
airway shows epithelial disruption (Epi) 
and thickening of the subepithelial 
basement membrane (BM). Airway 
smooth muscle mass is increased (M) and 
mucus gland (G) hypertrophy is shown. 
Original magnification is 100X Images 
provided by Dr. Aliya N Husain. Images 
taken from (Hershenson, Brown et at. 
2008). 
The developing respiratory system is susceptible to inflammatory damage 
during early life; studies suggest the risk of future asthma development relates to 
initial age of allergic sensitisation (peat, Toelle et al. 1996; Sherrill, Stein et al. 
1999). Although most wheezing in the immediate postnatal period is due to small 
airway diameter (Stein Sherrill et al. 1999), studies indicate that early infections 
(Stein, Sherrill et al. 1999) and sensitisation to inhaled allergens (Custovic, Simpson 
et al. 2001) in later infancy and early childhood (during fIrst three years of life) 
(patino and Martinez 2001; Moller, Dreborg et al. 2002) are associated with an 
increased risk of asthmatic symptoms and potential future asthma development (Holt 
and Sly 2002). In addition programming of T cell memory against environmental 
allergens (such as triggers for asthma) occurs early in life (Holt and Sly 2002). A 
predictive index has been produced for development of persistent asthma in children 
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less than three years of age who have experienced multiple episodes of wheezing 
during the previous 12 months. Positive predictions correlate with at least one of the 
following risk factors: major criteria i) parental history of asthma, sensitisation to 
aeroallergens, diagnosis of atopic dermatitis or, minor criteria ii) allergic 
sensitisation to food, ~ ~ 4% peripheral blood eosinophilia, diagnosis of allergic 
rhinitis or wheezing unrelated to colds (Castro-Rodriguez, Holberg et al. 2000; 
Guilbert, Morgan et al. 2006). Childhood asthma consists of many different subtypes 
however atopy associated asthma typically persists into adulthood ( P e a ~ ~ Toelle et al. 
1996; Ernst, Ghezzo et al. 2002; Kjellman and Gustafsson 2002). Therefore initial 
treatment is designed to provide acute symptomatic relief in children. Future 
therapeutic approaches involve minimising long term inflammatory damage to the 
growing lungs that may result from persistent asthma into adulthood (Holt, Sly et al. 
2004). 
For a clinical diagnosis of asthma, a detailed medical history and full medical 
examination is required including pulmonary function testing (for patients over five 
years). A spirometry test is used to demonstrate the degree of airway obstruction and 
to determine whether it is reversible by measuring the forced expiratory volume in 
one second (FEV t ) expressed as a percentage of the forced vital capacity (FVC, the 
maximal volume of air exhaled after maximal inhalation) (or if held over six 
seconds, FEV 6) (Bye, Kerstein et al. 1992; Li and O'Connell 1996; Llewellin, 
Sawyer et al. 2002). This may include testing before and after the patient inhales a 
short acting bronchodilator. Results are compared to a predictive baseline 
measurement based on age, weight and height of the patient. An annual reduction in 
FEV t is associated with increased episodes of wheezing or shortness of breath 
(Fuhlbrigge, Kitch et al. 2001; Fuhlbrigge, Weiss et al. 2006). An additional 
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approach for assessment of airway responsiveness is the bronchial challenge test; 
this requires the delivery of increasing doses of a bronchoconstrictor (such as 
methacholine) for determining the concentration at which a set percentage reduction 
in FEV l (typically 20%) is measured (Leuppi, Brannan et al. 2002). The dose of 
bronchoconstrictor causing a 20% decline in FEV 1 is known as the PD2o. Most 
asthmatics have a measureable PD20 value, where as subjects without lung disease in 
general do not. The use of this technique is limited to some extent in clinical practice 
by the severity of baseline airway obstruction. 
A stepwise approach for managing treatment m asthmatic patients is 
recommended based on the assessment of the initial severity of the disease and 
success of response to treatment in individual patients, guidelines are tailored to 
defmed patient age groups (British Thoracic Society 2009; Global initiative for 
Asthma (GINA) 2010; National Heart, Lung and Blood Institute, US Department of 
Health and Human Services 2007; Bateman, Hurd et al. 2008; Chen, Gould et al. 
2007) (see example, figure 1.5). 
OCS 
LABA LABA 
ICS high dose ICS high dose 
LABA - theophylline 
- an ·-lgE 
- ant i-leuliDtrine - immuno-
ICS low dose - ora11l2- agonist suppressants 
I ICS low dose combina on Inhale r - an -ch ine rgic 
short ac iog Ilz- agonist as required for symptom re lie 
m ild intermittent I m ild persistent moderate persistent severe persistent very severe 
persistent 
Figure 1.5 Stepwise approachfor managing asthma in adults and children over 12. 
Patients should start treatment at the step correlating to the diagnosis assigned for 
the initial severity of their asthma. Inhaled corticosteroids (ICS) are recommended 
for all patients with persistent asthma with the further addition of long acting fh-
agonists (LABA). Anti-IgE and immunomodulators or oral systemic corticosteroids 
(OeS) may be considered for patients with severe asthma. Taken from (Barnes ; 
Levine and Wenzel ; Bateman, Hurd et al. 2008). 
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Corticosteroids are the most effective therapy for chronic persistent asthma 
(Bames 2006). They suppress T H2 mediated inflammation through the inhibition of 
expression of cytokines, chemokines and adhesion molecules (Bames and Adcock 
2003). Free corticoids diffuse across the cell membrane and bind to cytoplasmic 
glucocorticoid receptors. This causes translocation to the nucleus and results in 
altered transcription of target genes. In addition through the transactivation pathway 
the glucocorticoid receptor binds to the glucocorticoid response element (GRE) in 
the promoter region of steroid sensitive genes leading to transcription of genes for 
anti-inflammatory mediators (inhibitor of nuclear factor-kB (lkBa». During 
transrepression the glucocorticoid receptor and GRE complex with histone 
acetyltransferase (HAT) activity switch off expression of the inflammatory genes. 
Although asthma is generally classed as a T H2 response; recent gene expression 
studies in mild asthma suggest that the T H2 profile is only shown in 50% of patients 
with asthma. This group was characterised by more AHR, eosinophils and 
remodelling. The T H2 profiled patients responded well to inhaled corticosteroids, 
where as the non-T H2 signature patients did not (Woodruff, Modrek et al. 2009). 
Inhaled short acting fu-adrenoreceptor agonists (SABA) such as salbutamol 
and terbutaline are used as bronchodilators for rapid relief. The long acting fu-
adrenoreceptor agonists (LABA) formoterol and saImeterol provide relief for up to 
12 hours. The fu-adrenoreceptor is in an active form when it associates with the a 
subunit of the Gs protein together with a molecule of guanisine triphosphate (GTP). 
The replacement of GTP with guanisine diphosphate (GDP) catalyses the conversion 
of A TP to cAMP and reduces the affinity of the a subunit for the receptor, to return 
to its disassociated, inactive form. cAMP catalyses the activation of protein kinase A 
(PKA). cAMP also inhibits release of Ca2+ from internal stores, reduces Ca2+ entry 
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into cells and induces sequestration of intracellular Ca2+, which leads to airway 
relaxation (discussed in detail in section 1.2). P2-adrenoreceptor agonists may act to 
temporarily stabilise the receptors in their active state (bound to Gs-GTP) (Onaran, 
Costa et al. 1993). Combination inhalers for corticosteroids and LAB As have been 
introduced for convenience to increase patient adherence (Palmqvist, Persson et al. 
1997; Usmani, Ito et al. 2005). There is also evidence of uncoupling of P2-adrenergic 
receptors in the airways of patients who die from asthma (Bai, Mak et al. 1992). 
Allergen specific immunotherapy has been trialled for the treatment of mild 
asthma, allergic rhinitis and selected allergies. Immunity tolerance is induced 
through repeated allergen exposure, leading to an increase in allergen specific IgA 
and IgG4 antibodies (Ab) and a decrease in the level of IgE Ab. Immunotherapy 
requires regular subcutaneous injection of allergen extracts or recombinant allergens, 
involving a build up phase (usually weekly injections) and a maintenance phase 
(monthly injections). However anaphylactic side effects may occur and the 
efficiency of this approach remains uncertain (Williams, Krishna et al. 2004). 
Mast cell inhibitors such as sodium cromoglicate were first introduced as an 
asthma therapy in 1968 (Edwards and Howell 2000), followed by nedocromil 
sodium. After inhalation the drugs inhibit early and late phase responses in the upper 
and lower airways (Bradding, Walls et al. 2006). However, many mast cell 
stabilising drugs are ineffective at inhibiting mast cell activation in chronic asthma. 
Anti-IgE therapies such as the humanised Ab Omalizumab have been shown 
to reduce serum levels of free IgE and down regulate expression of IgE receptors 
(FceRI) on mast cells and basophils. Tissue eosinophilia, B and T cells are reduced 
also. Omalizumab decreases FceRI expression on circulating dendritic cells, possibly 
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reducing further T H2 cell activation (Holgate, Casale et al. 2005). IgE Ab specific for 
the C3 domain of 19E that block 19E binding to FctRI, FctRII and CD23 lead to 
inhibition of the inflammatory response in human and mouse airways (Come, 
Djukanovic et al. 1997). Clinical trials with patients with poorly controlled 19E 
mediated asthma receiving subcutaneously administered Omalizumab showed 
improved symptom control and allowed patients to receive lower doses of inhaled 
corticosteroids (Holgate, Djukanovic et al. 2005). The efficacy of Omalizumab on 
asthma exacerbations was unaffected by patient age, gender, baseline serum 19E or 
by the 2/4 weekly dosing schedule (Bousquet, Cabrera et al. 2005). Lumiliximab, a 
low affinity anti- IgE F c receptor also went through to phase 11 studies (Ballow 
2006). 
Anti-cytokine targeting therapies investigated include altrakincept, a soluble 
recombinant human IL-4R. Initial trials showed promise as inhaled nebulized 
altrakincept over 12 weeks allowed patients to withdraw treatment with 
corticosteroids without relapse (Borish, Nelson et al. 1999). However, phase three 
trials failed to confirm efficacy for this treatment in asthma. Pitrankinra, is an IL-4 
variant which inhibits the binding of IL-4 and IL-13 to the IL-4R a subunit; 
pitrakinra reduced allergen induced late phase response in asthmatic patients 
(Wenzel, Wilbraham et al. 2007). The humanised anti-IL-4 Ab, Pascolizummab 
(Hart, Blackbum et al. 2002) has also been studied. However, in a study using grass 
pollen, it was reported that the secondary IgE response is not T cell dependent, 
raising doubts on the use of IL-4 inhibition in established disease (Linbart, 
Bigenzahn et al. 2007). Phase III studies of the anti-IL-5 agent Mepolizumab have 
shown a reduction in exacerbations and required oral corticosteroid dose in 
refractory eosinophilic asthma (Haldar, Brightling et al. 2009; Nair, Pizzichini et al. 
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2009). Currently MEDI-528, a humanised, monoc1onal anti-IL-9 Ab is being 
investigated in early phase trials for asthma (Antoniu 2011). IMA-638, a humanized 
IL-13 monoc1onal Ab inhibited both early and late allergen challenge response 
(Gauvreau, Boulet et al. 2010). Clinical trials have now been completed, evaluating 
the safety of CAT-354 (a humanized IgG1 anti-IL-13 Ab) (Singh, Kane et al. 2010) 
and AMG 317 (a human monoclonal IL-4Ra Ab which inhibits both IL-4 and IL-13 
pathways) (Corren, Busse et al. 2010). The humanised mouse anti-TNF-a 
Infliximab, showed benefit in conjunction with inhaled corticosteroids for asthma 
treatment in phase II trials (Cazzola and Polosa 2006; Erin, Leaker et al. 2006). 
Etanercept, an IgG1-TNF p75 receptor fusion protein showed a small but significant 
improvement in asthma control and systemic inflammation (Morjaria, Chauhan et al. 
2008). Golimumab, the human monoclonal anti-TNF-a Ab produced serious adverse 
effects (Wenzel, Bames et al. 2009) (refer to table 1.1 for summary). In addition, 
TNF-a may contribute to muscarinic M2 receptor dysfunction and airway hyper-
reactivity by decreasing receptor expression and promoting recruitment of 
eosinophils, containing major basic protein, an M2 antagonist. In a study showing 
antigen challenged animals with hyper-reactivity to vagus stimulation and 
dysfunctional neuronal M2 receptors; Entanercept prevented M2 receptor 
dysfunction and airway hyper-reactivity and reduced eosinophil infiltration (Nie, 
Jacoby et al. 2009). An anti-CD4, anti-CD I la and anti-IL-2 a chain are currently in 
clinical trials (Ballow 2006). Based on its role in recruitment of eosinophils and mast 
cells, CCLIl1CCR3 has been considered for therapeutic targeting (Dent, 
Hadjicharalambous et al. 2004; Garcia, Godot et al. 2005). 
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Despite the positive findings or specific end points in some of the above 
studies, the general utility of anti-cytokine approaches in the treatment of asthma 
remains to be determined. 
Table 1.1 Summary of anti-cytokine therapy clinical trials for asthma. Ab: 
antibody. 
IL-S 
IL-9 
IL-13 
TNF-a 
Altrakincept , recombinant human IL-4R as 
IL-4 
Pitrakinra, IL-4 variant, inhibits binding of 
IL-4 and IL- 13 to IL-4 Ra receptor 
and · 
Pascolizumab (SB240683), humanised anti-
IL-4 Ab 
AMG 317, human monoc1onal IL-4Ra Ab 
inhibits both IL-4 and IL-13 
mepolizumab, humanised monoc1onal anti-
IL-5 Ab (intravenous) 
SB-240563, 
humanised monoc1onal IL-5 Ab 
IMA-638 and IMA-026, humanised IgGJ 
anti IL-13 Ab veno 
Etanercept a soluble fusion protein 
combining two p75 TNF receptors with an 
Fc fragment of human IgGl (intravenous) 
Inf1iximab a chimeric mouselhumanised 
monoc1onal anti-TNF-a Ab 
Golimumab human monoc1onal anti-TNF-a 
Ab 
(Borish, elson et al . 
200 
(Antoniu· Wenzel 
Wilbraham et al. 2007) 
(Hart, Blackburn et al. 
(Corren, Busse et al. 2010) 
(Flood-Page Swenson et 
al. 2007· Haldar 
Brightling et al. 2009· 
air Pizzichini et al. 
200 
(Leckie ten Brinke et al. 
2000) 
(Kips O'Connor et al. 
(Gauvreau Boulet et al. 
201 
(Howarth, Babu et al. 
2005· Berry Hargadon et 
al. 2006· MoIjaria, 
Chauhan et al. 200 
(Erin Leaker et al . 2006) 
(Wenzel Bames et al. 
200 
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Gene silencing through anti sense oligonucleotides and small interfering 
RNAs (siRNAs) has been considered for post-transcriptional mRNA inhibition. 
siRNA against NF-KB by transfection of airway epithelial cells reduced TNF-a.-
induced IL-6 and IL-8 release (Platz, Pinkenburg et al. 2005). NF -KB is a 
transcription factor with regulatory roles for the expression of many cytokines, 
chemokines and adhesion molecules (Baldwin 2001). In resting cells NF-KB is 
inactive in the cytoplasm, bound to an inhibitory I-kB protein. With stimulation, the 
I-kB protein is phosphorylated by an I-kB kinase complex consisting of the catalytic 
subunits IKK-l, IKK-2 and a regulatory IKK-r subunit (Scheidereit 1998; Karin 
1999; Courtois, Smahi et al. 2001). With I-kB removed, the transcription factor 
translocates to the nucleus to activate gene transcription. Using the NF-KB inhibitor 
IKK-2 resulted in a reduction in the inflammatory response in primary human ASM 
cells and an antigen driven rat model of lung inflammation (Birrell, Hardaker et al. 
2005). Other inflammatory targets include MAPK (JNK, ERK, p38) as downstream 
pathways influence cytokine and chemokine expression (Schieven 2005) and cell 
survival (Manke, Nguyen et al. 2005). SB-6B1323, a p38 inhibitor made phase 11 
trials for COPD, rheumatoid arthritis and coronary disease (Behr, Berova et al. 
2003). 
Impaired barrier function as a result of defective tight junction assembly has 
been considered for trials to restore barrier function through growth factor 
administration. Keratinocyte growth factor has been shown to induce epithelial cell 
proliferation and significantly limited the allergen induced alterations in epithelium 
integrity in ovalbumin sensitised rats (Tillie-Leblond, Gosset et al. 2007). 
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Another approach is Bronchial Thennoplasty (Castro, Musani et al. 2010; 
Castro, Rubin et al. 2010). This involves delivering radio frequency generated heat 
to the airways via a catheter inserted in the bronchial tree using a flexible 
bronchoscope; to reduce smooth muscle quantity and contractility (Cox, Miller et al. 
2004). The results showed improved peak expiratory flow, symptom-free days and 
improved AHR (Cox, Miller et al. 2006). However, the long term side effects are not 
yet known and the airway burning can lead to mucous production and asthma 
exacerbations. 
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1.2 MECHANISMS OF AIRWAY SMOOTH MUSCLE CONTRACTION 
1.2.1 Ca2+ signalling pathways for ASM contraction 
As discussed above, asthma is characterised by an increase in airway 
resistance, which is contributed to by abnonnal contraction of the ASM (Barnes 
1998). ASM tone is primarily controlled by the release of neuronal acetylcholine 
(ACh) on the parasympathetic nerves via the muscarinic receptors. Of the five 
muscarinic receptor subtypes (MI-5), ASM cells express M2 and M3 (Mak and 
Barnes 1990), the less abundant M3 receptors are responsible for tracheal and 
bronchial contraction (Roffel, Elzinga et al. 1990) via the PLC pathway described 
below (Roffel, Elzinga et al. 1990). Release of ACh is controlled by inhibitory M2 
muscarinic receptors (Fryer and Jacoby 1998). The M2 receptor has been shown to 
be dysfunctional in models of airway disease (ten Berge, Santing et al. 1995; 
Coulson and Fryer 2003). In addition, the M2 receptors on ASM are coupled via an 
inhibitory G protein (Gi) for inhibition of adenyl cyclase (AC) and might counteract 
the bronchodilator effects of such drugs as P2-adrenergic receptor agonists, that 
require activation of adenyl cyclase via Gs (Sankary, Jones et al. 1988; Fernandes, 
Fryer et al. 1992; Barnes 1998). 
Calcium (Ca2+) serves as a second messenger in a diverse range of cell types, 
playing roles in gene expression, neurotransmission and contraction. In ASM, Ca2+ 
cytoplasmic concentrations are increased through entry across the plasma membrane, 
or through release from internal Ca2+ stores in the endoplasmic reticulum (ER) 
(Berridge, Lipp et al. 2000). Ca2+ release from stores involves the phosphoinositide 
(PI) pathway. G-protein linked, or tyrosine kinase plasma membrane receptors 
activate phospholipase C (PLC), leading to cleavage of phosphatidylinositol 4,5-
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bisphosphate (PIP2) into diacyglycerol (DAG) and inositol 1,4,S-triphosphate (IP3)' 
IP3 serves as a Ca2+ releasing agent, by activating ER membrane located IP3 
receptors, this binding results in channel opening and release of Ca2+ from the ER 
into the cytoplasm (Berridge 1993). Ca2+ is also potentially released by cyclic 
adenosine diphosphate ribose via ryanodine receptors (RyR) (Flynn, Bradley et al. 
2001) (see figure 1.6). Ca2+ is taken up from the cytosol to refill internal stores via 
the sarcoplasmic/endoplasmic reticulum Ca2+-A TPase (SERCA) pump. 
Activation of the phosphoinositide (PI) pathway also leads to two plasma 
membrane channel operated mechanisms of Ca2+ entry. Firstly, the second 
messengers DAG, arachidonic acid (AA) and Ca2+ itself (Bird, Aziz et al. 2004), 
generated downstream of the PI pathway activate receptor operated calcium entry 
channels {ROCC}. In addition, the depletion of ER stores resulting from IP3 induced 
release of cr+ results in activation of plasma membrane Ca2+ entry through stored 
operated calcium channels (SOCC) {Putney 1986). 
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Figure 1.6. Ca2+ influx pathways in airway smooth muscle cells, evoked by an 
agonist acting on the acetylcholine (ACh) receptors in the plasma membrane, 
Contraction is initiated by activation of the Ca2+ dependent phosphoinositide (PI) 
pathway (refer to text above), ER: endoplasmic reticulum; PM: plasma membrane; 
M2 R: muscarinic cholinergic receptor type 2; M3R: muscarinic cholinergic 
receptor type 3; MLCK: myosin light chain kinase; MLCP: myosin light chain 
phosphatase; myosin-P: phosphorylated myosin light chains; RyR: ryanodine 
receptor, SERCA: sarcoplasmic/endoplasmic reticulum Cif+ATPase, IP3: inositol 
triphosphate, IP3R: IP3 receptor, PLC-IJ.' phospholipase C, DAG: diacylglycerol, 
PIP2: phosphatidylinositol 4,5-bisphosphate. /32 R: /32-adrenergic receptor; AC: 
Adenyl cyclase; cAMP: cyclic adenosine monophosphate; P DE: phosphodiesterase; 
PKA: protein kinase A. Adapted from (Dietrich, Chubanov et al. 2006; Pelaia, 
Renda et al. 2008). 
In the cytosol Ca2+ binds calmodulin which results in the activation of 
myosin light chain kinase (MLCK). Activated MLCK phosphorylates myosin light 
chains leading to activation of myosin ATPase, this mediates interactions between 
myosin and actin; resulting in cross bridging (Kamm and StuB 1986; Word, Tang et 
al. 1994; Macklem 1996; Gunst and Tang 2000) leading to ASM force development 
and shortening (figure 1.7). Increased levels of MLC phosphorylation have been 
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shown in models of inflammation and allergic sensitisation induced AHR (Kong, 
Halayko et al. 1990; Jiang, Rao et al. 1992; Mitchell, Ndukwu et al. 1993). Myosin 
light chain phosphatase (MLCP) dephosphorylates myosin light chains and 
terminates actinlmyosin reactions, resulting in smooth muscle relaxation (Barnes 
1998). MLCP inhibition also acts on the RyR via the Rho kinase and CPI-17 
pathway without impacting on MLCK (Kitazawa, Eto et al. 2000). This allows the 
degree of contraction to be maintained at a lower [Ca2+]i; a phenomenon known as 
'calcium sensitisation' (Somlyo and Somlyo 2003) (discussed in 1.2.4). 
Figure 1. 7. ASM contraction through myosin-actin cross bridging. Myosin creates 
force through mechanical cycles of repeated interaction between the myosin head 
and actin (Warrick and Spudich 1987). The globular myosin head generates the 
energy required through enzymatic hydrolysis of adenosine triphosphate (A TP). The 
binding of ATP to myosin while it is interacting with actin is suggested to lead to 
conformational changes in the myosin globular head that reduces the affinity for 
actin and allows it to hydrolyze ATP to adenosine diphosphate (ADP) and inorganic 
phosphate (P) (Rayment, Smith et al. 1996; Gunst and Tang 2000). The light chain 
binding domain ('neck region') pivots where the globular head and light chain 
binding domain touch resulting in separation of the actin from the myosin (Guilford, 
Dupuis et al. 1997). In smooth muscle the phosphorylation of a serine residue in the 
N-terminus of the regulatory light chain leads to the cascade for actin activating 
adenosine triphosphatase (ATPase) activity and contraction (Wagner and Giniger 
1981; Sivaramakrishnan and Burke 1982). 
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Most ASM relaxation is mediated via ~ 2 - a d r e n e r g i c c receptors (found in all 
airway generations) (Carstairs, Nimmo et al. 1985) (table 1.2). As mentioned in 
1.1.4, the fu-adrenoreceptor associates with the a subunit of the Gs protein together 
with GTP. The replacement of GTP- with GDP catalyses the conversion of ATP to 
cAMP. After binding, the Gs dissociates and the a subunit activates adenyl cyclase, 
which breaks down ATP to cAMP. cAMP then catalyses the activation of protein 
kinase A (PKA) which leads to the dissociation of a catalytic subunit, which then 
phosphorylates specific cellular targets leading to relaxation (Johnson 1995; Hall 
2000; Tanaka, Horinouchi et al. 2005). cAMP also results in inhibition of Ca2+ 
release from intracellular stores, sequestration of intracellular Ca2+ and reduction of 
membrane Ca2+ entry contributing to ASM relaxation (Johnson 2006). Although 
most studies have investigated the cAMP dependent PKA pathway through Gs 
coupling, fu receptors have also been shown to couple to Gi proteins under some 
conditions. This can lead to stimulation of p38 mitogen-activated protein kinase 
(MAPK) and extracellular signal-regulation kinase (Daaka, Luttrell et al. 1997). This 
process decreases ~ 2 2 coupling to Gs, thus reducing the receptor signal response 
through this pathway. 
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Table 1.2. Agents known to influence ASM tone, their G-protein coupled receptors 
and associated G-proteins. '" Not in human airway smooth muscle. 
\!.!,olli ... , (, pnlll'ill ( ,- I- 11 JI dill JI i JI Rl' fl' ITJI l'l" 
l'OIl pint protl'iJl \S \ I 
I'l'Cl'ptol' 
Histamine HI Gq contraction (Barnes 200 I ; 
(HA) Nakayama, Hayashi et 
al. 2005) 
Serotonin * 5-HT2 Gq contraction (Barnes 200 I; 
(5-HT) Fanburg and Lee 
2000; Tolloczko, Tao 
et al. 2000) 
Endothelin-l,2,3 ETAIB Gq contraction (Nakayama, Hayashi 
et al. 2005) 
Bradykinin B2 Gq contraction (Adomeit, Graness et 
al. 1999) 
Cysleukotrine Cys Lt RI Gq contraction (Barnes 2001) 
LTC .. ,LTD4, 
LTE .. 
Acetylcholine M3 Gq contraction (penn and Benovic 
(ACh) 2008; Nakayama, 
(neurotransmitt Hayashi et al. 2005) 
er) 
M2 Gi inhibits (penn and Benovic 
contraction, 2008; Unno, 
inhibits Matsuyama et al. 
adenyl 2005) 
cyclase 
Noradrenaline J32-adrenergic Gs relaxation (Barnes 2001; Kohm 
Gi and Sanders 2001) 
The multilayered airway wall includes the epithelium, basement membrane, 
mucosa, ASM, cartilage and adventitia with vessels, glands and a network of elastin 
and collagen throughout layers (Baile, Minshall et al. 1994; Wagner and Mitmer 
1996; Wang, Tepper et al. 2000) (figure 1.8). In the trachea hyaline cartilage rings 
are interrupted by a strip of smooth muscle however, as branching continues down 
the airway generations the amount of smooth muscle increases while cartilage in the 
wall decreases and is absent in the distal airways (figure 1.9). 
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Figure 1.8. Cross section 
through trachea showing 
smooth muscle layer 
During ASM contraction the muscle layer is subjected to compressive stress, 
while the outer region experiences expansive stress (Mitchell 2009) (figure 1.9). 
Theories for the poorly understood dynamics of airway contraction have 
incorporated the stiffness of the parenchyma and airways and the force-velocity 
relationship first described for skeletal muscle (Hanks and Stephens 1981; Jiang, 
Rao et al. 1992; Blanc, Coirault et al. 2003; Stephens, Li et al. 2003; Bates and 
Lauzon 2007). Dynamic volume changes of the lung corresponding with tidal 
breathing and deep inspiration (DI) show bronchodilatory effects, impacting on 
ASM tone and responsiveness (SkIoot, Permutt et al. 1995; Kapsali, Permutt et al. 
2000; Gump, Haughney et al. 2001 ; Noble, McFawn et al. 2007). When the lung 
expands tension between the parenchyma and outer airway wall provides a load that 
opposes airway narrowing (MackIem 1996). Adjacent ASM cells are mechanically 
coupled with each other via attachment plaques therefore during contractile 
responses tension is exerted on neighbouring ASM (which impacts on the 
contraction and shortening of this muscle also) (SkIoot, Permutt et al. 1995; King, 
Moore et al. 1999; Crimi, Pellegrino et al. 2002). These small tidal stretches are large 
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enough to lead to detachment of the myosin head from actin, sooner than would 
occur during isometric contraction, reducing the amount of active force generated 
(Fredberg, Inouye et al. 1999; Fredberg 2000; Fredberg 2000; Fredberg 2001). 
However for asthmatics the ability of DI to relax airways is greatly diminished 
(Skloot, Permutt et al. 1995; King, Moore et al. 1999; Fredberg 2001 ; cichilone 
Pyrgos et al. 2001); due to increased muscle mass and imposed force fluctuations 
leading to ASM stiffening and less stretch (Fredberg 2000; Fredberg 2000; 
Mijailovich, Butler et al. 2000; Nguyen and Fredberg 2008). Compared with the 
effects of thickened submucosal or adventitial layers, a thickened smooth muscle 
layer is shown to produce the greatest ASM shortening; again supporting the 
explanation for AHR and the failure of DI to dilate asthmatic airways (Oliver, Fabry 
et al. 2007). 
a) 
lumen 
IlrwlY contrtcted 
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fobro elastic network! nsion 
Figure 1.9. During contraction of the distal airways the epithelial, lamina propria 
and airway smooth muscle (ASM) layers are subjected to compre ion and ten ion. 
The fibro elastic network between the ASM and outer airway wall layer i ubjected 
to tension which contributes to mechanical force for ASM contraction. Adapted from 
(Cooper, 2009; Mitchell 2009). 
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1.2.2 Plasma Membrane Ca2+ permeable channels 
In a wide range of cell types an influx of Ca2+ is essential for the transduction 
of functions as varied as action potentials, hormonal release, neurotransmitter release 
and muscle contraction. In previous decades the classification of Ca2+ channels has 
been based on pharmacological response and biochemical properties, however, 
recent categorisation has incorporated a sequence analysis (Ertel, Campbell et al. 
2000) and characterisation by al subunit. Of the Ca2+ channels classified, most are 
composed of four-five subunits, the largest of which is the a subunit which 
incorporates a conduction pore, voltage sensor and gating apparatus. These are the 
sites for channel regulation by second messengers, drugs and toxins. 
1.2.2.i Voltage Operated Calcium Channels (VOCC) 
Of the Ca2+ permeable channels, VOCC are activated by membrane 
depolarisation and are highly selective for Ca2+, over sodium ions. VOCC regulate 
such intracellular processes as gene expression, contraction and neurotransmission. 
In ASM cells the majority of VOCC are L-type in nature. They require a strong 
depolarization to be activated, are long lasting and are blocked by the L-type Ca2+ 
channel antagonists, benzothiazepines, phenylalkylamines and dihydropyridines 
(Ertel, Campbell et al. 2000). N, P/Q and R-type Ca2+ currents primarily play a role 
in neurotransmission and also require strong depolarisation for activation; they are 
blocked by specific toxins from snail and spider venoms (Neelands, King et al. 
2000), rather than the L-type antagonists. T-type Ca2+ currents are transient and are 
activated by weak depolarization, they are expressed in many cells types and play a 
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role in action potentials and firing (Sipido, Canneliet et a1. 1998; Ertel, Carnpbell et 
al. 2000). VOCC channels have therapeutic applications for the treatment of 
abnormal smooth muscle contraction, as in hypertension (Kochegarov 2003). 
However, inhibitors of VOCC are ineffective bronchodilators in the treatment of 
asthma (Gordon, Wong et al. 1987), (Patakas, Maniki et a1. 1987), (Lofdahl and 
Bames 1986). An explanation for the incomplete inhibition of agonist induced 
contraction is the existence of alternate Ca2+ entry pathways. 
1.2.2.ii Receptor Operated Calcium Channels (ROCC) 
The molecular identity of the ROCC is less clear although it is believed to be 
distinctive from the ER store sensing role of the SOCC (McFadzean and Gibson 
2002). Initial studies of ROCC showed that externally applied A IP produced rapid 
depolarisation of smooth muscle (Suzuki 1985) due to a cation channel with a high 
selectivity for Ca2+ (Benham and Isien 1987). Receptor operated Ca2+ influx 
channels are found in excitable and non excitable cells and open rapidly upon 
binding to an external ligand such as the M2 receptor agonist or the neurotransmitter 
noradrenaline (parekh and Putney 2005). ROCC activation involves signalling 
molecules stimulated through the PLC pathway such as DAG and IP3 (Albert and 
Large 2003; Putney 2007). The G-protein (GuGo sub-group) is suggested to play an 
important role in this transduction pathway to link the receptor and cation channel in 
smooth muscle cells (Komori, Kawai et al. 1992; Kim, Kim et al. 1998) and airway 
myoctes (Wang and Kotlikoff2000). To further understand the transduction pathway 
coupling receptors to activation of the ROCC, the distribution and TRP protein 
combinations for channel formation requires more investigation. 
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1.2.3 Store Operated Calcium Channels (SOCC) 
By the mid 1980's it was understood that stimulation of specific plasma 
membrane receptors lead to IP3 activated release of Ca2+ from non mitochondrial 
Ca2+ stores (Berridge and Irvine 1984), in which Ca2+ release was followed by Ca2+ 
entry. This Ca2+ influx was suggested to be due to a result of depleted ER Ca2+ 
stores; introducing the concept of store operated Ca2+ entry (Putney 1986). This 
SOCC pathway plays a role in maintaining Ca2+ levels for the ER and was thought to 
be important for protein folding and trafficking (Sambrook 1990; Berridge, Lipp et 
al. 2000). 
Over the next 20 years the mechanisms behind the correspondence of store 
depletion and the opening of the plasma membrane Ca2+ channels and the identity of 
the relevant channels was the subject of extensive research. Theories for the 
activation mechanism for SOCC included the diffusible messenger hypothesis in 
which an acid factor isolated from activated T lymphocytes, referred to as Ca2+ 
influx factor (CIF), showed the ability to activate Ca2+ influx for Ca2+ release 
activated Ca2+ currents (CRAC) (Randriamampita and Tsien 1993; Smani. Zakharov 
et al. 2003; Smani. Zakharov et al. 2004; Bolotina 2008). The conformational 
coupling hypothesis was taken from the excitation-contraction coupling mechanism 
in skeletal muscle. in which a plasma membrane dihydropyridine sensitive Ca2+ 
channel is coupled to a ryanodine receptor on the ER. The hypothesis for store 
operated entry was that the IP3 receptor in the ER was directly linked to a plasma 
membrane Ca2+ entry channel. Upon ER store depletion a conformational change in 
the IP3R was proposed to signal opening of the SOCC (Berridge 1995). However, 
further studies showed that interaction with the IP3R was not required, demonstrated 
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by inhibition of SOCC in IP3R knock out cell models (Prakriya and Lewis 2001; 
Sweeney, McDaniel et al. 2002). Establishing the identity of SOCC candidates still 
remained difficult, transient receptor potential (TRP) channels had been considered 
although they possess different pore properties to CRAC (Parekh and Putney 2005). 
Patch-clamp studies greatly contributed by characterising the store operated Ca2+ 
current; the CRAC current (Parekh and Putney 2005; Prakriya 2009) initially in T 
lymphocytes and jurkat leukemic T cells (Lewis and Cahalan 1989; Zweifach and 
Lewis 1993). Studies revealed that the CRAC channel is required for sustained Ca2+ 
influx during antigenic stimulation of T cells (Partiseti, Le Deist et al. 1994; Feske, 
Giltnane et al. 2001). It was also discovered that patients with severe combined 
immunodeficiency (SCID) had T cells that lacked SOCC and CRAC (Partiseti, Le 
Deist et al. 1994; Feske, Prakriya et al. 2005). Using large scale gene silencing 
through small interference RNA (siRNA) to target SOCC; in 2005, break through 
studies identified stromal interaction molecule 1 (STIM1), a mammalian ER Ca2+ 
sensor and conformational coupler between the ER and CRAC channels (Liou, Kim 
et al. 2005; Roos, DiGregorio et al. 2005), which worked through relocation towards 
the plasma membrane. By 2006, Orai 1 was identified as a pore component of the 
mammalian CRAC channel (Feske, Gwack et al. 2006; Vig, 2006; Vig, Beck et al. 
2006; Zhang, Yeromin et al. 2006) (figure 1.10). 
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Figure 1.10. Structural features 
of STIM1 and Orail proteins. 
STIMl senses ER Ca2+ depletion 
then translocates to sites 
adjacent to the PM to form 
puncta with Orail , a plasma 
membrane (PM) pore-forming 
sub unit of the CRAC channel. 
Orail possesses four PM 
spanning regions, Nand C 
termini. Critical residues are 
shown. Glutamates (yellow) and 
aspartates (light green) affect 
ion selectivity, permeation and 
blocking. A spontaneous 
mutation causes a loss of CRAC 
in patients with SCID (orange) . 
The C terminal region required 
for activation from STIMl is 
indicated (red) . 
STIMl features an 
unpaired EF hand and sterile (J.. 
motif (SAM) domain on the ER 
luminal side. In the cytoslic 
region, coiled-coil (CC), ezrin-
radixinmoesin (ERM), serine-
proline-rich (SIP) and lysine-
rich (K) domains are shown. 
Adapted from (Prakriya, Feske 
et al. 2006; Vig, Beck et al. 
2006; Yeromin, Zhang et al. 
2006; Lewis 2007; Feske, 2006). 
STIM 1 was first identified as a cell surface transmembrane phosphoprotein 
characterised as a tumour growth suppressor (Parker, Begley et al. 1996; Manji, 
Parker et al. 2000). In a large scale RNAi screening in drosophila and parallel study 
in mammalian homologues targeting proteins with transmembrane domains, STIMl 
proteins were found to be required for store operated entry and CRAC activation 
(Liou, Kim et al. 2005; Roos, DiGregorio et al. 2005). It was also noted that the 
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siRNA targeting STIM had no effect on intracellular Ca2+ stores or resting cytosolic 
Ca2+ concentration, despite the absence of store operated entry (Liou. Kim et al. 
2005), (Roos, DiGTegorio et al. 2005). Dr S. Peel (Therapeutic and Molecular 
Medicine, QMC, Nottingham) was the first to show the role of STIM 1 in human 
airway myocytes, acting as a signal for SOCC activation following intracellular Ca2+ 
store depletion (Peel, Liu et al. 2006). STIMl and its homologue STIM2 are type la 
single pass transmembrane proteins containing a coiled coil region, two N-linked 
glycosylation sites and feature a luminal helix-turn-helix EF hand Ca2+ -sensing 
module and a sterile alpha motif (SAM) (Ponting 1995; Williams, Manji et al. 2001; 
Williams, Senior et al. 2002). STIMl is predominantly localised to the ER but is 
shown to form puncta, accumulating in subregions of junctional ER located 10-2Srun 
from the PM just prior to CRAC opening (no STIM insertion into the PM was 
detected) (Williams, Manji et al. 2001; Liou, Kim et al. 2005; Zhang, Yu et al. 
2005). Puncta formation is suggested to be the result of decreased binding of Ca2+ to 
the EF hand motif, causing the oligomerization of STIMl leading to translocation of 
the multimers to corresponding PM adjacent sites for STIM 1 initiated Ca2+ influx 
(Stathopulos, Li et al. 2006; Liou, Fivaz et al. 2007). The aggregation of STIM 1 is 
shown to induce clustering of Orai on the PM (Xu, Lu et al. 2006; Putney 2007; 
Varnai, Toth et al. 2007; Barr, Bemot et al. 2008). 
1.2.3.ii Orail 
Orail was discovered through genetic linkage studies from mutations in a 
rare form of severe combined immunodeficiency (SCID) in which T cell store 
depletion failed to activate ea1+ entry (Feske, Prakriya et al. 2005), showing an 
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absence of CRAC activity (Feske, Gwack et al. 2006). Linkage analysis and 
positional cloning identified a region of interest on chromosome 12 (Feske, Gwack 
et al. 2006), further genome wide RNAi screening in S2 cells led to identification of 
a previously uncharacterized gene, given the name Orai (or CRACMl) (Vig, Beck et 
al. 2006; Zhang, Yeromin et al. 2006). Orail and its family members Orai2 and 
Orai3 are proposed to be 4 transmembrane domain, plasma membrane spanning 
proteins (Feske, Gwack et al. 2006). The main roles of Orai2 and Orai3 still remain 
unclear. Studies show that expression of Orail alone reduces SOCC, however 
coexpression with STIMl indicates a large Ca2+ influx or amplification of CRAC 
(Mercer, Dehaven et al. 2006; Peinelt, Vig et al. 2006; Soboloff, Spassova et al. 
2006). Similar properties were shown for Orai2 but not Orai3 (Mercer, Dehaven et 
al. 2006). Dr S. Peel (Therapeutics and Molecular Medicine) had previously shown 
that STIMl plays a role in SOCC activation following store depletion in HASM and 
set out to investigate whether Orai plays a role in this pathway of Ca2+ influx (Peel, 
Liu et al. 2008). Together results implicate both STIMl and Orai as potential 
modulators of Ca2+ influx through SOCC in HASM. 
1.2.3.iii STIM - Orai interaction 
Store depletion is sensed by STIM1, causing it to cluster in ER sites adjacent 
to the PM. In resting cells Orai 1 proteins show even PM distribution, however, upon 
store depletion Orail rapidly clusters to co-localize with STIMl forming puncta 
(Luik, Wu et al. 2006; Xu, Lu et al. 2006; Vamai, Toth et al. 2007), shown using 
TIRF-based Ca2+ imaging. Confusion still remains over whether there is direct 
interaction between STIM and Orai. The STIM proteins C-terminal polybasic 
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domain was suggested to facilitate interaction with the PM (Liou, Fivaz et al. 2007), 
however, studies showed that despite a deletion in the polybasic domain, CRAC 
activation was possible (Spassova, Soboloff et al. 2006; Li, Lu et al. 2007). There is 
also a suggestion that Orai 1 may associate with a larger protein complex within the 
PM allowing for a multi-protein site for interaction between STIMl and Orail, 
directly or indirectly (Vamai, Toth et al. 2007). In addition, TRPC channels have 
been shown to mediate receptor activated Ca2+ influx: (Venkatachalam and Montell 
2007). Electrostatic interaction studies indicate that STIMl's polybasic tail is 
required to gate TRPCI and TRPC3 by a similar mechanism. However, the 
polybasic and SIP domains ofSTIMI are not required for activation of OraiI (Zeng, 
Yuan et al. 2008). Studies have also demonstrated an interaction between Orai and 
TRPC supporting the possibility that TRPC channels play a role in SOCC (Cheng, 
Liu et al. 2008; Liao, Erxleben et al. 2008). Despite advancements the process for 
relocation, interaction and CRAC channel opening still remains unclear (relocation 
and formation of puncta for STIM 1 and Orai 1 is shown in figure 1.11). 
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Figure 1.11. Current model for Store Operated Calcium Channel (SOCC) entry. a) 
STIMl and Orail are dispersed throughout the endoplasmic reticulum (ER) and 
plasma membrane (PM), agonist stimulation of a G-protein coupled receptor (R) 
acting through the PLC-j3 pathway leads to ER stored ccl+ release via the IP3R. A 
TRPC complex is also present at the PM b) ER located STIMl senses this store 
depletion and relocates to cluster at sites adjacent to the PM Simultaneously Orail 
relocates in regions of the PM directly opposite the STIMl clusters. c) this 
interaction allows Ca2+ influx for store refilling. Adaptedfrom (Luik, Wu et al. 2006; 
Lewis 2007; Luik and Lewis 2007). 
The ability to manipulate the entry process has proven difficult due to the lack 
of available specific SOCC inhibitors (Putney 2001) (discussed in 3.4.8). Trivalent 
cations such as lanthanum (La3+) (IC50 = 10 - 100 mM) and gadolinium (Gd3+) (IC5o 
< 1.0 mM) still remain the most used inhibitors of SOCC in many cell types (Luo, 
Broad et al. 2001). However, these ions inhibit a wide range of Ca2+ entry channels 
(Trebak, Bird et al. 2002). As mentioned previously, ci+ is taken up from the 
cytosol into the internal stores by the sarcoplasmic/endoplasmic reticulum Ca2+-
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ATPase (SERCA) pump. Ca2+ entry can also be activated by inhibition of the 
SERCA pumps using cyclopiazonic acid and thapsigargin (Thastrup, Cullen et al. 
1990); showing that influx can be stimulated without the phospholipase C pathway 
(Putney 2007). In addition, Ca2+ chelators such as ethylene glycol tetraacetic acid 
(EGTA), can be used experimentally to bind extracellular Ca2+, reducing Ca2+ 
availability for influx and store refilling (Smyth, Dehaven et al. 2006). 
1.2.4 Ca1+ sensitivity through RhoA-Rho Kinase interactions 
ASM contraction is dependent on phosphorylation by MLCK and relaxation 
is dependent on dephosphorylation by MLCP. It is currently hypothesised that 
MLCP is regulated by RhoA kinase phosphorylation of the MYPT 1 subunit, protein 
kinase C (PKC) and the MLCP inhibitor CPI-17; this inhibition of MLCP activity 
increases ea2+ sensitivity (Somlyo and Somlyo 2003). A ligand binds the G protein 
coupled receptor which activates tyrosine kinase, this initiates a signalling cascade to 
activate RhoA to translocate to the membrane. RhoA then activates Rho kinase, 
which in turn phosphorylates MLCP, this causes inactivation of MLCP, leading to a 
net accumulation of phosphorylated myosin light chains, resulting in increased 
contraction (Janssen and Killian 2006). The RhoA-Rho kinase (ROCK) pathway 
therefore contributes to cholinergic stimulated sustained contraction. In addition, 
agonists increase Ca2+ sensitivity through activation of the G protein which 
stimulates Rho kinase, to activate PKC via DAG (Parekb, Ziegler et al. 2000). 
ROCK inhibitors have shown to be effective bronchodilators (Nakahara, Moriuchi et 
al. 2000; Liu, Zoo et al. 2006). RhoAl ROCK pathway members are also shown to 
be increased in allergic animal models (Chiba, Takada et al. 1999; Chiba, Sakai et al. 
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2001; Hashimoto, Nakano et al. 2002; Chi ba, Sakai et al. 2003; Chiba and Misawa 
2004; Sakai, Otogoto et al. 2004). Studies have linked the RhoA-Rho kinase 
pathway with hyper-responsiveness through experiments involving cytokines (Parris, 
Cobban et al. 1999; Hunter, Cobban et al. 2003) and mechanical stress (Smith, Roy 
et al. 2003). Telokin, a 17-KDa protein specific for smooth muscle is phosphorylated 
by cAMP and cGMP and reportedly promotes Ca2+ desensitisation via activation of 
MLCP in intestinal smooth muscle (Wu, Haystead et al. 1998; Choudhury, Khromov 
et al. 2004). Its presence and role in ASM are unknown. 
1.2.5 Ryanodine receptor (RyR) pathway involved in Ca2+ oscillations and 
internal Ca2+ store regulation 
Ca2+ oscillations are also suggested to be mediated through the RyR, based 
on studies showing that ACh induced Ca2+ oscillations were slowed or inhibited by 
RyR antagonists (Kannan, Prakash et al. 1997; Prakash, Kannan et al. 1997). While 
initiation of Ca2+ oscillations may be dependent on the IP3R, maintenance of these 
oscillations may require the RyR. It has been suggested that the RyR may be 
sensitised via the second messenger cyclic adenosine diphosphate ribose (cAD PR). 
CD38, a transmembrane glycoprotein catalyzes the synthesis and degradation of 
cADPR via ADP ribosyl cyclase and ADP ribosyl hydrolase. CD38 also uses ~ ~
NAD+ to generate nicotinic acid adenine dinucleotide phosphate (NAADP). In ASM 
cells, CD38 has been shown to be increased by such cytokines as IL-13 (Deshpande, 
Dogan et al. 2004), TNF-a (Deshpande, Walseth et al. 2003) and I L - l ~ . . cADPR 
mediated Ca2+ release may involve activation of the RyR2, the predominant isoform 
in ASM (Kannan, Prakash et al. 1997). Activation of RyR may occur indirectly via 
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such accessory proteins as FKBP 12.6 which maintains RyR2 in an inactive state 
(Berridge, Bootman et al. 2003). Studies suggest that increased cADPR could lead to 
increased Ca2+ responses. Addition of extracellular cADPR potentiates ACh induced 
contractions in bovine ASM (Franco, Bruzzone et al. 2001 ). Treatment of HASM 
with IL-13 increases CD38 expression and cADPR cyclase activity, cADPR 
antagonists have also been shown to abolish the effects of TNF -u and IL-1 3 on an 
agonist induced Ca2+ response (Deshpande, Dogan et al. 2004; Deshpande, Walseth 
et al. 2003). FKBP KO mice have also shown increased contractile responses to 
cholinergic stimulation (Wang, Zheng et al. 2004). 
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Figure 1.12. Summary of pathways involving store operated Ca2+ entry (blue), 
internal C C + + store regulation (green) and C C + + sensitivity (orange). Agonist 
activation leads to stimulation of the IP3 pathway (blue), activating release of ccl+ 
from the sarcoplasmic l endoplasmic reticulum (ER) via the IP3R. The depletion of 
internal stored ccl+ results in dissociation of ccl+ from STIMl in a 
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subcompartment of the ER, which causes STIM1 to relocate within the ER to areas 
near Orail channels located in the plasma membrane (PM); to activate Orail 
channels for ccl+ influx. The pathway in green shows activation of the M2 subtype 
muscarinic receptor, which is coupled to an aj G-protein. This recruits the CD38 
signalling pathway. fJNAD is transported out of the cytoplasm by connexin 43 
hemichannel proteins (Cx43). cyclic adenosine diphosphate ribose (cADPR) is 
generated by CD38 and transported back into the cytoplasm either through 
nucleoside transporters (NT) or via CD38. ADPR, a product of the CD38 enzymatic 
activity acts on transient receptor potential (TRP) channels to allow influx of 
divalent cations, including Ca2+. cADPR acts directly or indirectly with the 
ryanodine receptor (RyR) to open the ion channel. FK506-binding protein 12.6 
(FKBP 12.6) is associated with the RyR and keeps it in a closed state. Interaction of 
cADPR with the RyR causes disassociation of FKBP12.6 and increases the open 
probability of the receptor to release sarcoplasmic reticulum ccl+. Calmodulin 
(CaM) is shown to play a role in cADPR mediated events in some species, through 
recruitment of CaM kinase 11 (CaMI1) to phosphorylate the RyR, this 
phosphorylation also increases the open probability of the RyR. Finally, cAPDR acts 
directly on the RyR channel to open it. The pathway in orange depicts ccl+ 
sensitisation. Studies indicate that ccl+ sensitisation is linked to decreased MLCP 
activity; through phosphorylation and inhibition of the regulatory myosin 
phosphatase subunit (MYPTl) of MLCP by Rho kinase and by phosphorylation of 
CPI-17, an inhibitory protein of type 1 protein phosphatase, by protein kinase C 
(PKC). The production of Rho involving diacylglycerol (DAG) to active Rho kinase 
and P KC are processes that involve agonist activation of the G-protein coupled 
receptors, however, depolarisation by KCI has also lead to CcI+ sensitivity in 
vascular smooth muscle. Diagram adapted from (Parekh, Ziegler et al. 2000; Ratz, 
Berg et al. 2005; Smyth, Dehaven et al. 2006; Putney 2007; Sanderson, Delmotte et 
al. 2008). 
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1.3 DEVELOPING A MODEL TO STUDY AIRWAY SMOOTH MUSCLE 
CONTRACTION IN DISTAL AIRWAYS 
1.3.1 The distal airways 
In vivo, the influence of mechanical and physiological stresses during normal 
respiratory function on airway narrowing at varying generations of the bronchial tree 
have been difficult to study. Histological studies suggest the large airways as the site 
of greatest narrowing (Okazawa, Vedal et al. 1995), however imaging of isolated 
airways and lung preparations suggest the smaller and midsized airways show the 
greatest degree of narrowing (Arnirav, Kramer et al. 1993; Mitchell, Cvetkovski et 
al. 1998; Bai, Zhang et al. 2007). Despite the amount of smooth muscle, cartilage 
thickness and number of mucosal folds being greater in large airways; porcine 
studies have demonstrated that increased sensitivity to ACh, muscle shortening and 
degree and rate of luminal narrowing are shown to be greater in small airways than 
in larger airways (Noble, McLaughlin et al. 2010; Noble, West et al. 2010; Mitchell, 
Cvetkovski et al. 1998); possibly due to cartilage limiting contraction in larger 
airways. Taken together the majority of the evidence suggests the distal airways 
exhibit increased sensitivity, rate and degree of narrowing in comparison to proximal 
airways. 
In human, the airways are divided into 24 generations; the distal airways are 
classified as < 2mm internal diameter in adults, non-cartilaginous and spanning the 
8th generation down to terminal bronchioles and respiratory bronchioles (Burgel, 
Frachon et al. 2009). Studies of distal airways have proved difficult due to the 
limited techniques available. In asthmatic patients distal airways potentially 
contribute to up to 90% of airflow resistance (Van Brabandt, Cauberghs et al. 1983; 
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Yanai, Sekizawa et al. 1992); suggesting this is the main site of airflow obstruction 
(Ingram 1990; Ohrui, Sekizawa et al. 1992; Kuwano, Bosken et al. 1993; Wagner, 
Bleecker et al. 1998) and AHR (Wiggs, Bosken et al. 1992; Kuwano, Bosken et al. 
1993). Similar yet more severe inflammatory and structural changes occur in the 
distal lung and lung parenchyma of asthmatics compared to proximal sites (Carroll, 
Carello et al. 1996; Kraft, Djukanovic et al. 1996; Faul, Tonney et al. 1997). 
Regional variations in inflammatory cell distribution in asthmatics are also 
suggested, with distal airways predominantly showing CD45+ leukocytes and 
eosinophils in the outer airway wall regions (between the smooth muscle and 
alveolar attachments), in comparison large asthmatic airways showed a greater 
density of eosinophils in the inner airway wall regions, between the basement 
membrane and smooth muscle (Haley, Sunday et al. 1998). These differences in 
regional distribution of inflammatory cells may reflect different mechanisms of 
inflammatory cell recruitment and chemokine/cytokine production (Hamid and Tulic 
2007). 
While airway inflammation occurs throughout the airway generations, given 
the recent evidence highlighting the significance of the small airways in 
inflammation and airflow resistance in asthmatic patients; this raises concern over 
the efficiencies of delivery of current treatments. Inhaled corticoids reduce airway 
inflammation in mild-moderate asthmatics (Djukanovic, Wilson et al. 1992; Booth, 
Richmond et al. 1995); however fail to relieve airway inflammation and hyper-
responsiveness in severe asthmatics despite long tenn treatment (Jeffery, Godfrey et 
al. 1992; Gauvreau, Inman et al. 2002). Current therapy is largely based on inhaled 
drugs with a particle size of 3 - 5 flm (Burgel, Frachon et al. 2009). Deposition 
studies predict that deposition occurs predominantly in the proximal airways 
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(Esmailpour, Hogger et al. 1997). Strategies for targeting the distal airways include 
intravenous administration or inhaled medications using extra-fine particles to 
deposit in the proximal and distal airways. A few studies have trialled delivery of 
extra fine particles via metered dose inhaler (MDI); e.g a study quantifying lung and 
extra thoracic aerosol deposition of 1.5, 3 and 6 Ilm diameter particles found the 
smaller particles achieved greater total and peripheral lung deposition (Usmani, 
Biddiscombe et al. 2005). Use of hydrofluoroalkane-beclomethasone dipropionate 
(HF A-BDP) pressurised metered-dose inhaler extra-fine aerosol suggests improved 
targeting compared to the chlorinated fluorocarbon CFC (chlorofluorocarbon) 
propellants (Leach, Davidson et al. 1998; Busse, Brazinsky et al. 1999; Goldin, 
Tashldn et al. 1999; Hauber, Gotfried et al. 2003). 
1.3.2 Developing a physiologically relevant model for studying airway smooth 
muscle contraction in the distal airways. 
To explore the mechanisms involved in ASM contraction and the pathogenesis 
of hyper-reactivity implicated in asthma, previous studies have generally used lung 
function tests in whole airways. Given that the air to water interfaces within the lung 
create difficulty for imaging methods; most understanding of lung function in 
asthmatics is derived from measurements of spirometry and plethysmography, 
predominantly reflecting large airway contribution. Previously mentioned, 
measurement of lung function and airway obstruction in humans can be achieved 
through non invasive tests designed to measure forced expiration; from this, values 
for peak expiratory flow (PEF), forced expiratory volume in one second (FEV 1) and 
MMEF (maximal midexpiratory flow) can be calculated (Dawson and Elliott 1977). 
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Recently refined imaging techniques such as CT have also been used to measure the 
airway structure within the lung (Amirav, Kramer et al. 1993). 
A range of ex vivo and in vivo models have been used to study airway function, 
these are summarised in table 1.3. Measurement of expiratory flow rate in animal 
models is technically challenging, therefore methods to assess mechanical response 
have been designed. Trapped gas volume involves measuring the volume of gas in 
the lungs dissected from animals (Yiamouyiannis, Stengel et al. 1995), based on the 
theory that in induced airway constriction a greater proportion of airways are closed 
near functional residual volume (FRC). Animal models that require anaesthesia and 
instrumentation are used for airway pressure measurements during mechanical 
ventilation, by inserting a tracheal cannula with a side tap for measuring pressure 
(Levitt and Mitzner 1988). Anaesthesia and invasive instrumentation is also required 
for measuring pulmonary resistance and lung compliance (Drazen, Finn et al. 1999). 
The disadvantage of using anaesthetic agents is that they may cause agonist or 
antagonistic effects on some receptors, or alter neural response and lung blood flow. 
Contraction of isolated airway segments is a popular method for studying 
airway contraction and involves dissection of airways for organ bath. By attaching 
the tissue to force or motion transducers, either isotonic or isometric responses can 
be measured: However, this method of tissue dissection disrupts the neural and 
circulatory pathways which may alter pharmacological response (Larsen, Renz et al. 
1992). In addition, in general measurements are based on stretching of isolated 
muscle strips rather than assessment of cross sectional area of an intact airway. 
Models of mechanical response provide information about airway contraction, 
but not the underlying process. Use of isolated smooth muscle cells (ISMC) provides 
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insight into some processes of Ca2+ signalling, however the contraction cannot be 
observed and there is an argument that in culture the cells dedifferentiate and the 
contractile machinery is lost or significantly reduced (Widdop, Daykin et al. 1993). 
Such difficulties highlight the need for an intact airway model that allows 
simultaneous quantification of contraction and measurement of relevant signalling 
pathways. 
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Table 1.3. Common techniques used to assess airway contraction in human and animal models; a comparison of the advantages and 
disadvantages. 
Human I Isolated smooth 
muscle cells 
Lung function 
tests in whole 
aIrways 
Animal I Anaesthesia and 
invasive 
Airway pressure 
measurements 
during 
mechanical 
ventilation 
Measurement of 
pulmonary 
resistance and 
Provides infonnation about the cellular processes 
involved in contraction, non invasive. 
Non invasive, can be calculated from minimal 
expiratory effort. 
Intact anatomical structures in animal, meaning 
contraction can be influenced by neural and 
mediators. 
Simple procedure to measure pressure. 
Breath-by-breath measurements for pulmonary 
resistance and dynamic pulmonary compliance can 
be given; meaning changes due to agonists can be 
assessed. 
Technically easy to dissect. 
Cells may dedifferentiate in culture, 
contractility may be lost. Does not show 
contractile effects of signalling. 
Technically difficult to measure in animal 
models. No regional infonnation. 
Anaesthesia may alter neural pathways, 
vasodilatation and receptor behaviour. 
Measurements do not differentiate between 
changes in airway resistance or in lung 
elasticity . 
Technically difficult, invasive 
instrumentation in intact animals required. 
Requires multiple measurement variables 
to calculate 
Receptor stimulation, innervations and 
circulation may be altered with tissues 
dissected free of body; which may affect 
contractile 
(Widdop, Daykin 
et al. 1993; 
Bergner and 
Sanderson 
(Dawsonand 
Elliott 1977; 
Drazen, Finn et 
al. 1 
(Yamakage 2002; 
Yamakage and 
Namiki 
(Levitt and 
Mitzner 1988; 
Drazen, Finn et 
al. 1999) 
(Martin, Gerard et 
al. 1988) 
(Drazen, Finn et 
al. 1999) 
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isolated tissue contraction measured directly, ability to control segments is disrupted due to the tissue al. 1992; Manzini ; 
segments initial tissue segment length and tension. segments being dissected, which may alter 1992) 
contraction. I 
Trapped gas Technically easy to produce a measurement of Only one measurement is given for each (Yiamouyiannis, I 
volume trapped gas volume, all lung structures are intact anjmal, relevance of trapped gas volume Stengel et al. I 
measurement to airway obstruction is 1995; Drazen, 
unknown. Finn et al. 1999) 
Mechanical Static compliance and pulmonary resistance can be Static pulmonary compliance (Hirai, Hosokawa 
measw-ements of measured measurements reflect mechanisms of the et al. 1995) 
dissected lungs lWlg parenchyma rather than the airways, 
therefore there is little relevance to asthma 
models. I 
Human Precision cut lung One animal can be used for multiple experiments. Innervation and circulation of the tissue (Bergner and i 
and slices (PCLS) Applied to diverse range of techniques: segments is disrupted. Preparation of lungs Sanderson 2002) i I 
animal measurements of [Ca2li. siRNA gene silencing and for slicing may alter integrity of airways I 
phannacological methods to study influences on thus effecting contractile response. 
i contraction! signalling pathways. 
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1.4 AIMS 
Much of the work described in this thesis utilises Precision Cut Lung Slices 
(PCLS), allowing the study of distal airway behaviour. By preparing slices using a 
vibrating microtome tissue slicer, this method generates multiple experiments using 
small amounts of lung tissue. In addition to measuring contraction, PCLS can also be 
used to study other responses such as Ca2+ signalling in ASM using confocal 
microscopy (Bergner and Sanderson 2002). Through knock out mouse models and 
manipulation of the inflammatory environment, this lung slice technique allows 
insight into the pathogenesis of the airway inflammatory response and airway hyper-
reactivity at the distal airway level in a range of models of asthma. 
The aims of the studies described in this thesis were: 
• To characterise the contractile response of PCLS in wild type mice and pigs 
to serve as a prelude to future studies using human lung tissue. 
• To investigate the role of Ca2+ in ASM contraction and how dysregulation of 
Ca2+ homeostasis may contribute to AHR in patients with asthma. 
• To use the PCLS technique to characterise airway responses in murine 
models of allergic sensitisation designed to mimick specific features of the 
T H2 inflammatory response seen in human patients with asthma. 
• To define key inflammatory mediators influencing ASM contractile 
responses and to explore the pathway required for AHR in these models; also 
to investigate whether these mediators may contribute to AHR in human 
patients with asthma. 
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2. CHAPTER TWO 
2.1 ANIMAL TISSUE LUNG SLICE PREPARATIONS AND 
CONTRACTION EXPERIMENTS 
The precision cut lung slice (PCLS) technique was developed by Bergner and 
Sanderson (2002, University of Massachusetts, Worcester USA) for use on mouse 
lung slices. The slices are prepared by inflating the lung lobes with agarose and 
cutting the solidified lung tissue using an oscillating tissue slicer to obtain slices of < 
200 J.lm thickness. These slices contain airways that remain structurally intact with 
visibly beating cilia on the epithelia lining. This model provides a physiologically 
relevant system to study airway contraction. The contraction experiments described 
in this thesis required real time video caption using bright field settings, imaging 
software was then used to measure the airway lumen area at selected time points 
throughout the experiments. 
Materials for preparation of lung slices 
• HBSS buffer: HEPES mlrumum 99.5% titration 10 mM (H3375-5009, 
Sigma, Germany), magnesium chloride I mM (M2670-5009, Sigma, 
Germany), calcium chloride 2 mM (Code c/1500, FSA Laboratory Supplies, 
Loughborough, UK). Hank's Balanced Salt Solution (HBSS) (without Ca2+, 
Mg2+, Ph red (lOx) (CE) 500 ml cat. no. 14185, Invitrogen Ltd, UK). 
• DMEM D5796 (Sigma-Aldrich Inc., St Louis, Mo., USA), supplemented 
with 2 mM glutamine, Penstrep (2.4 mIll, Penicillin 10.000 U/ml + 
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Streptomycin 10.000 J..lg/mI) and Fungizone (4.8 mIll, Amphotericin B 250 
UG/ml). 
• Agarose Type IV low gelling (A9045-25G, cas. 39346-81-1, Sigma-Aldrich 
Inc., St Louis, Mo., USA). 
• Catheters: BD Saf-T-Intima 20 GA 1.00 IN 1.1 x 25 mm 55 mVmin (Beckton 
Dickinson cat. no. 383335, Denmark). 
• Quick Bond tissue adhesive glue (Type 221 AA.471, cat. no. 72588, Science 
services, UK). Sectioning blades (for EMS tissue slicer) (cat. no. 93020, 
Science services, Munich, Germany). 
• Oscillating Tissue Slicer EMS 5000 (Serial number 16234, Electron 
Microscopy Sciences, P.O. Box 550, Hatfield Pa 19440) and Bath medium 
refrigeration controller for EMS 5000 (http://www.emsdiasum.com). Power 
Cable for 93220 Tissue Slicer (E93220-pack, Science services, UK). Fuses 
(stock no. 563 633A BP, 500 milliamp, 5 mm x 20 mm anti surge, RS 
components, UK). 
2.1.1 Mouse Lung Slices 
Mice for Chapter Three: were taken from normal female, five - ten week old, 
C57BU6 mice. These mice were supplied by Dr Luisa Martinez-Pomares 
(Immunology, QMC, Nottingham). These mice were also used for an experiment in 
Results Chapter Four, as stated. 
Mice for Chapter Four: IL-33 as a key mediator of airway hyper-responsiveness in a 
murine model of airway inflammation. Female BALB/c mice were obtained from 
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Charles River. All mice were housed in the Medical Research Council Laboratory of 
Molecular Biology, Cambridge (McKenzie group). Mice were housed in pathogen 
free, environmentally controlled conditions and were six - twelve weeks old when 
euthanized. All animal experiments were undertaken with the approval of the UK 
Home Office. For ovalbumin sensitisation results shown, mice underwent acute, 
mid-chronic and chronic ovalbumin sensitisation with phosphate buffered saline 
solution (PBS) matched controls (described below). NaIve WT mouse lung slices 
(130 Jlm thickness) were also incubated overnight in selected cytokines (lOO ng/ml). 
Lungs were also obtained from IL-IRL-l KO (ST2 receptor knockout) mice on a 
BALB/c background (sixth generation backcross) generated as described 
(Townsend, Fallon et al. 2000) and the combination of IL-4, IL-5, IL-9 & IL-13 KO 
mice generated as described previously (Fallon, 2002). 
2.1.1.i Protocols for acute, mid-chronic and chronic ovalbumin sensitisation in 
BALB/c mice (allergic airway disease model) 
Sensitisation was performed by the McKenzie group at Cambridge. Mice 
were sensitised by intraperitoneal administration of endotoxin-low ovalbumin 
(OV A) on day zero and day twelve (20 Jlg/ dose in 50 JlI of PBS mixed with 50 JlI of 
aluminium hydroxide (alum)). Control animals received PBS. Mice were challenged 
with aerosolised 1% (v/v) OVA for 20 minutes in a custom made air tight gas 
chamber on day 19, 20 and 21. This three-day challenge protocol was repeated 
every seven days for up to three weeks. Lung tissue was taken 24 hours after the 
fmal aerosol treatment, either on day 22, 29, or 36 (see below). 
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Acute model 
Endotoxin cleaned Endotoxtn cleaned 
OVA/AJum Of OVA/Alum or 
PBSlAJum, I P PBSlAlUm, I P 
I I 
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Figure 2.1. Protocols for acute, mid-chronic and chronic ovalbumin sensitisation 
(described above}. OVA: ovalbumin; PBS: phosphate buffered saline solution; Alum: 
aluminium hydroxide; IP: intraperitoneal injection. 
2.1.1.ii Method for preparation of mouse lung slices: 
1. Prior to experiments 1 liter of HBSS buffer was made up: sterile distilled H20 to 
lL final volume; 10 mM (2.38 g) HEPES minimum 99.5% titration; 1 mM (1 ml 
of 1 M stock) magnesium chloride; 2 mM (2 ml of IM stock) calcium chloride; 
100 ml Hank's Balanced Salt Solution (HBSS) lOX; pH to 7.4 using NaOH. 
2. Prior to the experiments 2% (w/v) low gelling temperature agarose was made up 
in HBSS buffer and stored in a water bath at 37°C for 30 minutes. 
3. Mice were euthanized by intraperitoneal injection with 0.3 ml pentobarbitone 
sodium (Euthatol) followed by gentle neck dislocation. The mouse was opened 
from pharynx to diaphragm. The chest cavity was exposed by cutting along the 
sternum. A small hole was made midway along the trachea using a scalpel blade, 
a 20G intima, Beckton Dickinson catheter was then inserted into the trachea. 
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Attaching a 2 ml syringe (2 ml, Sabre, UK), the lungs were gently inflated with 
air to ensure the catheter was in the correct location and all lung lobes inflated, 
the lungs were then slowly deflated, string was tightened around the trachea to 
hold the catheter in place. 
4. The 2% (w/v) low gelling agarose was slowly injected (- 1.3 ml for eight - ten 
week mice) into the lungs until firm and 90% inflated, a syringe filled with air 
was also attached to the catheter and injected into the lungs following the agarose 
(- 0.5 ml) to ensure airways would not be filled with agarose. The catheter was 
clamped to maintain pressure. The inflated lungs were covered with HBSS 
soaked cotton wool and left for 20 minutes, to allow the agarose to solidify 
before withdrawing the catheter and placing the lungs in HBSS buffer in a 
universal tube on ice. The lungs were then transported to the oscillating tissue 
slicer to be cut (see figure 2.2). 
1) mouse dssec:ted to expose 
trachea and chest cavily 
2) sternum and 
rib cage rut to 
view lungs 
4) 1.3m1 agarose 
3) indsion in trachea 
to insert calheter 
Figure 2.2 Preparation of mouse lung slices (described above).T: trachea; Th: 
thyroids; L: left lobe; Ap: apical lobe; Az: azygous lobe; D: diaphragmatic lobe; C: 
cardiac lobe. 
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2.1.1.iii Overnight cytokine incubation of BALB/c and c57BL/6 WT mouse lung 
slices 
For cytokine sensitisation experiments, naive WT mouse lung slices were 
incubated overnight in 100 nglml of re comb in ant mouse IL-4, IL-S, IL-I3, IL-24, IL-
17A, IL-33 and TNF-a (R & D Systems, UK). Using a 96 well round bottomed plate 
(cat no. 163320, NUNc, Denmark), leaving the outer rows/columns empty (risk of 
evaporation), 150 ,.ll of DMEM media supplemented with Penstrep (2.4 mlll, 
Penicillin 10.000 U/ml + Streptomycin 10.000 ~ g l m l ) ) and Fungizone (4.8 mlll, 
Amphotericin B 250 UG/ml) was pipetted into each well. The cytokines were made 
up in sterile PBS to give stock concentrations (1 0 ~ g l m l l or 20 ~ g l m l l as specified). 
From this stock, cytokine concentrations were made up to 400 nglml in media, 50 ~ l l
was then added to each well of the round bottomed plate for a 1:4 dilution. Two 
slices were placed into each well and left overnight at 37°C in 5% C02 for 
contraction experiments the following day. 
2.1.2 Pig lung slices 
The method for preparation of precision cut lung slices for mouse lungs, taken 
from Bergner and Sanderson (2002), was adapted to obtain pig lung slices. This 
method involves cutting into the trachea and positioning tubing ts 1 mm diameter) 
down the bronchi into the lung lobes to access a portion of lobe to fill with agarose. 
This preparation required the tubing to be positioned far enough into the lung lobes 
to be airtight, if not it was difficult to inflate. If only a section of lobe was obtained, 
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inflation was attempted by inserting a catheter or tubing into an airway and trying to 
isolate the section or block off other airways using the tubing and suture thread. 
Pigs for Chapter Four Results: Domestic healthy pig whole lungs and trachea 
were obtained from Dr Richard Roberts (E34, QMC, University of Nottingham), 
freshly acquired from the Nottingham abattoir. 
Method for preparation of pig lung slices: 
I. Prior to experiments 1 L of HBSS buffer was made up: sterile distilled H20 to 1 L 
fmal volume; 10 mM (2.38 g) HEPES minimum 99.5% titration; 1 mM (1 ml of 
IM stock) magnesium chloride; 2 mM (2 ml of IM stock) calcium chloride; 100 
ml Hank's Balanced Salt Solution IOX; pH to 7.4 using NaOH. 
2. Prior to the experiment 2% (w/v) low gelling temperature agarose was made in 
HBSS buffer and stored in a water bath at 37°C for 30 minutes. 
3. The pig whole lungs and trachea were dissected free of excess connective and 
fatty tissue, the oesophagus and tongue. The trachea was cut superior to the 
bifurcation of the bronchus, at a level where the bronchi could be seen branching 
off. Tubing was connected to a 50 ml syringe via a three-way connection valve, 
this tubing was then inserted down the trachea into a bronchi and pushed through 
until a lobe was potentially located to be filled. Using the syringe this lobe was 
then filled with air to check for full inflation and slowly deflated again. 
4. The low gelling temperature agarose (2% (w/v) was pumped through the tubing 
to fill up the portion of lobe until it was 90% full and solid to touch, air was then 
pushed in (to clear the airways of agarose) (refer to figure 2.3). The tubing was 
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clamped in place and the tissue was left with cold HB soaked cotton wool 
covering it for 20 minutes until the agarose solidified completely, thi s portion of 
lung was then cut free and placed in a pot of HBSS on ice, to be cut using the 
oscillating tissue slicer. 
1) pig lung set dissected free of muscle, connective tissue and 
oesophagus Figure 2.3. Preparation of pig 
lung slices. Process for inflation 
of pig lungs with agarose 
fo llowed by air 10 clear airways 
free of agarose leaving 
surrounding tissue to olidify. Ap: 
apical lobes; C: cardiac lobes; D 
diaphragmatic lobes; Ac: 
accessory lobe. 2) tubing inserted through bronchi to 
lunglobe 
Figure 2.4. Preparation of pig lung 
slices. Tubing was in erted into the 
trachea, the agarose filled lobe is 
indicated. 
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Waste disposal and decontamination procedures: all dissection instruments were 
cleaned in 70% (v/v) ethanol, all syringes and catheters were disposed of in clinical 
I 
waste. Tissue was double bagged in clinical waste bags, labeled and disposed of via 
off site incineration. 
2.1.3 Use of EMS 5000 Oscillating Tissue Slicer for sections of agarose filled pig 
and mouse lung tissue 
The oscillating tissue slicer (figure 2.5) can be used for sectioning slices from 
fresh or fixed tissue for use in electrophysiology, histology, immunocytochemistry, 
immunohistochemistry and imaging. The slicer can also be attached to a separate 
refrigeration system for fresh tissue that may require bathing in a buffer at a specific 
temperature. For future studies described in this thesis the tissue slicer was used to 
cut mouse and pig lung tissue to a 130 - 170 IlM thickness for airway contraction 
experiments and 75 IlM thickness (where possible) for haematoxylin and eosin 
staining. Slices of such thickness can be perfused easily with drugs to study airway 
contraction whilst maintaining intact lung tissue structures with visible airways that 
possess beating cilia. 
Figure 2.5. The EMS 5000 
Oscillating tissue slicer with 
accompanying refrigeration bath. 
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Method: 
1. Segments of mouse/ pig lungs filled with agarose were cut into - 1 cm3 cubes 
using a scalpel. Only tissue segments with airways free of agarose were cut. 
2. The tissue segments were glued in position on the slicing stage using specimen 
adhesive glue, the tissue was positioned to be cut horizontally to show circular 
airways. 
3. The slicing stage was submerged in the oscillating slicer tray which was filled 
with cold HBSS. The thickness was set to 130 J.1m for mouse and 140 - 170 J.1m 
for pig depending on tearing risk of the slices and staged tissue segment. The 
first few slices were discarded until flat, even slices were obtained. The slices 
were stored in cold HBSS buffer in a six well plate for 30 minutes, to be later 
transferred to DMEM for incubation. 
4. Once all slices were cut, they were transferred to a 24 well culture plate, 
submerged in DMEM (Gibeo Inventory no. 5769) supplemented with 2 mM 
glutamine, Penstrep (2.4 mlJl, Penicillin 10.000 U/ml + Streptomycin 10.000 
J.1g/ml) and Fungizone (4.8 ml/l, Amphotericin B 250 UG/ml) and incubated at 
37°C in 5% C02. After cutting, slices were left to settle overnight prior to 
experiments the following day. Airway contraction experiments were performed 
one - three days after preparation. However, slices were deemed viable (based on 
appropriate behavioural response to agonist) for up to six days in cultured 
conditions (data not shown (Bergner and Sanderson 2002». 
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2.1.4 Haematoxylin & Eosin (H&E) staining of lung slice 
Haematoxylin stains basophilic structures blue-purple, while eosin stains 
eosinophilic structures bright pink. Staining was applied to the control and sensitised 
mouse lung slices to observe structural alterations in epithelial and smooth muscle 
layers and view inflammatory infiltration. 
Materials: 
• Haematoxylin (cat. no. 51275, 100 ml, Sigma-Aldrich, Chemie Gmbh), Eosin 
(cat. no. A5025, Batch D02. TII05, NUSTAIN Dept. Pathology, University 
Hosp. Nottingham). Parafonnaldehyde (cat. no. P6148, Sigma-Aldrich). 
Distilled water. 
Method: 
I. Lung slices were cut 20 ~ m m thick using a cryostat tissue slicer. 
2. The slices were submerged in parafonnaldehyde (three drops) in a petri dish for 
3 minutes. 
3. The slices were then transferred to a microscope slide, six drops of Haematoxylin 
was pipetted on the slice until completely covered, it was then washed by 
submerging the slide in distilled water. 
4. The slice was then positioned on another dry microscope slide and two drops of 
Eosin were pipetted on the slice until completely covered, the slice was then 
submerged in distilled water to wash. 
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5. Images of the slices were taken using a Nikon DIAPHOT 300 microscope at 100 
and 200x magnification. 
2.1.5 Measurement of contractile response in airways 
To ensure a standard of quality control for airway contraction experiments, intact 
airways with beating cilia and a lumen free from agarose were chosen. For Chapter 
Three, airways were tested for contraction prior to experiments, a contractile 
response of> 25% (in comparison to initial lumen area) to 10 ~ M M ACh was deemed 
suitable for experiments. Chapter Four included all results for contraction 
measurements in sensitised mouse airways and after cytokine incubation, with the 
parameter that cilia were beating and airways were free of agarose. 
2.1.S.i Chemicals/materials required for all mouse and pig lung slice contractile 
experiments: 
• Microscope slides (Fisher Brand ground edges, 76 mm x 26 mm, 0.8 mm -
1.0 mm thick FB59620, UK). Cover slips (200 pcs cover glass 22 x 22 mm 
cat. no. 631-0124 thickness no. 1 Borosillicate glass, VWR International). 
Grease (Dow Coming high vacuum grease cat. no. 2273554-1 ea 5.3 oz tube, 
Sigma-Aldrich, Germany). 
• 2 mM Calcium buffer: HEPES minimum 99.5% titration 10 mM (H3375-
5009, Sigma, Germany), magnesium chloride 1 mM (M2670-5009, Sigma, 
Gennany), calcium chloride 2 mM (Code cI1500, FSA Laboratory Supplies, 
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Loughborough, UK). Hank's Balanced Salt Solution (HBSS) «without Ca2+, 
Mg2+, Ph red (lOx) (CE) 500 ml cat. no. 14185, Invitrogen Ltd, UK), ph to 
7.4 with NaOH. 
• 0 mM Calcium buffer: HEPES minimum 99.5% titration 10 mM (H3375-
5009, Sigma, Germany), magnesium chloride 1 mM (M2670-5009, Sigma, 
Germany), HBSS (without Ca2+ Mg2+, Ph red (10x) (CE) 500 ml cat. no. 
14185, Invitrogen Ltd, UK), EGTA 1 mM (E4378, Sigma, Germany), pH to 
7.4 with NaOH. 
• DMSO Dimethylsulfoxide 2: 99.9% (cas. 67-68-5, Sigma, Germany). 
Acetylcholine chloride (made up in H20, A-6625 25 g, Sigma, Germany). 
Methacholine chloride (made up in H20, cat. no. 190231 MD Biomedicals, 
USA). Serotonin hydrochloride (made up in H20, H-9523-100 mg cas. 153-
98-0, Sigma, Germany). Histamine dihydrochloride (made up in H20, H7250-
5 g cas. 56-92-8 Sigma, Germany). Caffeine (made up in HBSS directly, 
sonicate well, c0750-100 g, cas. 58-08-2 Sigma, Germany). Nifedipine (made 
up in H20, kept on ice, N-7634-1g, Sigma, Germany). Nickel chloride (made 
up in H20, light sensitive, N-5756-100g, Sigma, Germany). 2-
Aminoethoxydiphenylborate (2-APB) (made up in DMSO, light sensitive, 100 
mg cas. 524095-8, cat. no. 100065, Calbiochem). Thapsigargin (made up in 
DMSO, light sensitive, T9033-1MG, Sigma, Germany), Cyclopiazonic acid 
(made up in DMSO, C1530, Sigma, Germany). 
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2.t.S.ii Set up of perfusion system for contractile response experiments 
A Scientifica Perfusion Control System CV ersion 1.10.16) was used to 
perfuse varying concentrations of drug though the slices. The system can be set up 
for eight different samples and can be controlled manually or programmed with 
protocol and pump speed using the perfusion LINLAB software for windows XP. 
Method: 
1. The perfusion system was set up with chosen chemicals for each experiment 
(specific protocols are included with each chapter), all perfusion system tubing 
ranged from 0.5 - 1 mm in diameter. Universal tubes containing buffer and 1 or 
10 J.1M acetylcholine/methacholine, used to induce maximum contractile 
response were also attached to the perfusion system. 
2. The slices were prepared for the perfusion system by using a 35mm diameter 
petri dish and creating two parallel lines in the dish with silicone grease (figure 
2.6). A small amount of HBSS buffer was pipetted into the centre of the petri 
dish and the slice (pig/mouse) was floated out into this buffer, the airways were 
located and nylon mesh was placed over the slice allowing a hole over the 
airways. A cover slip was placed over the slice and mesh, to ensure that it 
overlapped the grease and prevented any leaks from buffer. The petri dish was 
placed in position on the microscope stage. 
3. The perfusion system was connected to the stage via in and outlet tubing 
connections. The perfusion system was set to a pump speed of 2 ml/minute prior 
to recording. 
80 
.) perfusion out 
nylon net l £ E E ~ E E i ' '
lung slice _ 
silicone grease 
- - - t t t : t : t ~ ~
perfusion in cu lture petri dish 
cl 
automated perfusion 
system 
Chapter Two: Materials & Methods 
b) 
perfusion out 
'\ 
\ ::== -
~ ~ < J-le.: 1 ,. . ...:, " A' ;-
. 'J '. , ~ ~ . 
L ~ " " " " " "
,. , 
perfusion in 
perfusion out 
petri dish containing 
lung slice 
Figure 2.6 Set up jor lung slice to be attached to the perfusion system. a) The lung 
slice was floated in HBSS buffer and held in place under nylon mesh on a petri dish. 
A coverslip was p laced over the top to create an airtight seal, allowing for drug 
perfusion across the lung slice. b),c) The petri dish was held in place on a stage over 
an inverted microscope, with tubing attachments for a perfusion system to allow flow 
directly into the petri dish, over the lung slice. 
2.1.S.iii Measuring the ainvay contractile response 
To capture images of airway contractions, a laser scanmng confocal 
microscope (Zeiss Axio Observer D 1, Hamatsu electron multiplier CCD camera 
CI9100-13), with a Yokogawa Spinning disk system was used. However, it was only 
used on bright field settings. 
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Method: 
1. Once the airway of interest was located and in focus under the microscope, the 
imaging software 'Volocity' was opened and set to DIC transmitted light and 
caption at 0.5 or 1 time point per second (specified) (figure 2.7). 
2. The perfusion system (PPS perfusion system, Scientifica, LINLAB software) 
which was attached to the microscope stage was set to a pump speed of 2 
mllminute and using manual control, buffer was perfused through the slices. 
3. Using Volocity software, airway recording began with buffer being perfused 
through the slices (to set initial baseline relaxed airway measurement). The 
chemical protocol was then followed after 1 minute of buffer perfusion. 
b) cil ia of epithelial cells 
Figure 2.7 Microscope images of mouse airways showing airway lumen and 
epithelial cells. a) image taken using bright field, 100x magnification, airway lumen 
diameter -100 pm. b) During live imaging beating cilia are visible by eye on the 
epithelial lining, indicating healthy airways, 630x magnification (image taken by 
Michael Sanderson, University of Massachusetts, Worcester, US). 
82 
Chapter Two: Materials & Methods 
2.1.6 Analysis of contractile responses 
2.1.6.i Measurement of airway lumen area using Volocity analysis software 
The Volocity analysis software (PerkinElmer, USA) was used to measure 
airway lwnen area. Volocity can be used for 20, 30 and 40 imaging to identify, 
measure and track biological systems and will accept images from confocal and wide 
field microscopes. Using the measurements tool on the airway video clips, different 
methods of analysis were chosen depending on the shape and light intensity of the 
airway image. The software produces an area value (Jlm2) for every time point (one 
or 0.5 images/second, as stated) taken presented in the form of a spread sheet which 
can be exported into Excel software for further analysis. 
Method: 
1. With the video clip of the slice opened, the measurements tool was opened. 
Airway luminal area was measured initially using the tool for measuring % of 
light intensity and contrast between the lwnen and surrounding tissue, adjusted to 
the appropriate balance required for each slice. Other objects less than or greater 
than a specified size were excluded. Holes in the airway were filled using the 'fill 
holes tool' . 
2. Measurement of all time points gave a list of values for all time points that 
includes airway lwninal area, pixel count of airway lumen measured, perimeter 
and various other parameters. From these lists a method to analyse and discard 
incorrectly measured segments can be chosen. Most of these slices were further 
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analysed using the ' centroid' and 'area' tools and deleting values for objects 
measured other than the lumen (figure 2.8). 
3. Once all values other than those measuring the lumen were discarded, the spread 
sheet of values was exported into excel for further analysis. 
NB: If other images were incorrectly measured at the specified time points required, 
the airways were measured by hand using the region of interest (ROI) free hand tool 
and drawing around the airway lumen. 
d) 
Tools for measuring 
airway luminal area 
using the Volocity 
analysis software 
001/<11 t lO!! 
Figure 2.B. Using Voloeity analysis software to measure airway luminal area. a) 
The initial pig airway image prior to analysis. b) Measurement of the luminal area 
after being perfused with buffer at the beginning of the protocol. c) Measurement of 
luminal area after the airway was perfused with 10 pM ACh (for five minutes). d) 
The airway is shown being measured at the end of the experiment after buffer wash 
out, to the left are options selected to measure the airway image i. e measurement of 
the targeted object by grey contrast intensity and exclusion of unwanted objects by 
size. 
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2.1.6.ii Converting airway lumen area values to a percentage relative to 
maximum contractile response for Chapter Three 
Values measuring the airway luminal area were obtained using the Volocity 
, 
measuring analysis software. These raw values for area were then manipulated in 
Microsoft Excel to show contractile responses relative to either 1 j.1M ACh 
(submaximal concentration, included for testing of store operated calcium channel 
inhibitors) or 10 j.1M ACh representing the maximum contractile response (agonist 
and concentration are stated with results). The overall maximum lumen area 
represented 0% contractile response (to prevent negative values) and the minimum 
area represented 100%: i) raw values for airway luminal area, taken from Volocity 
were filtered to obtain the absolute maximum and minimum area values. These 
values were then used in the equation: (lOO-«(raw area - min. area)/(max. - min. 
area»*lOO» to give % values of maximum contraction. ii) From the new set of 
values generated, data corresponding to the real time values (measured in seconds) 
was measured for ten time points before the addition of the next dose concentration 
and tabulated. For example, the ten values for buffer were taken between 50 and 59 
seconds (real time at one time point/second), before the next drug was perfused 
through the system at 60 seconds. iii) The mean of the ten values for each dose 
concentration were then transported to the graphing software Prism. 
2.1.6.iii Statistics 
The GraphPad Prism (version 5.02) program was used for analysis of all data, 
with tools for biostatistics, curve fitting and graphing. 
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In Chapters Three and Four dose response data were analysed with PRISM 
software Graphpad 5.02 for ECso and ICso using dose response vs. nonnalised 
response for variable slope. The ECso (referring to agonist) or ICso (referring to 
inhibitor) is defined as the concentration of drug that provokes a response halfway 
between the baseline and maximum response. 
In Chapter Three all statistical significance was assessed using One-way 
ANOV A which compares the means of three or more unmatched groups. ANOV A 
measures the likelihood that the difference in means may be caused by chance. 
Dunnett's post test was chosen to individually compare all treatment conditions to 
the control data (either buffer or 1110 J..I.M ACh values). The experiments were 
designed specifically to assess the influence of the chosen drugs within each 
experiment compared to the reference drug. 
In Chapter Four all statistical significance was assessed using the Mann 
Whitney test (unless otherwise stated) for non-parametric distribution, which ranked 
the data and compared medians. Due to having too few data points, this was deemed 
the most conservative method to assess differences in airway contraction in the two 
lung slice groups (control vs. treatment by ovalbumin sensitisation or cytokine 
exposure). With such variation in results between individual mice, particularly in 
immune responses in the transgenic models, it was necessary to rank the results and 
compare between medians for significance (rather than inadvertently increasing the 
significance of the treatments effects by including high outliers that would increase a 
mean). 
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2.2 CELL CULTURE 
All cell culture reagents were obtained from SIGMA (Dorset, UK), unless 
otherwise stated, all cell culture plastics were obtained from Coming life sciences 
from Fisher Scientifica (Loughborough, UK). 
2.2.1.i Isolation of mouse trachea smooth muscle cells, collagenase method 
Tracheas were used for smooth muscle cell culture from BALB/c ovalbumin 
sensitised mice and PBS treated controls and C57BLl6 WT naIve mice; cultures 
were later used to measure differences in calcium signalling between treatment 
groups after ovalbumin sensitisation or cytokine exposure. The following methods 
for isolation of the trachea were taken from previous published methods (HeUi, 
Pertens et al. 2005) and refined by trial and error to optimise timings. 
Materials: 
• Papain (1.5 mg, cat. no. P4762, 100 mg, Sigma, Germany). DTT Collagenase 
(type H) (1.6 mg cat. no. c8051, 100 mg, Sigma, Germany). 
• HEPES solution: per lL of water, NaCl120 mM, KCl6 mM, Glucose 6 mM, 
Hepes 5 mM, MgS04 0.28 mM, CaCh 0.125 mM (all chemicals supplied by 
Sigma, Germany). 
• DMEM (D5796, Sigma-Aldrich, Inc., St Louis, Mo., USA) supplemented 
with foetal calf serum (FCS) (10% (v/v), Penstrep (2.4 mlIl, Penicillin 
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10.000 U/ml + Streptomycin 10.000 ~ g / m l ) ) and Fungizone (4.8 mlll, 
Amphotericin B 250 UG/ml). Distilled H20. 
Method: 
1. The tracheas were collected and placed in HBSS on ice. Using a dissection 
microscope, the tracheas were cleaned free of connective tissue. 
2. The tracheas were individually added into eppendorfs containing 1.5 mg of 
papain in 1 ml ofHEPES solution (prewarmed to 37°C for 30 minutes). 
3. Eppendorfs were centrifuged for 2 minutes at 200 rpm, papain was pipetted off. 
4. Collagenase (lml) was added (1.6 mg collagenase to 1 ml ofHEPES solution, 
prewarmed to 37°C for 30 minutes). Eppendorfs were again centrifuged for two 
minutes at 700 rpm, collagenase was pipetted off. 
5. The digested tracheas were washed with HBSS 5 times by adding 1 ml ofHBSS, 
centrifuging for five minutes at 700 rpm, taking off the HBSS and repeating with 
freshHBSS. 
6. Cells were pipetted up and down gently to loosen the pellet and viewed under a 
microscope to check for elongated airway smooth muscle cells. 
7. Cells were again centrifuged and HBSS was pipetted off, 1 ml ofDMEM was 
added (supplemented with 2 mM glutamine, FCS and Penstrep and Fungizone). 
Cells were then transferred to 25 cm2 cell culture flasks with a total volume of 7 
mls and incubated at 37°C in 5% C02. 
8. Once the cells reached confluent patches, they were dislodged from the flask 
surface by timed trypsinisation (leaving epithelial cells still on the flask) and 
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replated in a new 25 cm2 surface area flask to spread evenly with ASM cells (this 
stage is usually reached after six weeks). 
2.2.1.ii Isolation of mouse trachea smooth muscle cells, explants method 
Tracheas were used from WT BALB/c and C57BLl6 WT naIve mice. 
Although the previous method for isolation of mouse trachea smooth muscle was 
successful in growth of smooth muscle cells, the process took six weeks for a 25 cm2 
flask to reach confluency with a population of 50% epithelial cells surviving 
indefinitely despite the media being ASM specific. Therefore an explant method was 
trialled based on methods from previous publications (Hall, Widdop et al. 1992). The 
explant method produced a faster growing population « three weeks) of 
predominantly smooth muscle (> 70%) initially. However the epithelial cells still 
survived the duration of the CUlturing. This problem was reduced by timed 
trypsinising. In preparation for replating, the smooth muscle was detached from the 
flask surface after three minutes of incubation with porcine trypsin (2 mglml)IEDTA 
(5 mglml) (using 3 mlI25 cm2 flask), as compared to the epithelial cells which took 
five minutes to detach completely. This allowed the separation and collection of 
smooth muscle and epithelial cell populations separately. 
Materials: 
• DMEM (D5796, Sigma-Aldrich, Inc., St Louis, Mo., USA) supplemented 
with foetal calf serum (FCS) (10% (v/v), Penstrep (2.4 ml/l, Penicillin 
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to.OOOU/ml + Streptomycin to.OOO Jlg/ml) and Fungizone (4.8 mlll, 
Amphotericin B 250 UG/ml). 
Method: 
1. Similar to the approach to pig explants (section 2.2.2), all the mouse tracheas 
were dissected at the animal house and brought back to the lab on ice, in HBSS 
buffer (with 2 mM Ca2l. 
2. Under the dissection microscope the tracheas were individually cleaned of 
connective tissue and the oesophagus, in a petri dish with a small amount of 
HBSS. 
3. The tracheas were then transported to a sterile hood and transferred to a pot of 
DMEM supplemented with FCS (10% (v/v)), Penstrep (2.4 mllI, Penicillin 
10.000 U/ml + Streptomycin 10.000 Jlg/ml) and Fungizone (4.8 mllI, 
Amphotericin B 250 UG/ml) to be cleaned. 
4. Tracheas were individually taken from the pot and smeared across the petri dish, 
chopped in half using a scalpel, with the inner side exposed to the surface of the 
dish. After waiting five minutes for the trachea segments to stick down to the 
dish, DMEM was slowly pipetted into the dish, enough to cover the trachea 
segment but not to detach it from the base of the plate. Plates were incubated at 
37°C in 5% C02. 
5. The petri dishes were left undisturbed for five days, media was then changed. 
After five days ASM cells could be seen growing out from all tissue segments. 
6. Media was changed every five days, cells were allowed to grow until confluent 
for RNA extraction or further passaging. 
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b} Figure 2.9 a), b) Mouse 
trachea explants 14 days after 
intial plating. A mixed cell 
population can be seen 
growing out from the tissue. 
2.2.2 Isolation of pig trachea smooth muscle for cells, explant method 
This experiment was carried out in pig as a practice for future isolation of 
ASM from various generations of human airways to be cultured for later calcium 
signalling experiments comparing the response to selected agonists and inhibitors 
with decreasing airway size. 
Materials: 
• DMEM (D5796, Sigma-Aldrich, Inc., St Louis, Mo., USA) supplemented 
with foetal calf serum (FCS) (10% (v/v)), Penstrep (2.4 mlll, Penicillin 
10.000 U/ml + Streptomycin 10.000 )lg/ml) and Fungizone (4.8 mlll, 
Amphotericin B 250 UG/ml). 
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Method: 
1. Trachea and further airways were dissected free of excess connective and lung 
tissue being careful not to cut the airways, the right inferior lobe was chosen for 
lower generation explants. 
2. A segment of trachea (15 cm long) was cut, washed in DMEM with 2x Penstrep 
and Fungizone (PSF), then transferred to the sterile hood for further steps. The 
trachea segment was then cut in half and pinned down on a cork board. 
3. A cut was made down either side of the striated smooth muscle segment, the 
covering membrane was stripped back to reveal pale pink/transparent ASM. 
4. The ASM was picked off using curved scissors, four very small pieces were 
scraped along/dropped into each well of a six well plate until they appeared to 
adhere and dry on the surface (left only for five minutes). DMEM (3 ml) with 
FCS and supplemented Ix PSF was then pipetted very slowly into each well 
being mindful not to detach the ASM bundles from the bottom surface of the 
well. Plates were very carefully moved to the incubator and grown at 37°C in 5% 
CO2• 
5. The bronchial and distal segments were then cut and dissected as above in the 
sterile hood, by stripping back the covering membrane and picking off the ASM. 
6. The plates were left undisturbed for five days at which point the media was 
changed and loose tissue segments aspirated. 
7. Media was changed every five days and cells allowed to grow until confluent. 
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Figure 2.10. Pig trachea and bronchial segment dissection to collect airway 
smooth muscle cells. a) Dissected adult domestic pig lungs and trachea showing 
seven lung lobes. b) Dissection of right inferior lung lobe to show branching airway 
generations: trachea, bronchial segments, distal airways. c) Segment of trachea (15 
cm length), cut in half and striped of membrane on inside of trachea to expose pale 
pink airway smooth muscle bundles (arrow), usedfor explant method. 
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predominantly 
smooth muscle 
populations 
(elongated 
clusters) 
Figure 2.11. Cultured airway smooth muscle cells dissected from pig trachea and 
bronchial segments and grown using the explant method. Images of pig trachea 
ASM taken using a Diaphot 300 microscope at 200x magnification for panel ai), bi) 
taken a week after the tissue segments were plated. The tissue segment was visible, 
epithelial cells were still present; ASM cells were beginning to grow in patches. 
Panel aii), bii) images taken two weeks after the tissue segments were plated, most of 
the epithelial cells had died off and the ASM showed confluent patches. 
2.2.3 Isolation of human airway smooth muscle (HASM) cells 
Bronchial tissue was obtained from patients with no history of asthma 
undergoing surgery for lung cancer, with patient and ethical approval from the 
Nottingham local ethical research committee. All donors used were male and ranged 
in age from 55 - 70. The procedure for isolating the airway smooth muscle was 
performed by previous members of the department, primary airway smooth muscle 
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populations were expanded through culture using previous published methods 
(Daykin, Widdop et al. 1993). Bronchial segments were surgically removed from 
patients and placed in DMEM (without calcium or magnesium) on ice. The smooth 
muscle cells were accessed by removing the surrounding connective tissue and 
epithelial tissue. The smooth muscle was finely chopped with a scalpel and 
incubated with collagenase (2 mglml) for two - three hours at 37°C. Every hour the 
cells were filtered through a 100 Ilm cell strainer, a pellet was collected by 
centrifuging, cells were transferred to a 25 cm2 culture flask. For the first two weeks 
the cells were maintained in DMEM (with 4500 mg glucosel L pyridoxine, HCl and 
NaHC03, SIGMA cat. no. D5671) supplemented with 10% (v/v) FCS and 2 mM 
Glutamine, penicillin (200 U/ml), streptomycin (200 IlgIL) and amphotericin B (0.5 
Ilg/L) at 37°C, 5% CO2• After two weeks penicillin, streptomycin and amphotericin 
were removed from the culture media and cells were left to reach confluency. Cells 
were stored in liquid nitrogen in FCS with 10% (v/v) DMSO until required for 
experiments. 
When taken out of liquid nitrogen the cells were thawed and centrifuged at 
1200 xg for five minutes, using an MSE Mistral 3000i centrifuge (Sanyo 
Gallenkamp, Loughborough, UK) to remove FCS and DMSO, the cells were plated 
in DMEM in 75 cm2 culture flasks. Media was changed every three days, when 
confluent the cells were passaged by removing the media, using 3 ml of prewarmed 
porcine trypsin (2 mglml)/EDTA (5 mglml) to detach the cells from the flask. Cells 
were transferred to a new universal tube in DMEM and centrifuged at 1000 rpm for 
five minutes, the trypsin and media was removed. The cells were then resuspended 
in media and replated in a new 75 cm2 culture flask. Cells were routinely split 1:4 
95 
Chapter Two: Materials & Methods 
and allowed to grow to confluence, then passaged further. Cells between passage two 
and seven were used for experiments. 
2.2.4 Culture of human bronchial epithelial cells (HBEC) 
HBECs were purchased from Bio Whittaker (Cambrex Bioscience, MD, 
USA), taken from donors with no history of lung disease. Cells were cultured in 
bronchial epithelial cell basal medium (BEBM) (Cambrex Bioscience) supplemented 
with human recombinant EGF (0.5 nglml), epinephrine (0.5 nglml) , retinoic acid 
(0.1 nglml), triiodothyronine (6.5 ng/ml), amphotericin (50 nglml), bovine pituitary 
extract (52 J,lglml), hydrocortisone (0.5 J,lg/ml), transferrin (10 J,lg/ml) , insulin (5.0 
J,lg/ml) and gentamicin (50 J,lg/ml). HBECS were maintained at 37°C and 5% C02, 
cells were passaged within 24 hours of being confluent. Soybean trypsin inhibitor 
(0.5 mg/ml) was used to neutralise trypsin when detaching the cells. Cells were 
cultured to passage three and four for experiments. 
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2.3 MOLECULAR BIOLOGY 
2.3.1 RNA extraction from mouse lung slices (pBS and ovalbumin sensitised) 
using Nucieospin RNA XS kit 
RNA was extracted from mouse lung slices from PBS matched and 
ovalbumin sensitised mice after acute (PBS = four mice, OV A = five mice), mid-
chronic (PBS = eight mice, OVA = eight mice) and chronic protocols (PBS = four 
mice, OV A = four mice). RNA extraction from tissue was initially trialled using an 
alternative kit (Qiagen RNeasy mini protocol and Qia-shredder columns), the tissue 
was also passed up and down through a 2 mm needle; these experiments did not 
successfully separate the tissue. After optimisation of timings, a more successful 
approach involved the slices (five slices at 130 Ilm thickness each, per mouse, per 
eppendorf) being initially incubated in collagenase H, to allow break down of 
structures (also using a spatula (0.25 cm diameter»). Total RNA was then isolated 
and purified from the mouse lung slices using the Nucleospin RNA XS kit 
(Macherey-Nagel) following the manufacturers' instructions. The Nucleospin XS kit 
is designed to isolate total RNA from very small samples including micro dissected 
tissue or small amounts of cells. It uses a column design incorporating a funnel 
shaped ring that holds a smaller silica membrane which allows for smaller elution 
volumes. 
97 
Chapter Two: Materials & Methods 
Materials: 
• Nucleospin RNA XS kit (DNAse included) (cat. no. NZ74090250, Fisher, 
UK). Collagenase H (cat. no. C801, Sigma, Germany). Ethanol (96-100% 
(v/v), (Medical School stores cat. no. LH-M0120E). 
• Hank's Balanced Salt Solution (HBSS) (without Ca2+, Mg2+, phenol red, cat. 
no. 14175-095, Gibco). 
Method: 
1- For every individual mouse lung set five lung slices (130 f.1m thick, equivalent of 
1 - 5 mg of tissue) were transferred into 500 f.11 of collagenase H (1.5 mg in 
HBSS) in a 1.5 ml eppendorf tube and incubated at 37°C for five - ten minutes or 
until all the tissue had broken into smaller pieces (occasionally slices were 
pipetted up and down to break tissue). They were centrifuged at 100 rpm for 
seven minutes and collagenase H was pipetted off. 
2- Steps were then followed according to the Nucleospin XS protocol. 200 f.11 of 
Buffer RA1 and 4 f.11 TCEP was added to the tissue sample and pipetted to mix. 
3- Carrier RNA working solution (5 f.11, 20 ng) was added to the lysate and mixed 
by vortexing, then centrifuged. 
4- The Nucleospin filter column was placed in a 2 ml collection tube, the lysate was 
applied to the column and centrifuged for 30 seconds at 11,000 rpm. 
5- The Nucleospin filter column was discarded and 200 f.11 of70% (v/v) ethanol was 
added to the homogenized lysate and mixed by pipetting up and down. 
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6- A nucleospin RNA XS column was placed into a 2 ml collection tube and the 
lysate was loaded, it was centrifuged for 30 seconds at 11,000 rpm. The lysate 
was discarded and transferred to a new collection tube. 
7- Membrane desalting buffer (100 J.lI) was added and centrifuged at 11,000 rpm for 
30 seconds to dry the membrane. 
8- Reconstituted DNase (3 Ill) was added to a 27 J.lI reaction buffer for rDNase for 
each sample. They were mixed by gently flicking the bottom of the tube. 
9- DNase reaction (25 J.lI) mixture was applied directly onto the centre of the silica 
membrane of the column and incubated at room temperature for 15 minutes. 
10-Buffer RA2 (100 J.lI) was added to the Nucleospin RNA XS column. This was 
incubated for two minutes at room temperature then centrifuged for 30 seconds at 
11,000 rpm. The column was placed into a new collection tube. 
11- Buffer RA3 (400 J.lI) was added to the column, then centrifuged for 30 seconds at 
11,000 rpm. 
12- Buffer RA3 (200 J.lI) was added to the column then centrifuged for two minutes 
at 11,000 rpm to dry the membrane. The column was then placed into a nuclease 
free 1.5 ml tube. 
13- The RNA was eluted in 10 J.lI of RNase free H20 by centrifuging at 11,000 rpm 
for one minute. The RNA was stored at -80°C. 
2.3.2 RNA isolation from cultured HASM, HBEC, mouse trachea smooth 
muscle 
Total RNA was isolated and purified from mouse trachea smooth muscle 
cells, human airway smooth muscle cells (HAS M) and human bronchial epithelial 
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cells (HBEC) using the RNeasy mini kit and QIAshredders (Qiagen, Sussex, UK). 
RNeasy kits are designed to isolate total RNA from small quantities of starting 
material. The purified RNA can be used for RT-PCR and cDNA synthesis. With this 
particular procedure, all RNA molecules longer that 200 nucleotides are isolated. 
The manufacturers protocol was followed (RNase free DNase Set cat. no. 79254, 
Qiagen, QIAShredder Homogenisers cat. no. 79654, Qiagen). 
Method: 
1) Unless stated otherwise, cells were harvested from a single confluent T75 flask. 
Once confluent, cells were washed with PBS, a buffer containing guanidine 
thiocyanate and 1 % (v/v) Beta-mecaptoethanol 600 III was added to detach cells 
from the flask surface, they were then scraped from the flask and transferred for 
further homogenisation by passing through a QIAshredder. 
2) The QIAShredder spin column was placed in a 2ml collection tube and the lysate 
was applied (maximum 700 Ill) to column. It was centrifuged for two minutes at 
13,000 rpm. 
3) 70% (v/v) ethanol (600 Ill) was added to the homogenised lysate and mixed by 
pipetting. The lysate was kept for the next steps. 
4) Up to 700 III of the sample was applied to an RNase mini column placed in a 2 
ml collection tube and centrifuged at maximum speed for 15 seconds. The flow 
through was discarded (RNA should be bound to membrane). 
5) Buffer RWl (350 J.lI) was added into the RNeasy column and centrifuged at 
maximum speed for 15 seconds. The flow through was discarded. 
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6) DNase I stock solution (10 f.ll) was added to 70 f.ll of Buffer RDD and mixed 
gently by inverting the tube. 
7) This DNase I incubation mixture (80 f.ll) was added directly onto the RNeasy 
column silica-gel membrane and left at room temperature for 15 minutes. 
8) Buffer RWl (350 f.ll) was added into the column and centrifuged for 15 seconds 
at maximum speed. The flow through was discarded. 
9) The column was transferred to a new 2 ml collection tube. 500 f.ll of Buffer RPE 
was added onto the column, this was centrifuged at maximum speed for 15 
seconds, the flow through was discarded. 
10) Another 500 f.ll of Buffer RPE was added to the RNeasy column, this was 
centrifuged for two minutes at maximum speed to dry the silica-gel membrane, 
the flow through was discarded. The sample was centrifuged again for a further 
one minute at maximum speed. 
11) The column was transferred to a new 1.5 ml microfuge tube. 50 J.lI of RNase-free 
water was added directly onto the membrane. This was centrifuged for one 
minute at 13,000 rpm to elute. 
All RNA samples were quantified usmg a NanoDrop ND 1 00 spectrometer 
(NanoDrop technologies, Rockland, DE, USA), which requires 1 J.lI of RNA for 
analysis. The 260/280 ratio serves as a measure of RNA purity with respect to 
contamination from protein. The 260/230 ratio reflects contamination from reagents 
such as salts. An appropriate value for both ratios is between 1.80 - 2.1. All lung 
slice RNA and cell cultured RNA used for cDNA synthesis had values within the 
appropriate quality control parameters. 
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2.3.3 cDNA synthesis 
RNA (0.6 Ilg) was reversed transcribed to form first strand cDNA using the 
Superscript First Strand Synthesis kit (Invitrogen, Cambridge Bioscience) and 
random hexamers following manufacturers' instructions. Reverse transcriptase 
negative (RT -) samples were prepared as negative controls for genomic 
contamination. Superscript First Strand synthesis System for RT-PCR is used to 
generate first strand cDNA from total or poly(A) + RNA. In conjunction with PCR 
the system can be used to quantitate the amount of specific mRNA from small 
numbers of cells or to clone specific cDNAs. 
Materials: 
Superscript First Strand Synthesis System ofRT-PCR (cat. no. 110904-018, 
Invitrogen, UK). DEPC-treated water (cat. no. 10977-015, Invitrogen, UK). RNA 
samples. 
Method: example method for cDNA synthesis, for mouse trachea smooth muscle 
(TSM) 
1. The final concentration of RNA (600 ng/IlI) was determined using values taken 
from the NanoDrop spectrometer readings. RT - samples were also generated 
(see below). 
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2. Template master mixes were made up: 
Mouse TSM (130 ngllll) Ix (Ill) Ix (Ill) RT-
RT+ 
RNA (DNA free) 5.81 5.81 
Random Hexamers (50 1 
n g / ~ l ) )
10mMdNTP 1 
DEPCwater 2.19 14.19 (to make up 20 ~ l l total 
volume) 
Total 10 20 
3. Template master mixes were incubated at 65°C for five minutes. 
4. The RT master mix was made up. 
RT Master Mix Ix (Ill) 6x master mix (for RT+ only) 
IOx RT Buffer 2 12 
25 mM MgCh 4 24 
0.1 MDTT 2 12 
RNase Out (40 U) 1 6 
Total 9 54 
5. New eppendorfs for each cell set were labelled, 9 ~ l l ofRT master mix and 10 J.l.1 
of template master mix were added. Samples were incubated at 25°C for two 
minutes on a heat block. 
6. Superscript 11 reverse transcriptase (1 J.l.1, 50 U) was added to the RT + samples 
only (20 J.l.1 total). 
7. Samples were incubated at 25°C for ten minutes, 42°C for 50 minutes and 70°C 
for 15 minutes using a PCR block, then chilled on ice for one minute. 
8. Samples were centrifuged briefly and 1 ~ l l of RNAse Hltube (2 U) was added. 
Samples were then incubated at 37°C for 20 minutes. 
9. Finally the samples were diluted in DNase free H20, from the 20 J.d reaction to 
100 J.11 and stored at -80 or -20°C. 
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10. All samples were checked for synthesis or contamination using RI-PCR with 
such housekeeping primers as GAPDH, p-actin or 188 and by further using these 
products for agarose gel electrophoresis to show bands at the predicted size for 
RT+ samples and show RT- samples without bands present. 
2.3.4 Quantitative Taqman® PCR (Q-PCR) in lung tissue from sensitised mice 
Methods for relative quantification of mRNA expression allow comparisons 
of the expression level of a specific target gene between different samples. Q-PCR 
measures PCR amplification as it occurs, as opposed to PCR. 
The Taqman® process measures the fluorescence emitted by a probe specific 
for the target sequence. PCR is performed on a DNA template, which can be single 
or double stranded. The probe is labelled with a 5' reporter and 3' quencher dye 
(with minor groove binder (M), which increases the melting temperature without 
increasing the probe length) and is designed to anneal specifically to a 
complementary sequence between the forward and reverse primer sites during PCR. 
When the probe is intact, the close proximity of the reporter dye to the quencher dye 
results in suppression of the fluorescence emitted by the reporter dye. During PCR 
high temperature is applied to separate the DNA, the temperature is then lowered to 
let the primers anneal to the template, finally the temperature is increased to allow 
the polymerase to extend the primers (Kubista, Andrade et al. 2006; Lind, 8tahlberg 
et al. 2006). During the extension phase the 5' nuclease activity of the Taq DNA 
polymerase cleaves the probe when it is hybridised to the target. Cleavage separates 
the reporter dye from the quencher dye, allowing increased fluorescence by the 
reporter (figure 2.12). The measured fluorescence serves as quantification of 
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expression of the target gene (Afonina, Zivarts et al. 1997; Livak and Schmittgen 
2001). 
a) 
5' ~ ~3' 
3' Figure 2.12 Quantitative peR 
5' process. a) the Taqman® 
5' probe is labelled with a 
reporter dye (R) and a non 
fluorescent quench er (Q) with 
a minor groove binder (M) . 
The probe is designed to 
. <t ~ ~ anneal to the target sequence b) at a site between the forward 5' ~ ~
and reverse primers. When the 
3' probe is intact reporter 5' fluorescence is suppressed. b) 
5' the hot start DNA polymerase 
(P) cleaves the probe 
separating the reporter from 
the quencher, allowing $""\ fluorescence of the reporter. c) 
c) ~ ~ polymerisation of the strand 5' continues to completion. The 
3' level of fluorescence emitted 
5' indicates the amount of target 
III 
• 
5' amplified. 
Materials: 
• 96 well plates, 8 well strips, caps (Stratagene 410088 & 401425 Medical 
School Store, University of Nottingham). Universal PCR Master mix (20x) 
(cat. no. 1275, Applied Biosystems). cDNA of interest. Primers and Probes 
(listed in tables 2.1 and 2.2). Predeveloped Assay Reagents (PDAR) 
(Applied Biosystems). 
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Assays were designed to target murine IL-33 and the corresponding receptors 
ST2 soluble form (ST2s) and ST2 transmembrane form (ST2L) and key interacting 
proteins involved in ASM stored operated calcium entry, Stromal Interaction 
Molecule I (STIMI) and Orail. cDNA samples created used RNA isolated from 
lung slices obtained from mice that had undergone the acute, mid-chronic and 
chronic sensitisation protocol along with matched PBS controls. Samples were 
analysed by quantitative PCR using the Mx300SP real-time thermal cycler 
(Stratagene, La Jolla, California). Expression from each cDNA sample was 
normalised to ~ - a c t i n n expression (used as a house-keeping gene to correct for equal 
cDNA input) using a pre-designed assay (Applied Biosystems, Foster City, 
California), initially 18S was used as a second housekeeping gene to compare 
against ~ - a c t i n n to ensure uniform expression across all samples, both housekeeping 
genes gave similar results. Using Beacon designer 7 (Stratagene) and manual 
alignment between mRNA sequence and full length transcripts, all primer and probe 
assays were designed to span an intron-exon boundary (to eliminate genomic DNA 
contamination). Primers were purchased from Invitrogen. The probes were dual 
labelled with 5' FAM and 3' TAMRA dyes (unless otherwise stated) and were 
purchased from Applied Biosystems, also with the universal master mix and the ~ ~
actin and 18S pre-designed assays (PDAR). Each sample was run in triplicate using 
900 nM forward and reverse primers and 250 nM probe. RT- samples and no 
template controls were analysed also. A standard protocol was used to detect 
amplification consisting of two minutes at 50°C, 10 minutes at 95°C, followed by 40 
cycles of IS seconds at 95°C and 60 seconds at 60°C. The list of primers and probes 
used for comparison of gene expression between PBS matched and ovalbumin 
sensitised acute, mid-chronic, chronic mouse lung tissue is provided (table 2.1). 
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Table 2.1 Primers and probes used for quantification of mRNA between PBS 
matched and ovalbumin sensitised acute, mid-chronic and chronic mouse lung 
tissue. NFQ: Non-fluorescent Quencher, MGB: Minor groove binder, PDAR: pre-
designed assays, bp: base pairs, N A: data not available. All primers (40 nmol) were 
purchased from Invitrogen, all probes (40 nmol) were purchased from Applied 
Biosystems. 
( ,l'lll' I, on\ ani I{l" l'I"l' Pl'uhl' :;' Y \ III plil'oll I '\011" 
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IL-33 CAAGA TGGGA TCrrC FA TA 100bp 2-4 
CCAGG CTCAT CCATC M MR 
TGCTAC GrrCA CACAC A 
TACGC CCATC CGTCG 
AC CCTGA 
ST2s TTAAG ACAAG CCAAG FA TA 101bp 2 - 4 at 
AACTG TGTAG GTTCA M MR 583 -
CAAAG TCACC GGGCA A 683bp 
CTCTCC TTCAT CACAG 
AAG CATC GTCC 
ST2L CATTTA GTCTT CACCA FA TA 77bp 9 - 10 at 
TGGGA CTGCT CGGTG M MR 1391 -
GAGAC ATTCT GCTGC A 1467bp 
CTGTTA GGATA ATCTT 
CC CTGC GCC 
Orail TCTACT ACTTC TCAAA FA TA 85bp 1 - 2 at 
TAAGC CACCA GCTTC M MR 426 -
CGCGC TCGCT CAGCC A 510bp 
CAAG ACCAT GGACC 
G TCGG 
STIMl TGGAC TGTGC CTCCT FA NFQ 138bp 1175 -
ACAGT TCCTT CTCTT M (MG 1312bp 
GCTGTT AGAGT GACTC B) 
TGGG AACGG GC 
TTC 
18S, PDAR HEX NA NA NA 
f3-actin 
Method: example Quantitative peR protocol, using cDNA from OVA sensitised 
mouse lung tissue 
For OVA sensitised samples RT + (1,2,3,4), OVA sensitised RT- and PBS RT + 
(1,2,3,4) cDNA samples (nine samples) from RNA extracted from mouse lung slices 
for quantifying expression ofIL-33, normalised to f3-actin. 
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1. cDNA master mixes were made up 
OVA RT +, PB8 RT xl x3.5 (for triplicate for same gene set) x3 for all 3 
+,OVART- (tJl) gene sets (lL-33, 188, B-actin) 
Template cDNA 1 10.5 
Template H2O 3 
H2O 1.9 51.45 
Universal master mix 10 105 
Total 15.9 166.95 
2. Primer/probe master mixes were made up 
IL-33 xl (Ill) x33 188, B-actin xl(tJl) x33 
Forward primer 1.8 59.4 PDAR 1 33 
Reverse primer 1.8 59.4 H2O 3.1 102 
Probe 0.5 16.5 Total 4.1 135.3 
Total 4.1 135.3 
Reference PDAR requirements (for 20 III 
reaction) 
Template cDNA 4 tJI 
H20 5 III 
Universal master mix 10 tJ1 
PDAR 1 tJI 
3. Primer master mix (4.1 Ill) was added into each tube/well for the corresponding 
gene (IL-33, 188 or ~ - a c t i n ) ) (template controls were included). The cDNA 
master mix (15.9 Ill) was added to the corresponding tube/well (reagentIH20 
controls were included). Plates were centrifuged at 1000 rpm for five minutes. 
4. Using the Taqman® software MxPro- Mx3008P: The plate set up was checked, 
making sure HEX (corresponding to PDAR housekeeping genes) and FAM (for 
IL-33) analysis were selected. The thermal profile for all Q-PCR experiments 
was set (two minutes at 50°C, ten minutes at 95°C, followed by 40 cycles of 15 
seconds at 95°C and 60 seconds at 60°C, see figure 2.13); as recommended by 
manufacturer's instructions. 
S. For analysis using the MxPro software, HEX and F AM were selected, 
amplification plots were shown. To analyse results the ROX reference dye was 
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selected, the fluorescence dye selected was dRN. The Y axis scale was converted 
to log, thresholds were appropriately adjusted, the text report was exported to 
excel for tabulating. 
Thermal Profile 
(Estimated Run Time 01 33 47) 
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Figure 2.13 The thermal 
profile set up for the 
quantitative peR experiments. 
2.3.5 Quantitative Taqman® PCR in HASM, HBEC, HMC-l 
Expression levels of IL-33, ST2 soluble receptor (ST2s) and ST2 
transmembrane receptor (ST2L) mRNA were compared in human mast cell line-l 
(HMC-l), human airway smooth muscle (HAS M) and human bronchial epithelial 
cells (HBEC) using quantitative PCR (Mx300SP real-time thermal cYcler, 
Stratagene, La Jolla, California). Many different housekeeping genes expressed both 
at low and high Ct (threshold cycle) levels were trailed to standardise results. Due to 
relatively uniform expression in all samples and a similar Ct range, for the results 
shown, expression from each cDNA sample was normalised to the house keeping 
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gene HPRT (hypoxanthine-guanine phosphoribosyltransferase) using a pre-designed 
assay (Applied Biosystems, Foster City, California). All results shown are expressed 
as percentages relative to either HMC-l or HBEC expression levels serving as 100% 
expression. Using Beacon designer 7 (8tratagene), all primer and probe assays were 
designed to span an intron-exon boundary (to eliminate genomic DNA 
contamination). Primers were purchased from Invitrogen. The probes were dual 
labelled with 5' FAM and 3' TAMRA dyes and were purchased from Applied 
Biosystems, as was the universal master mix and the GAPDH, HPRT and 188 pre-
designed assays. Each sample was run in triplicate using 900 nM forward and 
reverse primers and 250 nM probe. RT - samples and no template controls were 
analysed in parallel. A standard protocol was used to detect amplification consisting 
of two minutes at 50°C, ten minutes at 95°C, followed by 40 cycles of 15 seconds at 
95°C and 60 seconds at 60°C. The list of primers and probes used for comparison of 
gene expression is provided (table 2.2). 
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Table 2.2. Primers and probes used for quantifICation of mRNA between HMC-l, 
human airway smooth muscle and human bronchial epithelial cells. PDAR: pre-
designed assays, bp: base pairs. N A: data not available. All primers (40 nmol) were 
purchased from Invitrogen, all probes (40 nmol) were purchased from Applied 
Biosystems. 
( .l'Ill· 101''' .Inl Rn l· .... l· Pn.lll' :,' J' \lIIplil'OIl I \ fill " 
hlllll.11l p.-iIlIlT Pl'illll'l' lalll·1 la Ill'! 1:II':.!.l'Inl 
IL-33 TAGGA GATATA CATCT FA TAM 117bp 2 - 3 at 
GAGAA CCAAA GGTAC M RA 197 -
ACCAC GGCAA TCGCT 3 13 bp 
CAAAA AGCACT GCCTG 
GG C TCAAC 
A 
8T2s CAAAC ACATTC TCGTGT FA TAM 148bp 3 - 4 at 
AAAAG GCATAT GTTTGC M RA 492 -
TATTC CCAGTC CTCAG 376bp 
CCACT CTATTG GCCAA 
CAGG CT 
8T2L CCTGG CGTTCT AGGGC FA TAM 145bp 10 - 11 
AGAAG GGATG AACCT M RA at 1547-
ATGTA AGGGC CCTGCT 1691bp 
GTCAC ACAG CGTAG 
TGC GCA 
188, PDAR HEX NA NA NA 
GAPD 
H 
2.3.6 Quantitative Taqman® peR analysis 
2.3.6.i Initial validation of primer sets 
When using the comparative Ct method, it is necessary to ensure that all 
targets and endogenous controls have similar assay efficiencies. Initially standard 
curves were set up to determine the assay efficiency, cDNA known to clearly express 
the target genes were chosen for six cDNA dilutions, decreasing with a two fold 
difference (1, 0.5, 0.25, 0.125, 0.0625, 0.03125). Each concentration was tested in 
triplicate, the mean of the three values were plotted against the -log of the six cDNA 
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concentrations (0, -0.3, -0.6, -0.9, -1.2, -1.5). The linear regression slope value was 
calculated, this value was then used in the equation: (10" (-11 slope value) -1)*100 
to calculate the primer efficiencies. A slope value of -3.3 equates to 100% primer 
efficiency. In these experiments all primer efficiencies were of similar values 
indicating the comparative method could be used for comparison of expression 
levels between genes. 
2.3.6.ii Comparative analysis using MCt 
For each of the three replicates of a sample, the mean cycle time (Ct), mean 
standard deviation and coefficient of variation were calculated. For each sample the 
mean Ct of the gene of interest (GO I) was normalised to the mean of the reference 
gene (rei) (housekeeping gene) for the same sample: ~ C t t = mean et (GOI) - mean 
Ct (rei). After this step a cell sample, or non treatment group was chosen to be the 
control group to which other samples would be compared (the mean values were 
calculated from the ~ C t t values generated for these samples to give ~ C t t control 
values for reference). For example when comparing expression of the GOI in PBS 
and OV A sensitised lung tissue, means were calculated for all the PBS ilCt values, 
this value generated was then used to calculate the ililCt using the equation: MCt = 
~ C t t (sample) - ~ C t t (control mean). Finally the fold difference was calculated 
relative to the control sample using the equation for each sample: fold difference = 
2(-MCt). 
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2.3.6.iii Statistics 
All Q-PCR data in Chapter Five, investigating up regulated gene expression 
in the OVA sensitised lung tissue vs. PBS controls, used the Mann Whitney test for 
analysis of non-parametric distribution, significance was calculated by ranking the 
data points within each group and comparing the medians between the two groups 
using PRISM software Graphpad 5.02. All data was represented as a scatter plot to 
indicate the variation between individual mice within each group, red lines indicate 
medians. 
For all Q-PCR results designed to look for expression of IL-33, ST2s and the 
STL receptor in human airway smooth muscle (HASM), bronchial epithelial cells 
(HBEC) and mast cells (HMC-l), data were compared against a selected cell type 
and represented as percentage expression. 
2.3.7 Affymetrix Microarray data 
For microarray results shown in Chapter Five, all data was obtained from a 
data base generated by Shailandra Singh, TMM (Singh, Billington et al. 2010). 
Studies aimed to create a gene expression profile using HASM low passage, HASM 
high passage and lung fibroblast (MRC5) cells. For data shown, screening was 
performed using Affymetrix oligonucleotide arrays. MRC5 cells were used as the 
reference cell type. Different housekeeping genes were assessed; results indicated 
comparatively little variation in expression between cell types. In preparation for the 
studies, cDNA was synthesised using the GeneChip WT (Whole Transcript) Sense 
Targeting Labeling and Control reagents kit, following manufacturer's instructions 
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(Affymetrix, Santa Clara, CA). The sense cDNA was then fragmented by uracil 
DNA glycosylase (UDG) and apurinic/apyrimidinic endonuclease 1 (APEl) and 
biotin-Iabeled with terminal deoxynucleotidyl transferase (TdT) using the GeneChip 
WT Terminal Labeling Kit (Affymetrix). Hybridization was performed by 
incubation with the Affymetrix GeneChip Human Gene 1.0 ST array; for 28,869 
well-annotated genes with 764,885 distinct probes. The arrays were scanned using 
the GeneChip Scanner 3000 7G (Affymetrix) using GeneChip Operating Software 
(GCOS). The data generated was analysed using GeneSpring (version 9.0; Agilent 
Technologies). The Affymetrix data produced can be accessed online at National 
Center for Biotechnology Information (NCBI) Gene Expression Omnibus using the 
accession reference GSE 18038 (http://www.ncbLn1m.nih.gov/ geo/). 
The results shown in Chapter Five were generated from data obtained by first 
searching for each gene of interest in the full Affymetrix data set to locate a 
corresponding ID reference. ID references for individual genes were then searched in 
the individual data sets for low passage HASM, high passage HASM and lung 
fibroblasts to obtain the corresponding robust multi-array average (RMA) signal 
intensity value. RMA is a normalisation approach which reflects background 
corrected perfect match intensities for each perfect match cell on every GeneChip. 
This is generated by summing an estimated probe affinity with an estimated 
GeneChip-specific log-scale expression value (Bolstad, Irizarry et al. 2003; Irizarry, 
Hobbs et al. 2003; Hochreiter, Clevert et al. 2006). Results shown were expressed as 
a % of the HPRT (housekeeping gene) RMA signal intensity value in low passage 
HASM. 
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3. CHAPTER THREE 
3.1 INTRODUCTION 
To explore the mechanisms involved in airway smooth muscle (ASM) 
contraction and the pathogenesis of the airway hyper-reactivity seen in asthma, 
previous studies have either used lung function tests in vivo or mechanical 
studies performed in large airway preparations ex vivo, discussed in 1.3. To 
explore Ca2+ homeostasis in murine and porcine peripheral airways, this project 
made use of the precision cut lung slice (PCLS) technique; an intact airway 
model that allows real time quantification of contraction. 
The lung slice technique forms the foundation for further experiments 
throughout this thesis. Initially the lung slice technique and pharmacological 
protocols were optimised for mouse to demonstrate the effects of selected agents 
which could potentially alter ASM tone (table 3.1). These experiments provide a 
baseline for interpreting the contractile behaviour of the airways in naIve wild 
type mice and establish the appropriate conditions, concentrations and protocols 
to use; to serve as a template for future experiments in sensitised mouse models. 
The peLS technique was then adapted for pig as a prelude to future human 
studies. The ultimate goal for this project was to apply the lung slice technique 
to human. However, human lung tissue is difficult to acquire and when received 
as surgically removed un-intact lobe segments with many holes, it is difficult to 
inflate. It was therefore necessary to optimise the lung slice technique in a larger 
animal such as pig. 
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In order to explore responses for both mouse and pig distal airways, a range of agents were utilised; the rationale for these is 
shown in table 3.1. 
Table 3.1. Summary of the agents used in this chapter, mechanisms of action known and reasoningfor the conditions selected. ACh: 
acetylcholine; 5-lfI': serotonin; HA: histamine; PI: phosphatidylinositol; PLC-P: phospholipase C; IP3: inositol triphosphate; IP3R: IP3 
receptor; RyR: ryanodine receptor; SERCA pump: sarcoplasmic/endoplasmic reticulum ccl+ -ATPase pump; ROCC: receptor operated 
calcium channel; VOCC: voltage operated calcium channels; SOCC: store operated calcium channels; CP A: cyclopiazonic acid; 2-
APB: 2-Aminoethoxydiphenyl borate; L ~ + : : lanthanum; Ni2+: nickel; TRPC: transient receptor potential canonical. 
Acetylcholine ACh mediates smooth muscle ACh is a common agonist Previously concentration (Mak and Barnes 
(ACh), dose contraction through stimulation causing increased airways dependent contractions have been 1990; Roffel, 
response of the muscarinic M3 receptors resistance, used to study the IP3 demonstrated in mouse tracheal Elzinga et al. 
which activate the pathway. This protocol was smooth muscle preparations and 1990; Bergner 
phospholipase C pathway, designed to establish in the PCLS model by Bergner and Sanderson 
resulting in IP3 release. 1P3 appropriate dose response and Sanderson. 2002; Coulson 
then binds to the SR located ranges in naIve mice. and Fryer 2003; 
IP3R allowing release of Ca2+ Berridge 2007) 
from internal stores, increasing 
cytosolic Ca2+ and leading to 
contraction. 
Serotonin (S-HT), I In many species, excluding 5-HT plays a role in increased Previous studies in mouse (Levitt and 
dose response human, 5-HT constricts airway resistance and has been isolated tracheal segments and Mitzner 1989; 
airways via the 5-HTI receptor implicated in the remodelling PCLS suggest 5-HT induces Barnes 1998; 
and also increases ACh release process in a murine model of airway smooth muscle Eum, Norel et al. 
from airway nerves. In mice asthma (Lima, Souza et al. contraction. 1999; 
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the S-HT induced mechanisms 2007). and Sanderson 
ofbronchoconstriction may 2002; Moffatt, 
depend on the cholinergic Cocks et al. 2004; 
parasympathetic pathway, as 5- Lima, Souza et al. 
HT induced constriction is 2007; Konig, 
blocked by atropine. Krain et al. 2009) 
Histamine (HA), Histamine is synthesised and HA is shown to mediate Bergner and Sanderson previously (Dale and 
dose response released by mast cells in the anaphylactic shock in animal demonstrated that no contractions Laidlaw 1910; 
airway wall and by circulating studies. Inhaled HA causes were induced to HA in mouse Curry 1946; 
basophils. It stimulates PI bronchoconstriction in PCLS. Grandordy and 
hydrolysis and increases the asthmatic subjects. Bames 1987; 
concentration of IP3 in ASM. Barnes 200 I; 
Bergner and 
Sanderson 2002). 
Contraction with 0 CPA is an inhibitor of the This experiment was designed Previous reports in non excitable (Thastrup, Cullen 
mM and 1 mM sarcoendoplasmic reticulum to determine whether SERCA cells show an increase in et al. 1990; Low, 
extracellular Ca1+ Ca2+ ATPase pump (SERCA pump inhibition would lead to [Ca2+Ji.after adding CP A. Gaspar et al. 
pump), which plays a role in a passive outward leak of Ca2+ However, in excitable vascular 1991; Henry, 
maintainin§ and replenishing great enough to stimulate a smooth muscle tissue, addition of 1994; Shima and 
internal Ca + stores depleted contraction. In addition I SERCA pump inhibitors does not Blaustein 1992; 
through agonist stimulation. determined whether prolonged appear to affect tension. It was Henry 1994) 
internal store ci+ deprivation, predicted that airway treatment 
induced by a state of 0 mM 
extracellular Ca2+ in the 
with SERCA pump inhibitors 
might lead to a rise in [Ca2+li, 
presence of a SERCA pump however, this would probably not 
inhibitor, would encourage induce contraction; based on the 
store operated calcium entry hypothesis that in airway smooth 
(SOCC) due to stimulation via muscle, internal Ca2+ store 
internal store sensors. refilling regulation is maintained 
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separately from cytosolic Ca.l+ 
concentrations. 
Caffeine with 0 mM In cells expressing the This protocol was designed to It has previously been shown that (Perez and 
and 2 mM ryanodine receptor (RyR), a demonstrate the role of store agonists can initiate but not Sanderson 2005) 
extracellular Ca2+ concentration of 20 mM refilling and release to induce maintain airway contraction in 
caffeine opens the RyR and maintain airway smooth Ca2+ free conditions. It was 
allowing Ca2+ release, leading muscle contractions. Caffeine predicted that only an initial 
to a transient contraction. was chosen for its ability to transient contraction could be 
Extracellular Ca2+ is required stimulate the RyR. There is induced in a state of 0 mM I 
for internal store refilling and controversy over the role of extracellular Ca2+. 
release to initiate contraction RyR in controlling Ca2+ release 
upon ~ o n i s t t stimulation. in ASM. 
ACh and caffeine in Caffeine (20 mM) opens the To determine the effects of Previous studies in mouse have Previous studies 
o mM extracellular ER located RyR for Ca2+ caffeine on stimulating and shown that a transient contraction in mouse. (Perez 
Ca2+ release, leading to contraction. maintaining contractions in the is induced to ACh in a state of 0 and Sanderson 
ACh targets the pathway presence of physiological and 0 mM Ca2+. In mouse the ability to 2005) 
activating IP3R release of Ca2+ mM extracellular [Ca2i. induce contraction via caffeine in 
from the ER. OmM and 2 mM Ca2+ is variable; 
this raises further questions about 
the ryanodine receptors role. The 
behaviour of the pig airways in 
I 
response to ACh and caffeine in 
the absence of extracellular Ca2+ 
I 
may help to distinguish receptor I 
roles. 
Effects of CP A on CPA inhibits the SERCA This protocol was designed to SERCA pump inhibition should (Thastrup, Cullen 
ACh induced pump, which plays a role in show the effects of SERCA decrease the amount of Ca2+ taken et al. 1990; Low, 
contraction m a i n t a i n i n ~ ~ and replenishing pump inhibition (preventing up to be released for contraction; Gaspar et al. 
internal Ca + stores. store r e f i l l i n ~ ~ on the which was predicted to be 1991; Henry, 
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magnitude and maintenance of displayed as a reduction in 1994; Shima and 
agonist induced contraction. magnitude or ability to sustain Blaustein 1992; 
contraction. Henry 1994) 
Effects of L-type voltage operated To determine whether L-type Previous studies have suggested (Ahmed, Foster et 
Nifedipine on ACh calcium channel (VOCC) VOCCs contribute to that maintenance of contraction is al. 1985; Perez-
induced inhibitor, used in the treatment maintenance of peripheral reliant on SOCC or ROCC based Vizcaino, 
contraetion. of hypertension. airway contraction. on pharmacological tools Tamargo et al. 
targeting these pathways. In 1993; Perez and 
vascular smooth muscle, Sanderson 2005) 
nifedipine has shown no relaxant 
effect on arterioles (perez and 
Sanderson 2005). 
2- Inhibitor of IP3 receptors and To determine the significance 2-APB inhibits both IP3 and (Maruyama, 
Aminoethoxydiphe also SOCC at concentrations of the SOCC and IP3 receptor SOCC mediated increases in Kanaji et al. 
nyl borate (2-APB), greater than 100 J..lM in which communication pathways intracellular Ca2+ concentrations; 1997; Luo, Broad 
inhibitory dose inhibition of SOCC entry required for Ca2+ influx and in theory 2-APB should et al. 2001; 
response through TRPC3, TRPC5,6,7 is release from internal stores to prevent/reduce a sustained Bootman, Collins 
suggested. maintain a contraction. contraction stimulated by an et al. 2002; 
agonist acting on the PLC Trebak, Bird et al. 
pathway. 2002) 
Lanthanum ( L a ~ , , Inhibit Ca.l-t- influx through To determine the significance The selectivity of these drugs is (Morganand 
Nickel (Ni2l, SOCC. Lanthanides such as of the SOCC channels in Ca2+ not clearly known. In theory a Jacob 1994; 
inhibitory dose La3+ and gadolinium (Gd3+) are influx required to maintain reduction in contraction should be Zamponi, 
response used in the characterisation of contraction. seen after stimulation though the Bourinet et al. 
TRPCs. They block TRPCs cholinergic pathway. 1996; Lee, 
1,3,6 in the 100 J..lM range. Gomora et al. 
La3+ is shown to potentiate and 1999; Schaefer, 
also inhibit TRPC4 and 5, with Plant et al. 2000; 
potentiation occurring in the Luo, Broad et al. 
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10-100 J.1M range. 2001; Putney 
2001; Trebak, 
Ni2+ is a Ca2+ channel binding Bird et al. 2002; 
inhibitor. Only one mammalian Jung, Muhle et al. 
T -type Ca2+ channel, Cay3.2 is 2003; Dietrich, 
strongly inhibited by Ni2+. Ni2+ Mederos y 
works in part by occlusion of Schnitzler et al. 
the pore and is also shown to 2005) 
bind to a site on the 
extracellular side of the 
channel, affecting current 
through the channel 
allosterically, demonstrated in 
neuronal Ca2+ channels. 
Icrac inhibitors: Mechanism of action unknown, Inhibition of Cal + influx Studies focus on the use of Icrac (Feske, Gwack et 
JS (GSK1349571A) compounds were acquired for through this channel in inhibitors in T cells and the al. 2006; 
N117 (N11764-14- testing from GlaxoSmithKline. physiological and SOCC immune response. Using JS Prakriya, Feske et 
1), Activation of the Ca2+ release induced conditions should ((GSK1349571A) also referred to al. 2006; 
inhibitory dose activated Ca2+ channel (CRAC) highlight the importance of as Synta 66) inhibition of CRAC Yeromin, Zhang 
response, current is initiated by STIM SOCC in maintaining channel function decreased the T et al. 2006; Di 
effects of Icrac proteins, which sense ER contraction. cell response in lamina propria Sabatino, 
inhibition in SOCC [Ca2i and upon store mononuclear cells of Rovedatti et al. 
favoured conditions depletion, relocalise to fonn inflammatory bowel disease 2009) 
puncta closely associating with patients. aSK has previously 
the plasma membrane pore reported inhibition of OVA-
fonning channel subunit of the induced contractions of rat trachea 
CRAC channel, Orai. and allergen evoked contractions 
of human bronchus (through mast 
cell degranulation). No studies 
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have been cited for the effects of 1 
these Icrae inhibitors on skeletal i 
or smooth muscle tone. , 
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3.1.1 AIMS 
The aim of the work described in this chapter was to establish a precision cut 
lung slice model for mouse and pig to provide a platform for investigating agents 
that alter smooth muscle tone and the signalling pathways that mediate contraction. 
The rationale for studying specific agents is shown in table 3.1. 
3.2 METHODS 
Detailed methods for the preparation of the lung slices for mouse and pig, use 
of an oscillating tissue slicer, measuring contractile response, staining of slices and 
statistical analysis used are provided in section 2.1 and form the foundation for most 
experiments throughout this thesis. A range of different chemical perfusion protocols 
were used for the experiments in this chapter and are shown with the corresponding 
airway contraction results throughout the chapter. All chemicals were perfused at a 
constant flow rate (2 ml/minute) over the lung slice during real time video image 
capturing of the airway contraction. 
3.2.1 Statistical analysis 
All data shown in this chapter for airway contraction experiments are derived 
from the raw values measured for individual airway lumen area (fJ.m2) and 
manipulated to show percentages relative to the maximum contraction induced by 
ACh (either 1 or 10 fJ.M) and the initial relaxed airway measurements (baseline) (see 
2.1.5). For all results shown, at least three airways from three WT C57BLl6 mice 
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and three airways from three WT domesticated pigs were used. Dose response 
experiments were analysed with PRISM software Graphpad 5.02 using analysis tools 
for dose response for the log of the agonist against the response for variable data; 
ECso and ICso measurements with confidence intervals (Cl) are provided, error bars 
indicate standard deviation (SD). The ECso (referring to agonist) or IC50 (referring to 
inhibitor) is defmed as the concentration of drug that provokes a response halfway 
between the baseline and maximum response. This measure helped me to determine 
the concentration range and potency of the drugs investigated. All other data are 
shown as scatter plots; each dot represents an individual mouse or pig airway. Blue 
lines indicate the mean value within each group. For these studies all slices came 
from naive WT lung tissue and the same slice was exposed to each condition 
throughout the protocol. Therefore, data in this chapter were analysed using one-way 
ANOVA followed by the Dunnett's post test comparing means within treatment 
(drug) groups to the mean of the control (buffer) group. The underlying mathematics 
is the same for aT-test however, designed for three or more treatment groups. 
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3.3 RESULTS 
Approximately 300 slices were obtained from each set of mouse lungs for 
experiments. Slices used for mouse contractile experiments were 130 ~ m m thick, 
slices used for haematoxylin and eosin (H & E) staining were 20 ~ m m thick. For each 
segment of pig lung tissue inflated (average lung segment volume of 35 mls), 300 
slices were cut. Pig slices used for contractile experiments had a thickness of 140 -
170 ~ m , , slices used for H & E staining were 75 ~ m m thick. Only distal airways were 
used for experiments (airway diameter 100 - 300 ~ m ) . . For contractile experiments 
airways with beating cilia and a lumen free from agarose were chosen. An initial test 
contraction with 1 0 ~ m m ACh was performed to ensure airways were capable of 
generating a contractile response; only airways with a reduction in lumen area of> 
25% were used for the studies. Leaving each drug condition perfusing for five 
minutes minimum was enough time to allow the airway to react accordingly (relax or 
contract) before changing the conditions or altering the concentration for the next 
step of the protocol. -90% of the maximum contraction to ACh was achieved within 
four minutes ofperfusion, however, further contraction was observed with prolonged 
agonist stimulation (as shown in figure 3.2). Due to protocol time constraints, to 
obtain 'maximum airway contraction measurements'; airways were perfused with 
ACh for five minutes and values for contraction level were taken at the end of this 
period. For store operated ci+ inhibitor airway relaxation experiments (section 
3.3.6), ACh was present initially to contract the airway and maintained for 35 
minutes. Even in the presence of the inhibitors the degree of contraction often 
increased beyond that measured in the first five minutes of exposure to ACh. Airway 
behaviour showing further contraction or failure to relax to base line levels was also 
seen (see section 3.3.4) for airways exposed to abnormal extracellular Ca2+ 
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conditions. Previous experiments indicated that airway relaxation in mouse and pig 
was achieved within five - seven minutes of perfusion with wash buffer. After 
contraction to a maximum concentration of agonist, 90% of airways relaxed 
(indicated by a plateau after relaxation movement). Therefore in all experiments a 
ten minute wash buffer perfusion phase was used to allow airway relaxation. The 
slices were kept in media supplemented with glutamine, penicillin and streptomycin, 
the media was changed after four days (see section 2.1). Airways still produced a 
contractile response on the sixth day; however, the airways did not maintain their 
contractile response and showed 'twitching' making airway tracings difficult to 
interpret. In view of this, for the experiments performed in this thesis, slices were 
used one - three days after preparation. In some airways variability in degree of 
contraction, relaxation or baseline drift occurred (reflected in results). 
3.3.1 Images of mouse and pig airways 
Mouse airways chosen for experiments were circular in shape (elongated 
airway shapes were avoided). Images captured in real time required either 100x or 
200x magnification, for airways of 100 - ISO J.Ull in diameter. Mouse airway lumen 
areas ranged from 16,000 J.LIIl2 to 100,000 J.Ull2• Pig peripheral airway structure 
differs anatomically from mouse (discussed in section 3.4.1), airways are circular or 
weblike in shape. Airways chosen for analysis in pig had a diameter of 100 - 150 J.Ull 
and initial airway lumen areas ranging from 10,000 J.Ull2 to 100,000 J.IlD2. 
126 
Chapter Three: Characterisation of the lung slice model 
ai) aii ) Figure 3.1 Mouse and pig 
peripheral airways, bright 
field and H &E images. L: 
airway lumen; B: blood 
vessel; E: epithelium; A: 
alveolus. 
ai) Representative 
image of a WT C57BU6 
mouse airway slice of 130 
jJM thickness at 100x 
magnification with a 
diameter of ~ ~100 jJm; 
beating cilia were visible 
by eye on the epithelial 
lining during live imaging. 
bi) bii) aU) Representative image 
for H & E staining of a WT 
C57BLI6 mouse lung slice 
of 20 jJM thickness taken 
at 200x magnification. 
bi) Representative 
image of a pig airway slice 
of 140 jJM thickness, at 
100x magnification with a 
diameter of ~ ~100 jJm, 
beating cilia were visible 
on the epithelial lining 
during live imaging. bii) Representative image for H & E staining of a pig 
peripheral airway slice at 75 jJM thickness, taken at 100x magnification. 
3.3.2 Differences in mouse and pig contractile response to acetylcholine, 
serotonin and histamine 
For the following results shown, PCLS were used from at least three 
C57BLl6 WT mice and three domestic pigs to examine contractile responses. For 
each airway, experiments were preformed to assess contractile responses to ACh (10 
1lM) prior to further studies. The following graph (figure 3.2) shows that the airway 
contraction is maintained with stimulation of ACh over a prolonged period of time 
(20 minutes) before buffer wash out to relaxed state (results consistent in both mouse 
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(n = ten) and pig (n = ten) data not shown). This indicates a prolonged state of 
contraction can be maintained with agonist stimulation present. 
_ 40000 
N 
~ ~ 35000 
'" ~ ~ 30000 
'" ~ ~ 25000 
E 
~ ~ 20000 
ia' ~ ~ 15000 
< 10000 
5000 
Contraction maintained to 101-1 MACh 
Figure 3.2 ACh 
induced contraction is 
maintained until wash out. 
Example of an original 
airway tracing 
(representative of n = ten 
airways, ten C57BV6 
mice), the contraction is 
induced (88.0% contraction 
compared to relaxed airway 
at buffer per fusion) and 
bufferW8sh maintained by ACh for 20 
~ ~ " " ": ; ; - ; ; - : ; ;- ; ;- : ; ;- ; ; ; -:;; -;;- :;;- ;;- :;;- ;; -:;; - ; ; - : ; ; - ~I i i- : ; ;- -- O O-:;; -s-:;;- ;;- :;;i.;;- :;: - ; ; - : ; ; - s - ~ ~ minut es. The airway only 
__ ~ ~ M M ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
partially relaxed after ten Time (seconds) 
minutes of perfusion with 
agonist .free buffer wash. This experiment shows an initial maximum contraction 
followed by a sustained phase which requires extracellular ccl+ to maintain the 
airway contraction; as demonstrated throughout this chapter. 
The following agonist dose response protocols for acetylcholine (ACh), 
serotonin (S-HT) and histamine (HA) were designed to rank agonist potency and 
provide a comparison for distal airway behaviour between mouse and pig. Results 
are compared to published data using different techniques and species. Differences in 
airway behaviour between airway generations of the same species were also 
considered. For the following experiments all buffers and agonists contained 2 mM 
(physiological) extracellular Ca2+. Individual lung slices were perfused with buffer 
for one minute (image capture of relaxed airway), followed by five minute intervals 
of increasing concentrations of the agonist (maximum concentration 1 00 ~ M ) . . A 
[mal ten minute wash relaxed the airway. In 5-HT and HA protoco\s, 10 \lM ACh 
perfusion was included for comparison of magnitude of contraction. Perfusion 
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system timings are shown below (table 3.2). A representative example of an 
individual airway contraction tracing throughout the experiment is shown for each 
agonist, followed by graphed data (three airways from three mice, or three airways 
from three pigs, figures: 3.3,3.4,3.5,3.6,3.7,3.8). 
Table 3.2. Airway agonist dose response perfusion timings for buffer and increasing 
agonist concentrations until relaxation of the airway with wash buffer. 
Time 
(minutes) 
o 
1 
6 
11 
16 
21 
26 
31 
36 
46 
Contractile agonist dose response (in 2 mM Ca2l 
Acetylcholine Serotonin Histamine 
(ACh) (5-HT) (HA) 
2 mM Ca2+ buffer 2 mM Ca2+ buffer 2 mM Ca2+ buffer 
0.0001 ~ M M 0.001 ~ M M 0.001 ~ M M
0.001 ~ M M 0.01 ~ M M 0.01 ~ M M
0.01 ~ M M 0.1 ~ M M 0.1 ~ M M
O.l ~ M M 1 ~ M M 1 ~ M M
I ~ M M 1 0 ~ M M 1 0 ~ M M
10 f.lM 100 f.lM 100 f.lM 
2 mM Ca2+ buffer 10 f.lM ACh 10 f.lM ACh 
wash 
end point (41 
minutes) 
2 mM Ca2+ buffer 
wash 
end point 
2 mM Ca2+ buffer 
wash 
end point 
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a) 5-HT dose response 
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Figure 3.3a 5-HT induces a concentration dependent contraction in mouse 
peripheral airways. a) an example of an airway lumen area tracing for contractile 
responses to 5-HT (10.9-10.4 M) from a 130 pm thick C57BLI6 mouse lung slice 
(representative of n = three airways from three mice). The arrows shown on the 
graph correspond to the images of the airways in panel b). The maximum 
contraction induced to 5-HT 100 pM is 68.8% of the contraction induced by A Ch. 
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Figure 3.3b 5-HT induces 
a concentration dependent 
contraction in mouse 
peripheral airways. 
Concentration dependent 
contractions to 5-HT in 
C57BLI6 mouse lung slices 
(10.9-10.4 M), (EC50 = 1.1 
pM, Cl = 289.7 nM - 3.8 
pM). The mean maximum 
response to 5-HT (10 pM) 
was 77.9 + 13%, of the 
response to 10 pM ACh 
(100%). At concentrations 
of 5-HT > 10 pM a reduction in the degree of contraction was observed. Each data 
point represents the mean value for n = three mice, one airway each. Error bars 
indicate SD of values. EC50 values were calculated in PRISM Graphpad 5.02 using 
log of agonist vs. response for variable slope (for 10gM concentrations from -9 to -
5). 
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5-HT dose response 
10J,lM 100pM 
5HT 
buffer wash 
o ~ ~____ ~ ~__ ~ ~__ ~ ~ ~__ ~ ~__ ~ ~____ ~ ~ ~ ~ ~______ __ 
lime (seconds) 
Figure 3.4 5-HT does not induce contraction in pig peripheral airways. An airway 
lumen area tracing in pig peripheral airways showing no contractile response to 5-
HT (representative of n = three, three pigs). A control response is shown to 10 pM 
A Ch. 
As 5-HT failed to elicit a response in pig airways, mean results for n = three 
airways have been omitted. 
HA dose response 
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Figure 3.5 HA does not induce a contractile response in mouse peripheral 
airways. An example of an airway lumen area tracing in a C57BV6 mouse lung slice 
(130 pm thick, representative of n = three, three mice) showing no contractile 
response to HA; a control response to 10 pM ACh is shown. 
As HA failed to induce a contractile response in mouse airways, mean results 
have been omitted. 
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HA dose response 
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Figure 3.6a HA induces a concentration dependent contraction in pig peripheral 
airways. An example of an airway lumen area tracing for contractile responses to 
HA (10-9 - 10-4 M) in a 170 pm thick lung slice (representative of n = three airways, 
three pigs). In some tracings relaxation was observed after initial contraction to a 
set concentration (shown on the graph at 10 pM and 100 pM HA) . 
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Figure 3.6b HA induces a 
concentration dependent 
contraction in pig 
peripheral airways. 
Concentration dependent 
contractions were observed 
(10-9 - 10-4 M) (EC5o = 2.2 
pM (Cl = 230.2 nM - 21.7 
pM). The maximum mean 
contractile response to HA 
was 80.3% + 29.5% 
-a ·7 ~ ~ ~ ~ -4 induced by 100 pM HA in 
log[HA]M comparison to 10 pM ACh 
(100% contraction). Each data point represents the mean value for n = three 
airways, three pigs. Error bars indicate SD. EC50 values were calculated in PRISM 
Graphpad 5.02 using log of agonist vs. response for variable slope. 
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ACh dose response 
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Figure 3.7a ACh induces concentration dependent contractions in mouse 
periftheral airways. A representative tracing of an ACh induced contractile response 
(10- o_1(J5 M) in a WT C57BU6 mouse lung slice (representative of n = three 
airways, three mice). 
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Figure 3. 7b ACh induces 
concentration dependent 
contractions in mouse 
peripheral airways. 
Concentration dependent 
contractions were 
observed in C57BV6 
mouse lung slice airways 
(10-JO_1ff5 M), (EC5o = 
106.9 nM, Cl = 87.7 nM 
- 130.3 nM). Each data 
point represents the mean 
value for n = three mice, 
one airway each. Error 
bars indicate SD. EC50 values were calculated in PRISM Graphpad 5.02 using log of 
agonist vs. response for variable slope. 
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ACh dose response 
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Figure 3.8a ACh induces concentration dependent contraction in pig peripheral 
airways. A representative tracing of an ACh (10-10_10-5 M) contractile response in a 
pig lung slice peripheral airway (n = three, three pigs). 
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Figure 3.8b ACh induces 
concentration dependent 
contraction in pig 
peripheral airways. 
Concentration dependent 
contractions were 
observed to ACh in pig 
lung slices (10- /0_10-5 M). 
EC50 = 112.5 nM (Cl = 
59.7 nM - 211.9 nM). 
Each data point 
represents the mean 
value for n = three 
airways, three pigs. 
Error bars indicate SD of 
values. EC50 values were calculated in PRISM Graphpad 5.02 using log of agonist 
vs. response for variable slope. The graph does not initially start at 0% contraction, 
due to airway relaxation. 
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3.3.3. Significance of extracellular Ca2+ and store released Ca2+ in initiating and 
maintaining a contraction 
The following experiments were designed to explore the requirement of 
extracellular ci+ for i) intracellular store refilling and ii) the direct role of store 
released Ca2+ for further contraction induction and maintenance. Initial experiments 
were performed under unstimulated (i.e. no agonist) conditions to investigate the 
effect of changing from 2 mM (physiological) extracellular Ca2+ to 0 mM 
extracellular Ca2+ (figure 3.3.3.0). As can be seen, neither the change to 0 mM Ca2+ 
nor return to 2 mM Ca2+ altered airway calibre (also performed in pig, n = three, 
results not shown). 
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Figure 3.9 No 
contraction is 
induced with the 
readdition of C';+. 
Airway tracing in a 
130 pm thick, 
C57BU6 mouse lung 
slice (representative 
of n = three, three 
mice) showing initial 
perfusion with 2 mM 
Ct/+ buffer followed 
by 0 mM Ct/+ buffer. 
No alteration in calibre of the airway was induced by reintroducing extracellular 
ctl+ (2 mM) after perfusion with 0 mM ctl+ buffer. 
Having demonstrated that altering extracellular Ca2+ by itself does not alter 
airway calibre in PCLS, I next explored the effect of depleting the intracellular Ca2+ 
store by the use of the SERCA inhibitor cyclopiazonic acid (CPA) in the presence of 
o mM extracellular Ca2+. Prior to experiments the slices were kept in 2 mM Ca2+ 
buffer. The perfusion protocol (table 3.3) involved initial perfusion of 0 mM Ca2+ 
followed by CPA (to prevent Ca2+ SERCA pump uptake into SR stores), in addition 
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passive outward leak of Ca2+ from internal stores should be occurring at this time. 
This store depletion should trigger SOCC for Ca2+ entry. At eight minutes 2 mM 
Ca2+ was perfused, to determine whether a contraction would be seen at this point 
due to activated SOCC and replenish of internal stores for Ca2+ release. CP A in 2 
mM Ca2+ was perfused to show that with physiological extracellular Ca2+ conditions 
(2 mM) SERCA pump inhibition does not lead to a contraction. This was followed 
by a control contraction to 10 IlM ACh for analysis comparison and fmally a wash 
with buffer. A corresponding representative airway contraction tracing and collective 
results for mouse (three airways from three mice) and pig (six airways from three 
pigs) are shown (figures: 3.10,3.11). 
Table 3.3 Perfusion timings designed to show the influence of altering extracellular 
CtJ+ concentrations on indUCing SOCC entry and SR release for airway contraction 
(described above in text). 
CP A with 0 mM and 2 mM extracellular Ca2+ 
Time 
(minutes) 
o 
3 
8 
13 
18 
23 
28 
38 
Perfusion 
o mM Ca2+ buffer 
10 J.1M CP A, 0 mM Ca2+ 
2mMCa2+ 
10 J.1M CP A, 2 mM Ca2+ 
2mMCa2+ 
10 J.1M ACh 
2 mM Ca2+ buffer wash 
end point 
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CPA with OmM and 2mM extracellular Ca2+ 
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Figure 3.10a 0 mM cti+ and SERCA pump inhibition induce SOCC for 
contraction in mouse peripheral airways. Example of an airway tracing in a 130 
pm thick, C57BU6 mouse lung slice (representative of n = three airways, three 
mice) showing initial perfusion with 0 mM cel+ buffer, then addition of 1 0 pM CPA, 
followed by 2 mM ceI+ buffer then 10 pM CPA in 2 mM cel+. A control contraction 
is shown to ACh prior to buffer wash out. A small airway contraction is observed 
following cel+ readdition. In contrast, following CP A exposure in 2 mM cel+, 2 mM 
extracellular cel+ alone failed to elicit a response. 
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Figure 3.106 0 mM cti+ and SERCA pump inhibition induce SOCC for 
contraction in mouse peripheral airways. Contractile responses in WT C57BU6 
mouse lung slice airways (n = three mice), normalised to 0 mM cel+ buffer alone as 
relaxed and 10 pM ACh in 2 mM cel+ as 100% contracted. Data is analysed using 
one-way ANOVA followed by the Dunnett's post test comparing all means to 0 mM 
ell+ buffer values, ••• p < 0.001, • P = 0.01 - 0.05. Individual dots represent 1 
airway from an individual mouse, blue lines indicate means. Although a small 
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contraction was seen with the introduction of CPA in 0 mM Ca2+ (mean = 14.2% 
contraction) this was not significant in comparison 10 0 mM Ca2+ values (mean = 0) . 
The addition of 2 mM Ca2+ significantly reduced airway lumen area (p = 0.01 - 0.05, 
mean = 24.8% contraction). A significant airway contraction was seen to 10 f-JM 
A Ch in 2 mM cd+ as indicated, p < 0.001. 
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Figure 3.11a 0 mM Ctl+ and SERCA pump inhibition for SOCC activation does 
not induce significant contraction in pig peripheral airways. Example of an airway 
tracing in a 170 f-Jm thick pig lung slice (representative of n = six airways, three 
pigs) showing initial perfusion with 0 mM cd+ buffer, then addition of 1 0 f-JM CP A, 
followed by 2 mM cd+ buffer (a very small contraction was seen) then 10 f-JM CP A 
in 2 mM cd+. A control contraction is shown to ACh prior to buffer wash out. 
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CPA with OmM and 2mM Ca2+ 
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Figure 3.11 b 0 mM ctl+ and SERCA pump inhibition for SOCC activation does 
not induce significant contraction in pig peripheral airways. Contractile responses 
in pig lung slice airways (n = six airways, three pigs), normalised to 0 mM cQ1+ 
buffer alone as relaxed and 10 pM ACh in 2 mM Cif+ as 100% contracted. Data is 
analysed using one-way ANOVA followed by the Dunnett's post test comparing all 
means to 0 mMCQ1+ buffer values, *** p < 0.001, * p = 0.01 - 0.05. Individual dots 
represent 1 airway from an individual mouse, blue lines indicate means. Little or no 
contraction was seen with the introduction of CP A in 0 mM cQ1+ and the addition of 
2 mM cQ1+ (mean = 10.2% contraction), this was not significant in comparison to 0 
mM cQ1+ values. A significant airway contraction was seen to 10 pM ACh in 2 mM 
cQ1+ as indicated, p < 0.001. 
Results show that using the same protocol the readdition of 2 mM Ca2+ 
produced a significant contraction in mouse; this contraction was not significant in 
pig. Although there were small sample sizes, these results hint at differences between 
mouse and pig in sensitivity to CP A, or SR store regulation required for release of 
Ca2+ for contraction. 
In ASM contraction involves agonist induced mobilisation of Ca2+ from the 
SR. This process occurs through a GPCR receptor-mediated pathway that frees 
inositol-l,4,5-trisphosphate (IP3) which in turn acts on the IP3 receptor located on the 
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SR to release Ca2+ leading to downstream contraction of the smooth muscle 
(discussed in detail in section 1.2) (Berridge 1993; Flynn, Bradley et al. 2001; 
Dietrich, Chubanov et al. 2006). Another SR located Ca2+ channel is the ryanodine 
receptor (RyR). Cyclic adenosine diphosphate ribose (cAD PR) is suggested to be the 
endogenous ligand (Tazzeo, Zhang et al. 2008; FIynn, 2001). The role of the RyR in 
ASM remains unclear, although indicates involvement in regulating [Ca2+]i within 
the cytolsolic space between the plasmalemma and the SR (Tazzeo, Zhang et al. 
2008). 
The next experiment was designed to investigate if internal Ca2+ store 
refilling for Ca2+ release is required to induce airway contractions. Caffeine was used 
to deplete the internal stores by opening (at a concentration of 20 mM) of the 
ryanodine receptor. Perfusion timings were designed to show airway contractions 
intermittently induced by caffeine in conditions of 0 mM and 2 mM extracellular 
Ca2+ (see table 3.4). Representative airway contraction tracings throughout the 
protocol are shown for mouse and pig (figure 3.12 and 3.13). 
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Table 3.4 Perfusion system timings designed to show that extracellular CtJ+ is 
required for internal CtJ+ store release (using caffeine stimulated ryanodine 
receptor release); to induce airway smooth muscle contraction. 
Caffeine with 0 mM and 2 mM extracellular Ca1+ 
Time Perfusion 
(minutes) 
o 
3 
6 
9 
12 
15 
18 
24 
27 
30 
33 
36 
39 
44 
49 
59 
o mM Ca2+ buffer 
20 mM caffeine, 0 mM Ca2+ 
OmMCa2+ 
20 mM caffeine, 0 mM Ca2+ 
OmMCa2+ 
20 mM caffeine, 0 mM Ca2+ 
2mMCa2+ 
20 mM caffeine, 2 mM Ca2+ 
2mMCa2+ 
20 mM caffeine, 2 mM Ca2+ 
2mMCa2+ 
20 mM caffeine, 2 mM Ca2+ 
2mMCa2+ 
10 IlM ACh 
2 mM Ca2+ buffer wash 
end point 
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Caffeine with OmM and 2mM extracellular Ca2+ 
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Figure 3.12 Extracellular Ca2+ is required/or internal 01+ store release to induce 
airway smooth muscle contraction in mouse peripheral airways. Airway tracing in 
a 130 pm thick, C57BU6 WT mouse lung slice (representative of n = four mice). 
After perfusion with 0 mM ccl+ buffer, an initial transient contraction was seen to 
20 mM caffeine, no other contractions were seen with further perfusion of 20 mM 
caffeine in 0 mM ccl+ buffer. The slice was then washed with 2 mM Ca2+, ccl+ 
stores were replenished with intermittent perfusion of 2 mM ccl+ buffer between 
transient contractions induced by 20 mM caffeine. A maximum contractile response 
maintained to 10 pM ACh was shown prior to final wash out in 2 mM ccl+, 
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Caffeine with OmM and 2mM extracellular Ca2+ 
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Figure 3.13 Extracellular Ca l + is required for internal C ~ + + store release to 
induce airway smooth muscle contraction in pig peripheral airways. Original 
airway tracing in a 170 pm thick, pig lung slice (representative of n = four airways, 
two p igs). After perfusion with 0 mM Ca2+ buffer, an initial transient contraction 
was seen to 20 mM caffe ine, no other contractions were seen to further perfusion 
with 20 mM caffeine in 0 mM Cal + buffer. The slice was then washed with 2 mM 
cif+, Ca2+ stores were replenished with intermittent perfusion of 2 mM Ca2+ buffer 
between transient contractions induced by 20 mM caffeine. A maximum contractile 
response maintained to 1 I'M ACh was shown prior to final wash out in 2 mM Cal +. 
In both mouse and pig, following the initial challenge with caffeine in 0 mM 
Ca2+ buffer a small contraction was induced. However, in the absence of 
extracellular Ca2+ further challenge with caffeine failed to induce additional 
contractions. When this experiment was repeated in the presence of extracellular 
Ca2+ at physiological levels, repeated contractions to caffeine could be induced. 
Having demonstrated that store replenish and release is required for ASM 
contraction (figure 3.12, 3.13); I next explored the roles of the sarcoplasmic 
reticulum (SR) located IP3R and RyR in Ca2+ release for initiating contraction and 
regulating [Ca2+] and also, whether separate Ca2+ sub-stores supplied these channels. 
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These studies were performed using pig lung slices only due to tissue availability at 
the time. Prior to experiments all lung slices were kept in 2 mM extracellular Ca2+. 
The protocols involved initial perfusion with 0 mM Ca2+ (with 1 mM EGTA, a 
chelator preferential for Ca2) any Ca2+ already in the internal stores was then 
released by activation of either the IP3R (through stimulation with ACh) or RyR 
(through stimulation with 20 mM caffeine). The lung slice was further perfused with 
o mM Ca2+ followed by stimulation of the alternative SR located channel. The slice 
was then further perfused with 0 mM Ca2+. Finally, 2 mM Ca2+ was reintroduced for 
ten minutes (to measure any contraction induced due to SOCC activation from 
prolonged store depletion of Ca2+ and sudden influx of reinstated Ca2). The logic 
being that if the IP3R is directly involved in contraction then after initial depletion of 
internal stores through the RyR pathway, ACh would not be able to induce further 
contraction (as shown in figure 3.14) (although this assumes a common Ca2+ store 
for IP3R and RyR release). However, if the main role of the RyR is internal store 
regulation (rather than contraction) and therefore RyR has access to Ca2+ from 
separate sub-stores then a second contraction to stimulation of caffeine would be 
possible (as is shown figure 3.15). 
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Table 3.5 Perfusion system timings designed to highlight differences in Ca2+ store 
arrangement and receptor roles of the JP3R and RyR; required for airway smooth 
muscle contraction or internal Ca2+ store regulation. 1 mM EGTA was present in 0 
mM Ca2+ buffer throughout the protocol (protocol described in text). 
IP3 and RyR effects on contraction 
Time Perfusion Perfusion 
(minutes) 
o mM Ca2+ buffer o mM ci+ buffer 0 
3 1 ~ M M ACh, 0 mM Ca2+ 20 mM caffeine, 0 mM 
Ca2+ 
8 o mM Ca2+ o mM Ca2+ 
16 20 mM caffeine, 0 mM 1 ~ M M ACh, 0 mM Ca2+ 
ci + 
21 o mM Ca2+ o mM Ca2+ 
26 2 mM Ca2+ buffer wash 2 mM Ca2+ buffer wash 
36 end point end point 
Caffeine then ACh in OmM Ca2+ 
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Figure 3.14 Following RyR stimulated contraction, no further contraction can be 
induced by ACh stimulation in pig peripheral airways. Representative tracing of 
pig peripheral airway lumen (n = four airways, two pigs), in a 170 pm thick pig lung 
slice. The tracing shows initial perfusion of 0 mM Ca2+ buffer (with 1 mM EGTA) 
which was maintained throughout the majority of the experiment. A contraction was 
then stimulated by 20 mM caffeine (RyR release) . The slice was further perfused with 
o mM cd+ buffer followed by 1 fJM ACh (IP3R cd+ release). 0 mM cd+ buffer was 
then perfused followed by 2 mM Ca2+ buffer. In the absence of extracellular cd+ an 
initial transient contraction was induced to caffeine via RyR release. Following this 
store depletion, no further contraction was seen with ACh stimulation of the IP3R. 
Despite prolonged cd+ store deprivation, the reintroduction of extracellular cd+ 
did not induce a contraction. 
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Figure 3.15 Following IPJR stimulated contraction, further contraction is seen to 
RyR induced stimulation in pig peripheral airways. Representative tracing of pig 
peripheral airway lumen (n = four airways, two pigs), in a 170 pm thick pig lung 
slice. The tracing shows initial perfusion of 0 mM Ca2+ buffer (with added EGTA) 
maintained throughout the majority of the experiment. A contraction was then 
stimulated by 1 pM ACh (Cd+ release via the 1P3R). After further perfusion of 0 mM 
cif+, a smaller contraction was observed with stimulation from 20 mM caffeine 
(RyR release). The slice was then perfused with 0 mM and finally 2 mM cif+. 
Despite initial store depletion via the IP3R, the contraction observed with caffeine 
stimulation may suggest another existing supply of cd+ for the RyR. No contraction 
was induced with the reintroduction of extracellular cd+ at the end of the protocol. 
These results suggest that 1P3R release is directly involved in the pathway to 
activate contraction and must share Ca2+ stores with the RyR (figure 3.14). Results 
also show that the RyR may have access to separate internal Ca2+ stores as after ACh 
stimulation, a second contraction is seen to caffeine (figure 3.15). This supports the 
notion that the RyR is involved in regulation of [Ci+]i rather than contraction 
maintenance (and would be consistent with the transient contraction and variable 
magnitude of contraction often seen with caffeine stimulation). However, it is also 
possible that a single ACh stimulation does not release all Ca2+ from the store. 
Therefore, this protocol was extended to incorporate a second challenge to ACh prior 
to stimulation with caffeine (figure 3.16). A contraction was seen with a second 
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stimulation of ACh (although magnitude of contraction was reduced) and seen again 
with caffeine stimulation. 
12000 qrrM 
~ a l . .
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ACh, ACh, caffeine in OmM Ca2+ 
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TIme (0.5 seconds) 
Figure 3.16 Despite depletion of intracellular stores, repeated airway contractions 
are induced to IP3R and RyR release. Representative tracing of pig peripheral 
airway lumen (n = four airways, two pigs), in a 170 j.Jm thick pig lung slice. The 
tracing shows initial perfusion of 0 mM ccl+ buffer (with added EGTA), maintained 
throughout the majority of the experiment. A contraction was then stimulated by 1 
j.JM ACh (Ca2+ release via the IP3R). After further perfusion of 0 mM ccl+, another 
much smaller contraction was seen to ACh, further 0 mM ccl+ was perfused, 
followed by afinal small contraction to 20 mM caffeine (RyR release). The slice was 
then perfused with 0 mM and finally 2 mM ccl+. Despite initial store depletion via 
the IP 3R, a second contraction was observed through this pathway of ccl+ release. A 
final contraction was observed with caffeine stimulation of the RyR. No contraction 
was induced with the reintroduction of extracellular ccl+. 
Following the same protocol as in figure 3.16, a control experiment with 2 
mM extracellular Ca2+ was included to demonstrate that magnitude of contraction is 
reliant on ci+ supply. Results show that stimulation of IP3R and RyR release 
produces repeated significant contractions (figure 3.17); as compared with figure 
3.16 showing a reduced contraction after OmM Ca2+. 
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ACh, ACh, caffeine in 2mM Ca2+ 
Time (0.5 seconds) 
2rrM Ca" 
buffer wash 
Figure 3.17 Magnitude of contraction is reliant on Ca2+ supply. Representative 
tracing of pig peripheral airway lumen (n = four airways, two p igs), in a 170 pm 
thick pig lung slice. The tracing shows initial perfusion of 2 mM ccl+ buffer, 
maintained throughout the majority of the experiment. A contraction was then 
stimulated by 1 pM ACh (Ccl+ release via the IP3R). After further perfus ion of2 mM 
ccl+, another contraction was seen to ACh, further 2 mM ccl+ was perfused, 
followed by a final contraction to 20 mM caffeine (RyR release). The slice was then 
perfused with 2 mM ccl+. Repeated contractions with large magnitudes were 
observed via stimulation of the IP 3R and with caffeine stimulation of the RyR. 
These results suggest that a Ca2+ store reserve may supply the RyR release 
pathway only which could possibly mobilise RyR stored Ca2+ to supply the 
1P3R1RyR shared pathway. Alternatively, this may reflect an inability by ACh to 
deplete the stores completely. The roles of the 1P3R and RyR are explored further in 
the next section using prolonged SERCA pump inhibition (figure 3. 19, figure 3.20). 
3.3.4 Influence of SERCA pump inhibitors on magnitude and maintenance of 
contraction 
The following experiments were designed to study the influence of inhibition 
of Ca2+ uptake into internal stores (and therefore supply of Ca2+ to be released for 
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cytosolic Ca2+ increase) on the ability to induce and maintain a contraction. Parallel 
experiments were run using both SERCA pump inhibitors, cyclopiazoinc acid (CPA) 
and thapsigargin. As both inhibitors produced similar results, only CP A data is 
shown here. Perfusion system timings were designed to show an initial control 
contraction to ACh. Throughout the protocol, airways were perfused with varying 
conditions: CP A and ACh together for five minutes and both CP A and ACh 
separately. An eight minute interval for replenish of internal Ca2+ stores was 
included. Combinations were designed to determine whether perfusion with CPA 
(prior to/ or in combination with) perfusion with ACh affected the magnitude of 
contraction (see table 3.6). Results are shown for both mouse and pig with 
representative airway tracings and collective data (figures: 3.17, 3.18). 
Table 3.6 Perfusion system timings designed to show effect of SERCA pump 
inhibition using CPA, on magnitude and maintenance of ACh induced contraction. 
Effects of CP A on ACh induced contraction 
Time Perfusion 
(minutes) 
o 
1 
6 
11 
19 
24 
29 
37 
42 
47 
57 
2 mM Ca2+ buffer 
1 j..lMACh 
10 j..lM CPA, 1 j..lM 
ACh 
2mMCa2+ 
10 j..lMCPA 
10 j..lM CPA, 1 j..lM 
ACh 
2mMCa2+ 
10 j..lMCPA 
1 j..lMACh 
2 mM Ca2+ buffer 
wash 
end point 
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Effects of CPA on ACh induced contract ion 
Time (seconds) 
2mM Ca2• 
bufferwash 
Figure 3.17a SERCA pump inhibition does not affect magnitude or maintenance 
of mouse peripheral airway contraction. Example of an airway tracing representing 
contractile responses in n = three C57BLI6 WT mouse lung slices. The slice was 
perfused with 2 mM ccl+ buffer, a contraction was shown to ACh followed 
immediately by perfusion with 10 pM CPA and 1 pM ACh. The slice was then 
washed with buffer, pretreated with 10 pM CP A and then perfused with both CP A 
and ACh. Finally, the slice was washed again with buffer, pretreated with 10 pM 
CPA and then perfused with ACh (1 pM) alone. Final wash out to buffer was shown. 
A similar magnitude of contraction was shown for all conditions. 
Effects of CPA on ACh induced contraction 
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Figure 3.17b SERCA pump inhibition does not affect magnitude or maintenance 
of mouse peripheral airway contraction. Results for n = three in C57BU6 WT 
mouse lung slices, normalised to 2 mM ccl+ buffer alone as 0% contraction and 10 
pM ACh as 100% contractile response. 2 mM ccl+ buffer was maintained 
throughout the experiment. Individual dots represent one airway from one mouse, 
blue lines indicate the mean value for that group. Contractions of similar magnitude 
are shownfor all conditions: a) ACh alone, b) ACh and CPA with no pre-treatment 
with CPA, c) ACh and CPA with pre-treatment with CPA alone and d) ACh alone 
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with pre-treatment with CPA alone. Data for b) 10 pM CP A, 10 pM A Ch, c) 10 pM 
CPA, 10 pM ACh and d) final 10 pM ACh were analysed using one-way ANOVA 
followed by Dunnett 's post test comparing all means to the control; a) initial 10 pM 
ACh. Results were not significant with all p values > 0.05. Note: the airways had not 
fully relaxed to baseline levels with the second perfusion of 2 mM ccl+ buffer alone 
as indicated at e), baseline drift is discussed in section 3.4. 
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Figure 3.18a SERCA pump inhibition significantly reduces magnitude of 
contraction in pig peripheral airways. Example of an airway tracing representing 
contractile responses in n = six airways, three pig lung slices, The slice was 
perfused with 2 mM Ca2+ buffer, a contraction was shown to ACh followed 
immediately by perfusion with 10 pM CPA and 1 pM ACh. The slice was then 
washed with buffer, pretreated with 10 pM CPA and then perfused with both CPA 
and ACh. Finally, the slice was washed again with buffer, pretreated with 10 pM 
CP A and then perfused with A Ch (1 pM) alone. Final wash out to buffer was shown. 
A significant reduction in contraction to ACh (alone and in presence of CPA) was 
shown after perfusion with CP A alone for five minutes. 
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Figure 3.18b SERCA pump inhibition significantly reduces magnitude of 
contraction in pig peripheral airways. Results for n = six airways, three pigs, 
normalised to 2 mM ctt+ buffer alone as 0% contraction and 1 pM ACh as 100% 
contractile response. 2 mM CcJ+ buffer was maintained throughout the experiment. 
Individual dots represent one airway, blue lines indicate the mean value for that 
group. Datafor b) ACh and CPA with no pre-treatment with CPA, c) ACh and CPA 
with pre-treatment with CPA alone and d) final ACh alone with pre-treatment with 
CPA alone were analysed using one-way ANOVA followed by Dunnett's post test 
comparing all means to the control; a) initial 10 pM A Ch. Contractions of similar 
magnitude are shown for a) ACh alone (100% contraction) and b) ACh and CPA 
(mean = 112.3% airway contraction). However, pre-treatment with CPA alone (five 
minute perfusion) followed by c) ACh and CPA significantly reduced the magnitude 
of contraction (p < 0.001, mean = 66.3% contraction), as did pre-treatment with 
CPA alone followed by d) ACh alone (p = 0.001 - 0.01, mean = 73.7 % airway 
contraction). 
These results indicate differences between mouse and pig in CP A sensitivity 
or SR store release regulation for contraction. In pig magnitude of contraction 
appears to correlate with the amount of stored Ca2+ available for release. 
Results in section 3.3.3 hinted at differing roles and Ca2+ store supplies for 
the IP3R and RyR. To further investigate the roles of these channels and their 
relationship to magnitude of contraction by preventing internal store uptake using a 
SERCA pump inhibitor, CPA; 2 mM extracellular Ca2+ was maintained throughout 
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the experiment. This was studied by using an initial maximum contraction to either 
ACh or caffeine followed by perfusion with CPA alone (CPA was then present until 
wash out), followed by stimulation with ACh or caffeine by the same release 
pathway. After further CPA perfusion, a final contraction was stimulated by the 
alternative release channel (to determine if contraction would be absent/significantly 
reduced in magnitude). Due to tissue availability, the following experiments were 
performed for pig lung slices only (figures: 3.19,3.20). 
Table 3.7 Perfusion system timings using SERCA pump inhibition (by CPA) to 
highlight differing roles of the RyR (caffeine stimulation) and 1P3R (ACh stimulation) 
release pathWays in influencing magnitude of contraction. 
Effeds of CP A on magnitude of repeated contraction 
Time Perfusion Perfusion 
(minutes) 
2 mM Ca2+ buffer 2 mM Ca2+ buffer 0 
1 1 /lM ACh 20 mM caffeine 
6 10 /lM CPA 10 /lM CPA 
14 1 /lM ACh, 10 /lM CP A 20 mM caffeine, 10 /lM 
CPA 
19 10 /lM CPA 10 /lM CPA 
27 20 mM caffeine, 10 /lM 1 /lM ACh, 10 /lM CPA 
CPA 
32 2 mM Ca2+ buffer wash 2 mM Ca2+ buffer wash 
42 end point end point 
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Effects of CPA on magnitude of repeated contraction 
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Figure 3.19a SERCA pump inhibition reduces magnitude of contraction following 
1P3R stimulation in pig peripheral airways. Example of an airway traCing 
representing contractile responses in n = six airways, three pig lung slices. The slice 
was perfused with 2 mM ccl+ buffer, a contraction was shown to ACh followed by 
perfusion with 10 pM CPA, then CPA with 1 pM ACh. Further CPA was perfused 
followed by 20 mM caffeine with CP A. Finally the slice was washed with 2 mM 
ccl+. In this experiment, following 1P 3R stimulation, the magnitude of further 
contractions via 1P3R release and RyR release appeared to be reduced in the 
presence of CPA. Note: the airways did not relax back to base line in between CP A 
washes. 
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Figure 3.19b SERCA pump inhibition reduces magnitude of contraction through 
RyR release following 1P3R stimulation in pig peripheral airways. Results for n = 
six airways, three pigs, normalised to 2 mM ccl+ buffer alone as 0% contraction 
and I pM ACh as IOO% contractile response. 2 mM ccl+ buffer was maintained 
throughout the experiment. Individual dots represent one airway, blue lines indicate 
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the mean value f or that group. Data were analysed using one-way ANOVAfollowed 
by Dunnett 's post test comparing all means to the control; a) initial 1 pM A Ch. Data 
for b) 10 pM CPA, 10 pM A Ch, showed a reduction in magnitude of contraction via 
IP3R release, however this was not significant (mean = 76.4%). Final stimulation via 
the RyR also produced a contraction of decreased magnitude (p = 0.01 - 0.05, mean 
= 65.2%). During CPA washes, the airways did not relax to base line levels. 
Effects of CPA on magnitude of repeated contraction 
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Figure 3.20a Following RyR release, IPJR stimulation does not lead to reduction 
in magnitude of contraction despite prolonged SERCA pump inhibition. Example 
of an airway tracing representing contractile responses in n = six airways, three pig 
lung slices. The slice was perfused with 2 mM ccl+ buffer, a contraction was shown 
to caffeine followed immediately by perfusion with 10 pM CP A, then CPA with 
caffeine. Again CPA was perfused followed by a final contraction to ACh. Finally 
the slice was washed with 2 mM Ca2+. In this experiment, following initial 
contraction to RyR release, the magnitude of the second contraction stimulated 
through RyR release was not reduced in magnitude, nor was the final contraction via 
ACh stimulated IP3R release. 
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Figure 3.20b Following RyR release, IPJll stimulation does not lead to reduction 
in magnitude of contraction despite prolonged SERCA pump inhibition. Results 
for n = six airways, three pigs, normalised to 2 mM ccl+ buffer alone as 0% 
contraction and 1 pM ACh as 100% contractile response. 2 mM ccl+ buffer was 
maintained throughout the experiment. Individual dots represent one airway, blue 
lines indicate the mean value for that group. Data were analysed using one-way 
ANOVA followed by Dunnett's post test comparing all means to the control; a) 
initial 20 mM caffeine (mean = 75.6%). A second contraction was shown to caffeine 
b) (mean = 69.7%). Although there was a trend towards a higher magnitude of 
contraction being produced to ACh (c), results are not significantly different. 
With SERCA pump inhibition, these results showed a reduction in magnitude 
of contraction following repeated stimulation of the IP3R pathway (3.19). However 
no reduction in degree of contraction was shown for IP3R release after repeated RyR 
stimulation (3.20). Results from sections 3.3.3 and 3.3.4 suggest that i) IP3R release 
is directly involved in contraction and shares a common store supply with RyR. ii) 
SERCA pump inhibition reduces the magnitude of contraction in pig peripheral 
airways. iii) Importantly, results suggest differences between mouse and pig in 
internal Ca2+ store regulation required for release for contraction. 
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3.3.5 Significance of Voltage Operated Calcium Channels (VOCC) for Ca2+ 
entry to maintain contraction 
In the next set of experiments I explored the contribution of VOCCs to Ca2+ 
entry for maintaining ASM contraction using the L-type VOCC inhibitor, nifedipine. 
As can be seen in figure 3.21 and 3.22, nifedipine had no relaxant effect on ACh 
induced contractions. The protocol involved an initial contraction to ACh followed 
by the addition of nifedipine with ACh present, to compare magnitude (table 3.8). 
The corresponding representative airway contraction tracing and mean values are 
shown for mouse and pig (figures: 3.21, 3.22). 
Table 3.8 Perfusion system timings designed to show effect of voltage operated 
calcium channel inhibition (nifedipine) on magnitude and maintenance of ACh 
induced contraction. 
Effects of Nifedipine on ACh induced contraction 
Time Perfusion 
(minutes) 
o 
1 
6 
11 
19 
24 
2 mM Ca2+ buffer 
10 JlMACh 
10 JlM ACh, 10 J.1M 
Nifedipine 
2mMCa2+ 
10 JlM ACh 
2 mM Ca2+ buffer wash 
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Figure 3.21 a Nifedipine does not induce airway relaxation in mouse peripheral 
airways. Representative airway tracing for a C57BLI6 lung slice (representative of n 
= three, three mice) showing initial buffer perf usion, pre-contract ion with 10 f.J M 
ACh, perfusion of 1 0 f.J M nifedip ine with ACh, wash, contraction to 10 f.JM ACh and 
final wash out to relaxed state. 
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Figure 3.21 b Nifedipine does not induce airway relaxation in mouse peripheral 
airways. Results for percentage contractile response in (n = three, three mice) 130 
f.Jm thick, C57BV6 mouse lung slices. Individual dots indicate one airway from one 
mouse, blue lines indicate mean values. Means for pre-contract ion with a) initial 10 
f.JM A Ch, perfusion, b) 10 f.JM nifedipine with ACh and final contraction to c) 10 f.JM 
ACh are shown. Results indicate that nifedipine does not significantly contribute to 
airway relaxation. Analysed using one-way AVOVA and Dunnett 's post test 
comparing means for b) and c) to a) 10 fJM A Ch, all results were not significant, p 
values > 0.05. 
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Figure 3.22a Nifedipine does not induce airway relaxation in pig peripheral 
airways. Representative airway tracing in a pig lung slice (representative of n = six, 
three pigs) showing initial buffer perfusion, pre-contraction with 1 pM A Ch, 
perfusion of 10 pM nifedipine with ACh andfinal wash out to relaxed state. 
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Figure 3.22h Nifedipine does not induce airway relaxation in pig peripheral 
airways. Results for percentage contractile response in (n = six airways, three pigs) 
pig lung slices. Individual dots indicate one airway, blue lines indicate mean values. 
Means for pre-contraction with a) 1 pM ACh perfusion were compared with b) 10 
pM nifedipine with ACh (mean = 90.3% contraction) using one-way AVOVA and 
Dunnett 's post test. 
3.3.6 Characterisation of inhibitory response to selected calcium channel 
binding agents and Store Operated Calcium Channel (SOCC) inhibitors 
Given the results suggesting no apparent role for VOCCs in control of 
peripheral airway contraction! relaxation in both mouse and pig, I next explored the 
contribution of store operated calcium channel entry (SOCC) for maintained airway 
contraction. These experiments were complicated by a lack of specific SOCC 
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inhibitors. SKF-96365, a commonly used SOCC inhibitor in other cell types, does 
not inhibit SOCC Ca2+ influx in smooth muscle; instead showing inhibition of ROCe 
and other non specific effects (Guibert, Marthan et al. 2004). Both La3+ and Ni2+ 
inhibit SOCC in a variety of smooth muscle types, however, they also inhibit ROCe 
in others (McFadzean and Gibson 2002). 2-APB is shown to inhibit IP3 receptor 
mediated Ca2+ release at concentrations of 1 - 10 J.1M. However, it also inhibits 
SOCC at concentrations> 100 J.1M (Mizuta, Gallos et al. 200S). In all protocols, the 
airways were pre-contracted with 1 J.1M ACh (sub maximal concentration) which 
was present throughout the dose response. All buffers, agonists and inhibitors were 
made up with 2 mM extracellular Ca2+. For each inhibitor representative airway 
contraction tracings and corresponding graphed data for mouse (three airways from 
three mice) and pig (six airways from three pigs) are shown (figures: 3.23, 3.24, 
3.25,3.26,3.27, 3.2S, 3.29). 
Table 3.9 Perfusion system timings for store operated calcium channel inhibitor 
dose responses in the presence of ACh (described in text). 
in 2 mM Ca2+ 
Time Lanthanum JS (Icrac N117 (Icrac 
{minutes (La31 inhibitor) inhibitor) 
) 
2mMCa2+ 0 2mMCa2+ 2mMCa2+ 2mMCa2+ 2mMCa2+ 
buffer buffer buffer buffer buffer 
1 1 ~ A C h { t o o I ~ A C h h I ~ A C h h 10 J.1M ACh 10 pMACh 
precontract) {to {to {to (to 
precontract) precontract) precontract) precontract) 
6 0.01 pM 0 . 0 1 ~ ~ 0.01 J'M 0.001 J'M 0.001 ~ ~
11 0.1 pM 0 . 1 ~ ~ 0.1 pM 0 . 0 1 ~ ~ 0 . 0 1 ~ ~
16 1 ~ ~ 1 ~ ~ 1 ~ ~ 0.1 J1M 0.1 J1M 
21 1 0 ~ ~ 1 0 ~ ~ 1 0 ~ ~ 0.5 ~ ~ 0.5 J.1M 
26 l 0 0 ~ ~ 1 0 0 ~ ~ 1 0 0 ~ ~ 1 ~ ~ IJ.1M 
31 ImM ImM ImM 1 0 ~ ~ 10 pM 
36 2mMCa2+ 2mMCa2+ 2mMCa2+ 2mMCa2+ 2mMCa
2+ 
buffer wash buffer wash buffer wash buffer wash buffer wash 
46 end point end point end point end point end point 
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Figure 3.230 2-APB produces airway relaxation in mouse peripheral airways. 
Representative airway tracing in a C57BU6 WT mouse lung slice (representative of 
n = three, three mice). The slices were perfused with buffer then pre-contracted with 
1 I'M A Ch, which was present with the addition often-fold increasing concentrations 
of2-APBfrom 0.01 I'M to 1 mM 
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Figure 3.23b 2-APB produces airway relaxation in mouse peripheral airways. 
Results are shown for n = three airways from C57BLI6 WT mouse lung slices, 
normalised to buffer as 0% contraction and 1 I'M ACh as 100% contractile 
response. Data points represent mean values; error bars indicate SD. At higher 
concentrations (> 10 I'M), relaxation was seen. At 1 mM 2-APB, 81 .0 + 19. 7% 
airway relaxation was induced. 
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2-APB dose response 
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Figure 3.24a 2-APB produces airway relaxation in pig peripheral airways. 
Representative airway tracing in a pig lung slice (representative of n = six airways, 
three pigs). The slices were per/used with buffer then pre-contracted with 1 pM A Ch, 
which was present with the addition of ten-fold increasing concentrations of 2-APB 
from 0.01 pMto 1 mM 
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Figure 3.24b 2-APB produces airway relaxation in pig peripheral airways. Results 
are shown for n = six airways, three pigs. Normalised to buffer as 0% contraction 
and 1 pM ACh as 100% contractile response. Data points represent mean values at 
each concentration. Error bars indicate SD. At 1 mM 2-APB, 34.4 + 12.6% airway 
relaxation was measured. 
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Ni2+ dose response 
Time (seconds) 
Figure 3.25 Ni+ induces airway relaxation at high concentration in mouse 
peripheral airways. Representative airway contraction tracing during a dose 
response to N/+ in a C5 7BLI6 WT mouse lung slice (representative of n = three, 
three mice). The slices were perfused with buffer then pre-contracted with 1 J.lM ACh 
which was present throughout the dose response with the addition of ten-fold 
increasing concentrations of N;2+ from 0.01 J.lM to 1 mM 
As the airways did not relax until a maximum contraction, mean values are 
not shown. At 100 J.lM Ni2+ 5.5 + 6.5% relaxation was found. At maximum 
concentration (1 mM) 36.2 + 3.5% relaxation was measured (n = three airways 
from three mice). 
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Figure 3.26 Nr+ induces small airway relaxation at high concentration in pig 
peripheral airways. Representative airway contraction tracing during a dose 
response to Ni2+ in a pig lung slice (representative of n = six airways, three pigs). 
The slices were perfused with buffer then pre-contracted with 1 pM ACh which was 
present throughout the dose response with the addition of ten-fold increasing 
concentrations ofN/+ from 0.01 J.lMto 1 mM 
Pig airways did not show relaxation until a maximum contraction, therefore 
mean values are not shown. At maximum concentration (1 mM), 12.0 + 8.6% 
relaxation was measured. 
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La3+ dose response 
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Figure 3.27a Ltt+ induces airway relaxation in mouse peripheral airways. A 
representative airway tracing for a dose response to La3+ in a C57BLI6 WT mouse 
lung slice (representative of n = three, three mice). The airway was pre-contracted 
with 1 pM A Ch, which was present with the addition of ten-fold increasing 
concentrations of La3+ from 0.01 pM to 1 mM Relaxation was observed with La3+ 
concentrations above 1 pM 
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Figure 3.27h La3+ induces airway relaxation in mouse peripheral airways. Results 
for dose responses to L;+ in n = three, C57BU6 WT mouse lung slices, normalised 
to buffer as 0% contraction and 1 pM ACh as 100% contractile response. Data 
points represent mean values. Error bars indicate SD. An lC50 of 12.1 pM and Cl of 
2.8 pM - 50.9 pM was found. At 1 mM La3+, 68.1 + 25.5% relaxation was measured. 
164 
Chapter Three: Characterisation of the lung slice model 
La3- dose response 
lime (0 5 seconds) 
Figure 3.28a La3+ induces small airway relaxation at high concentration in pig 
peripheral airways. A representative airway tracing for a dose response to La3+ in a 
pig lung slice (representative of n = six, three pigs). The airway was pre-contracted 
with 1 pM ACh, which was present with the addition of ten-fold increasing 
concentrations of La3+ from 0.01 pM to 1 mM A small degree of relaxation was 
observed at maximum concentration (l mM). 
As La3+ fa iled to induce relaxation of pig airways until a maximum 
concentration, mean values are not shown. At maximum concentration of 1 mM 
La3+, 5.2 + 8.9% relaxation was measured. 
As many of the reported SOCC inhibitors trialled did not induce aIrway 
relaxation in physiological conditions in mouse and pig; it was apparent that I 
needed a specific Icrac inhibitor and that airways had to be exposed to conditions 
that would favour SOCC in order to assess the potential contribution of SOCC. Icrac 
inhibitors were made available to me from GlaxoSmithKline: JS (GSK1349571A) 
and NI17 (N I 1764-14-1)). The Icrac inhibitors are predominantly used for inhibition 
of T-cell and mast cell function (ICso of 100 nM - I ~ M ) . . Interestingly, Icrac 
inhibition abolished OVA-evoked contractions of the rat trachea and allergen evoked 
contractions of the human bronchus (possibly through mast cell degranulation) (GSK 
data presented at Winter BPS, 2009). 
Initially I followed the same protocol as for previous inhibitory dose response 
experiments; by first precontracting the airways with ACh which was present with 
increasing concentrations of the Icrac inhibitors. Representative airway tracings and 
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results are shown for both JS and Nl17 (figure 3.29). Experiments were performed 
in 2 mM Ca2+; to assess whether in physiological conditions, the Icrac inhibitors 
would prevent contraction maintenance. 
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Figure 3.29 Icrac inhibitors (JS and Nl17) do not contribute to airway relaxation 
in pig peripheral airways under normal physiological conditions. A representative 
airway tracing for a dose response to JS (n = seven, two pigs) and N11 7 (n = six, 
two pigs). The airways were pre-contracted with 10 fJM A Ch, which was present 
with the addition of increasing concentrations of either JS (a) or Nl1 7 (b). Even at 
maximum concentration no relaxation was seen to the Jcrac inhibitors in the 
presence of ACh and 2 mM ccl+. 
Results suggest that in physiological conditions the Icrac inhibitors, JS 
(GSK134957lA) and Nl17 (NI 1764-14-1) did not contribute to airway relaxation in 
the presence of ACh (therefore mean results are not shown). Experiments were also 
performed to show an ACh dose response in lung slices that were either untreated, or 
pretreated with 10 JlM JS (GSKI34957lA) and Nl17 (N11764-14-1) (maximwn 
concentration) for an hour. The Icrac inhibitors were maintained throughout the 
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experiment. Again results suggested that Icrac inhibition did not prevent airway 
contraction maintenance (data not shown). 
Therefore the following protocols were designed to investigate effects on 
contraction under conditions favouring SOCC activity. The protocol involved 
prolonged exposure to 0 mM Ca2+ (with EGTA, a chelator of Ca2+ and the SERCA 
pump inhibitor, CPA) followed by depletion of internal stores by ACh (IP3R release) 
in 0 mM extracellular Ca2+ (also with CPA present). SOCC activation was indicated 
by a transient contraction seen with a readdition of Ca2+ (2 mM). To show the effects 
of the Icrac inhibitors, slices were pre-treated for an hour with either JS 
(GSK1349571A) or N117 (N11764-14-1) (maximum concentration, 10 J.lM), which 
were present throughout the protocol. Time matched untreated controls were 
included (perfusion timings table 3.10). All airways (untreated, JS (GSK1349571A) 
treated and N117 (N11764-14-1) treated) followed a similar pattern, representative 
airway tracings are shown (figure 3.30a). Summarised data is shown in figure 3.30b. 
Table 3.10 Perfusion timings designed to favour SOCC activity and to measure 
contraction with the addition of 2 mM ccl+. Slices were either untreated through the 
experiment, or pre-treatedfor an hour with either JS or N117 (10 pM), which was 
present throughout the protocol. 
Effect of Icrac inhibition in SOCC 
induced conditions (0 - 2 mM Ca1) 
Time (minutes) Perfusion 
o 0 mM Ca2+ buffer 
(with 1 mM EGTA, 10 
J.lM CPA) 
3 10 ACh, 0 mM Ca2+ 
(with 1 mM EGTA, 10 
J.lM CPA) 
8 2mMCa2+ 
11 10 uM ACh, 2 mM 
Cai + 
16 2 mM Ca2+ buffer wash 
26 end point 
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Figure 3.30a Effect of Icrac inhibition in SOCC induced conditions. 
Representative airway tracings in 170 pm thick lung slices, Airways were either a) 
untreated prior to experiments (n = eight, two pigs) or exposed to b) 10 pM JS (n = 
ten, two pigs), or c) 10 pM N117 (n = seven, two pigs) one hour prior to 
experiments; 10 pM JS or 10 pM N 117 was maintained throughout the full length of 
the experiment protocol. For all protocols, the airway was perfused with 0 mM ccl+ 
(with 1 mM EGTA and 10 pM CPA added, a transient contraction was induced by 
10 pM ACh in 0 mM ccl+, a transient contraction was also seen with the readdition 
of 2 mM ccl+, a contraction to 10 pM ACh in 2 mM ccl+ was maintained before 
final wash with 2 mM ccl+. All treatment conditions produced similar airway 
contractile behaviour, although in general a smaller degree of contraction was 
observedfor N117 treated slices. 
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Effects of Icrac Inhibition In SOCC Induced conditions (O-2mM Ca2+1 
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Figure 3.30b Icrac inhibition (JS and NIl 7) did not prevent contraction in SOCC 
activated conditions. Results shown for % airway contraction in 170 pm thick lung 
slices. Airways were either untreated prior to experiments (n = eight, two pigs) or 
exposed to 10 pM JS (n = ten, two pigs), or 10 pM N 11 7 (n = seven, two pigs) one 
hour prior to experiments; 10 pM JS or 10 pM N 11 7 was maintained throughout the 
full length of the experiment protocol. Airway contraction is shown relative to initial 
airway area during 0 mM Ca2+ perfusion. Individual dots represent individual 
airways, lines indicate mean values. The Jcrac inhibitor JS failed to inhibit the 
contraction seen to SOCC activity with the readdition of 2 mM Ca2+. Nl1 7 did 
appear to reduce the magnitude of the contraction after readdition of ccl+ however, 
this was not significant (as indicated with red arrow (ns), % contraction compared 
untreated to treated airways in 2 mM Ca2+). 
Results suggested a reduction in magnitude of contraction with Icrac 
inhibition by N117. To provide a larger contraction in untreated airways to compare 
against, I next exposed the slices to extreme conditions (10 mM extracellular Ca2+, 
50 J..lM CPA), following the same protocol as in figure 3.30. Control experiments 
were performed showing no contraction is induced with change from 0 mM to 10 
mM extracellular Ca2+. Results showed a lot of variation in degree of contraction 
therefore data are not shown. Although all airways showed the ability to contract, 
airways exposed to Icrac inhibition were less likely to maintain the contraction and 
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more likely to relax at the end of the protocol. Untreated airways showed continuous 
increasing contraction with very little final relaxation; due to the extreme conditions. 
Although there was a decreased mean magnitude of contraction measured in lung 
slices exposed to the inhibitors, although this was not significant. 
Experiments in section 3.3.6 were designed to determine the contribution of 
SOCC to maintenance of peripheral airway contraction. Results from Icrac inhibition 
experiments suggest that in conditions of SR store depletion and abnonnal 
extracellular [Ca2l, SOCC may contribute to contraction maintenance. 
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In pig, slicing using the Oscillating tissue slicer was more difficult as the larger 
airway diameter and structures had a tendency to tear the slice. The best method for 
avoiding tearing was to locate a lung lobe which inflated at the very tip, which 
increased chance of uniform dispersion of agarose and there were no larger airways 
to disrupt the slice blade. The pig airways showed a greater contractile response than 
mouse, often to complete airway occlusion. Differences in airway sensitivity and 
behavioural response are most likely due to differences in receptor density and Ca2+ 
handling between the mouse and pig (discussed throughout this section). 
3.4.2 Contractile responses to acetylcholine, serotonin and histamine in mouse 
and pig 
Serotonin (5-HT) produced concentration dependent contractions in mouse 
peripheral airways (ECso = 1.0 J.lM). The maximum response to 5-HT (1 J.lM) was 
78% of the response to 10 J.lM ACh (100%). The reduction in degree of contraction 
measured at 5-HT concentrations > 10 J.lM may be due to the presence of different 
receptor subtypes in the mouse lung producing varying effects on 
contraction/relaxation at different concentrations of 5-HT. Studies on various strains 
of rat have also confirmed that 5-HT reaches a plateau at I J.lM (Tao, Tolloczko et al. 
1999). Guinea pig PCLS gave a 5-HT ECso value of 69 nM (Ressmeyer, Larsson et 
al. 2006). In pig no contractile response was shown for 5-HT (10.9 - 10-4 M); 
suggesting that, as in hwnan, pig airways do not respond to 5-HT. No literature was 
found describing the distribution of the serotonin 5-HT2 receptors in pig at the 
peripheral airway level. 5-HT was selected for these contractile experiments as it is 
known to cause bronchoconstriction in many mammalian species (Barnes, Chung et 
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al. 1998), (Moffatt, Cocks et al. 2004). However, there is limited evidence to suggest 
5-HT directly alters human ASM tone (Cazzola and Matera 2000) but may facilitate 
modulation of cholinergic activation of ASM. The major source of 5-HT is platelets 
(Cazzola, Matera et al. 1995), although 5-HT is also localised to peripheral nerves 
and found in neuroendocrine cells of the respiratory tract (Barnes 2001). In human 5-
HT acts on airway smooth muscle via the 5-HT2A and 5-HT1A receptor and also acts 
on prejunctional 5-HT3 and 5-HT7 receptors to facilitate increased release of ACh 
(Cazzola and Matera 2000; Bames 2001). However, studies suggest species 
differences in the receptor subtype targeted for the direct actions of 5-HT on ASM 
and effects on cholinergic nerves. In mice the 5-HT induced mechanisms of 
bronchoconstriction may depend in part on the cholinergic parasympathetic pathway, 
as 5-HT induced constriction is blocked by atropine (Levitt and Mitzner 1989), 
(Eum, Norel et al. 1999). A recent murine model of asthma showed 5-HT release 
from mast cells during allergen challenge, 5-HT has also been implicated in the 
development of remodelling via the release of cytokines and fibrogenic mediators 
(Lima, Souza et al. 2007). 5-HT has also been shown to increase cilia beat frequency 
and particle transport speed although independent of ACh (Konig, Krain et al. 2009). 
Given its ability to be sourced from many non neuronal cells in the lung, 5-HT may 
also play a significant role in transport required to clean airways free of mucus and 
foreign particles. 
Histamine (HA) is a known bronchoconstrictor in humans, however 
stimulation with HA produced no contractile effect in mouse lung slices in the 
concentration range of 10.9-10-4 M. These findings are supported by other studies on 
murine PCLS (Heinz-dieter and colleagues, 1999). Little or no response was shown 
to HA in rat (Lulich and Paterson 1980; Van de Voorde and Joos 1998). In pig, 
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concentration dependent contractions were observed (ECso 2.2 J.1M (maximum 
contraction of 80.2% to 100 J.1M HA, compared to 10 J.1M ACh response). In human 
PCLS an ECso of 2.7 J.1M was reported (Ressmeyer, Larsson et al. 2006). In horse 
PCLS an ECso of 0.6 J.1M was shown (Vietmeier, Niedorf et al. 2007). HA is 
synthesised and released by mast cells in the airway wall and by circulating 
basophils (Schroeder and MacGlashan 1997; Bames, Chung et al. 1998). HA acting 
on the HI receptor, has been shown to stimulate PI hydrolysis in ASM leading to 
contraction (Grandordy, Cuss et al. 1987; Hall and Hill 1988). Inhaled and 
intravenously administered HA contracts central and peripheral (with greater 
potency) airways in vitro; bronchoconstriction effects are increased in patients with 
asthma. 
In mouse, concentration dependent contractions were observed for 
acetylcholine (ACh) (ECso = 106.9 nM). These results are consistent with previous 
results; Sanderson and colleagues, (2002), found that concentrations of 1 j.lM ACh or 
higher resulted in a plateau contraction in mouse lung slices. In pig, concentration 
dependent contractions were also shown (ECso 112.5 nM). In human PCLS, 
methacholine (MCh) (a stable analogue of ACh) gave an ECso of 0.4 j.lM (Wohlsen, 
Martin et al. 2003). Horse PCLS showed an MCh ECso of 1.1 J.1M (Vietmeier, 
Niedorf et al. 2007). ACh released from parasympathetic nerves activates 
postjunctional muscarinic receptors present on ASM submucosal glands and blood 
vessels (Mak and Bames 1990) resulting in bronchoconstriction (Roffel, Elzinga et 
al. 1990), mucus secretion and vasodilation (Coulson and Fryer 2003). ACh also 
feeds back on prejunctional muscarinic receptors to increase or inhibit further ACh 
release. ACh has also been shown to increase cilia beat frequency and particle 
transport speed via muscarinic activation (Klein, Haberberger et al. 2009). 
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Table 3.11 Comparison of EC50 values for acetylcholine, serotonin and histamine in 
human, pig and mouse airways. PCLS: Precision cut lung slices. 
\!.!olli,t .... pl'l' il" , i"lIl' "dhoti 1'01' I ( ,11 I ~ ~ l' fl' n'lIl'l' 
'l'!! IIIl'lI t ,tlllhill!! 
l'Ollt I·al.'l ill-
1"l"POII'l' 
Acetylcholi mouse distal PCLS 106.9nM Results 
ne (ACh) bronchio Chapter 3 
les 
pig bronchi high frequency 15 nM (Iizuka, 
ultrasound Dobashi et al. 
1992) 
pig distal PCLS 112.5 nM Results 
bronchio Chapter 3 
les 
Serotonin mouse bronchio isolated perfused 0 . 7 ~ M M (Held, 1999) 
(5-HT) les and ventilated 
mouse bronchio peLS 2 . 0 ~ M M (Held, 1999) 
les 
mouse distal peLS 1.0 ~ M M Results 
bronchio Chapter 3 
les 
plg distal PCLS no Results 
bronchio response Chapter 3 
les 
human distal PCLS no (Ressmeyer, 
bronchio response Larsson et al. 
les 2006) 
Histamine mouse distal PCLS no Results 
(HA) bronchio response Chapter 3, 
les (Held, 1999) 
pig distal peLS 2 . 2 ~ M M Results 
bronchio Chapter 3 
les 
human bronchi organ bath, 0 . 6 ~ M M (Finney, 1985) 
isometric tension 
measurements 
human distal PCLS 2 . 7 ~ M M (Ressmeyer, 
bronchio Larsson et al. 
les 2006) 
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3.4.2.i Comparison of agonist contractile responses 
In comparing results from this study with previous reports it is important to 
acknowledge the tissue segment used and method by which response was measured. 
Due to easy accessibility previous studies have generally used isolated preparations 
of tracheal, bronchial segments and parenchymal strips in organ baths. The 
difference in distribution of nerves between large and small airways and the 
differential distribution of receptor expression at different airway levels could result 
in differences in response and suggests a need for pharmacological characterisation 
of small airway preparations in animal and human models. 
Collective evidence suggests an increase in sensitivity with decreasing airway 
generation. One study using large and small branches of three - six generation canine 
bronchi found an increase in HA sensitivity correlated with a decrease in airway size 
(Chitano, Sigurdsson et al. 1993). In keeping with these observations, studies using 
rabbit airway preparations of trachea, main bronchi subsegments and parenchyma, 
found that distal airways were more sensitive to HA, while proximal airways showed 
increased sensitivity to carbachol (Armour, Black et al. 1985). MCh induced 
contractions using PCLS in rats also increased in sensitivity with decreased airway 
size (for airways less than 35000 J.1M2 in size) (Martin, Vhlig et al. 1996). Another 
study using canine tracheal and bronchial strips in organ bath found an ACh -
logECso of 8.1, 7.1, 7.9 and 6.1 respectively in top, middle, bottom trachea and 
bronchi (Mapp, Chitano et al. 1989), also suggesting a decrease in sensitivity to ACh 
with decreasing airway order (Gray and Mitchell 1996). However, a study using 
trachea, main bronchi and bronchioles in rats found that small airways were less 
sensitive to carbachol and 5-HT than large airways (Van de Voorde and Joos 1998), 
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also supported by a study showing less sensitivity to 5-HT in lung parenchymal 
strips than in trachea and main bronchus (Cadieux, Lanoue et al. 1990). Despite the 
lower sensitivity, 5-HT appeared to induce a stronger contraction in small airways 
(Van de Voorde and Joos 1998). 
There is also evidence of strain dependent differences in response. A study 
comparing various inbred strains of rat for intracellular signalling pathways 
stimulated during airway contraction found that concentration dependent increases in 
intracellular Ca2+ were seen in Fisher, Lewis and ACI strains of rat, however Fisher 
and ACI showed higher responses than Lewis (Eidelman, DiMaria et al. 1991; Tao, 
Tolloczko et al. 1999). Using video microscopy to measure rates of bronchial 
contraction in various strains of mouse, bronchial responsiveness was found to be 
greatest in AlJ > Balb/C > C3H1HeJ > C57BV6J (Duguet, Biyah et al. 2000). These 
strain differences in response could be attributed to differences in muscarinic 
receptor density (Tao, Tolloczko et al. 1999). 
In the work described in this thesis the majority of studies used C57BLl6 mice 
for pharmacological characterisation experiments and BALB/c mice for ovalbumin 
allergen sensitisation studies. Taken together these data suggest that sensitivity to 
contractile agents varies with species strain and regional location of the airway. 
3.4.3 Significance of extracellular Ca2+ and store released Ca2+ in initiating and 
maintaining a contraction 
To investigate the role of extracellular Ca2+ in the induction and maintenance 
of contraction, lung slices were perfused with either 0 mM extracellular Ca2+ and 
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added EGTA (1 mM) (a divalent cation chelator with a high affinity for Ca2l or 2 
mM extracellular Ca2+. Experiments showed that agonist induced contractions 
required Ca2+ release from internal stores. Inhibition of Ca2+ uptake into internal 
stores and passive outward leak of Ca2+ did not lead to contraction. 
3.4.3.i Readdition of extracellular Ca2+ after store depletion leads to contraction 
Experiments involving SERCA pump inhibition by cyclopiazonic acid (CPA) 
in conditions of 0 mM and 2 mM Ca2+ were designed to determine whether the 
inhibition of Ca2+ uptake alone would increase cytosolic [Ca2+] enough to induce 
contraction; no contraction was seen. In mouse, the small contraction observed with 
the readdition of 2 mM Ca2+ buffer after a prolonged state of 0 mM extracellular 
Ca2+ suggests a Ca2+ store depletion sensing pathway triggering extracellular Ca2+ 
entry (although this was not significant in pig). 
The amount of Ca2+ in the SR is balanced between the depletion of Ca2+ via 
passive outward leak or agonist induced leak and repletion of Ca2+ via reuptake 
through the SERCA pump (Low, Gaspar et al. 1991). In the presence of CPA the 
passive outward leak of Ca2+ is not balanced by repletion leading to a rise in 
cytosolic Ca2+ (Henry 1994). CP A is an indole tetrameric acid metabolite of 
Aspergillus and Penicillin which also inhibits the ATP driven sequestration system 
(Shima and Blaustein 1992). CPA decreased carbachol stimulated Ca2+ transients in 
bovine tracheal single cells loaded with fura-2AM (Ethier, Cappelluti et al. 2005). 
Isometric tension recordings in rat tracheal SM indicated that transient contractions 
were induced by CPA (Henry 1994). In support of these studies, a study in isolated 
178 
Chapter Three: Characterisation of the lung slice model 
rat bronchioles noted that despite the presence of atropine, a contraction was seen 
with the readdition of Ca2+, suggesting capacitative Ca2+ entry through the SOCC 
was triggered for store refilling, this led to a rise in cytosolic Ca2+ levels enough to 
induce contraction (Sweeney, McDaniel et al. 2002). The results presented here 
suggest that a similar response is present in murine PCLS. 
3.4.3.ii Extracellular Ca2+ is required for store refilling to maintain and 
repeatedly induce airway contractions. 
To investigate the role of extracellular Ca2+ in store refilling and Ca2+ release 
to induce airway contraction, 20 mM caffeine was chosen to open the SR located 
RyR. Repeated contractions were shown in 2 mM extracellular Ca2+, however, only 
an initial contraction was shown in 0 mM Ca2+. This experiment demonstrates that 
the contractile pathway requires Ca2+ derived from internal store release. 
In most non excitable cell types, such as parotid acinar cells, pancreatic acini 
and human leukemia cells, an increase in cytosolic [Ca2l was shown to be necessary 
for refilling of intracellular stores (Madison, Ethier et al. 1998). However, in 
vascular smooth muscle, Ca2+ influx was shown to refill stores on store depletion, 
without inducing contraction (Karaki, Kubota et al. 1979; Casteels and Droogmans 
1981). Furthermore, in canine smooth muscle, stores were shown to be refilled 
without tension development, suggesting a refilling pathway that is separate from 
inner cytosolic Ca2+ concentrations (Bames 1985; Bourreau, Abela et al. 1991; 
Janssen and Sims 1993). 
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The physiological role of the ryanodine receptor still remains unclear. 
Currently adenosine diphosphate ribose (cADPR) is hypothesised to be the 
endogenous ligand for this receptor. RyR also shows great sensitivity to intracellular 
Ca2+ fluctuations. A rise in Ca2+ may activate RyR on the SR, leading to a release of 
Ca2+ resulting in contraction, referred to as Ca2+ induced Ca2+ release (CICR) 
(Coronado, Morrissette et al. 1994). Based on studies investigating the role of bovine 
and human RyR in ASM using Ca2+ dye fluorometry, mechanical tension and K+ 
currents, Tazzeo and collegues (2008), suggest that RyR are not directly important in 
mediating ASM contraction or relaxation, however the RyR may direct SR Ca2+ 
towards the plasmalemma and associated Ca2+ extrusion mechanisms, essentially 
preventing SR Ca2+ overloading and increasing the SR Ca2+ buffering capacity 
(Tazzeo, Zhang et al. 2008). They noted that single cells loaded with fluo-4 and 
stimulated with caffeine showed a quick elevation in [Ca2+]i that rapidly reached a 
peak and then decayed, even when more caffeine was applied. 
3.4.4 InOuence of SERCA pump inhibiton on magnitude and maintenance of 
contraction 
Based on previous results indicating that airway contraction was dependent 
on Ca2+ derived from internal store release, protocols were designed to determine the 
effect of internal Ca2+ store uptake inhibition on the magnitude and maintenance of 
contraction. The inhibition of internal Ca2+ store uptake did not appear to 
significantly influence the magnitude or ability to maintain contraction in the mouse 
peripheral airways. Interestingly, a significant reduction in magnitude was seen after 
SERCA pump inhibition using the same protocol in pig. Although the ability to 
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induce and sustain contraction was not affected, results in pig suggest that the supply 
of store released Ca2+ relates to the magnitude of the contraction. This information 
reflects species differences in internal Ca2+ handling. 
Further studies were designed to demonstrate functional differences between 
the IP3R and RyR. SERCA pump inhibition did not prevent contraction or highlight 
significant receptor driven differences. Previous papers measured differences in 
sensitivity of the IP3R and RyR to SERCA pump inhibition, suggesting the existence 
of separate stores for receptor supply (Tribe, Borin et al. 1994; Golovina and 
Blaustein 1997; Nazer and van Breemen 1998; Janiak, Wilson et al. 2001). 
Interestingly, a study showed two functionally segregated SR Ca2+ stores within 
pulmonary arterial smooth muscle cells (Clark, Kinnear et al.), each served by a 
different SERCA pump. One in close proximity to the plasma membrane, is served 
by SERCA2b and releases Ca2+ via RyRI to promote pulmonary artery dilation. The 
other appears to be located centrally, is served by SERCA2a and releases Ca2+ via 
RyR3, which may in turn recruit RyR2 by Ca2+-induced Ca2+ release to elicit a 
propagating global Ca2+ wave and consequent pulmonary artery constriction. 
Interestingly, the expression of SERCA-2 is significantly reduced in ASM from 
asthmatic patients, these ASM cells showed an attenuated rise in [Ca2i and delayed 
return to baseline (Mahn, Hirst et al. 2009). In a follow up study by the same group, 
healthy ASM cells treated with IL-13 and T G F - ~ ~ showed reduced SERCA-2 
expression. Formoterol, the long acting ~ 2 - a g o n i s t t also suppressed SERCA-2 
expression. Additionally, chronic ~ 2 - a g o n i s t t stimulation is also shown to impair 
cardiac relaxation via reduced SERCA-2 activity (Ryall, Schertzer et al. 2008). 
Collective evidence implicates a diverse network of candidates required for SR 
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[Ca2+] regulation and complicates further by suggesting a divided SR Ca2+ store 
arrangement. 
3.4.5 Luminously ~ o n t i n u o u s s s a r ~ o p l a s m i ~ ~ r e t i ~ u l u m m or separate Ca2+ stores for 
IP3R and RyR release? 
In order to investigate the functional roles of the SR located IP3R and RyR 
and to determine whether separate Ca2+ stores supply these receptors, I hypothesised 
i) that the IP3R shares a common Ca2+ store with the RyR for release and has a main 
role in contraction maintenance and ii) that the RyR plays a role in [Ca2+] regulation 
between the SR and cytoplasm and may therefore have access to separate SR Ca2+ 
stores. Numerous studies investigating the structural arrangement of the SR have 
suggested the all or none physiological response observed to pharmacological agents 
may be explained by multiple separate Ca2+ store elements (Parker and Ivorra 1990; 
Bootman, Berridge et al. 1992; Hirose and lino 1994). Exhaustion of response was 
measured via each receptor using conditions to deplete the store. Stimulation of the 
IP3R for release by ACh was unable to stimulate contraction following depletion of 
stores via RyR release, suggesting a common pool. Despite prolonged store 
depletion and following IP3R release, contractions were seen with RyR release, 
which could be interpreted as a structurally separate Ca2+ store for the RyR release 
pathway. However, against this hypothesis was the observation of a second 
contraction following repeated exposure to ACh. Other studies suggested after the 
SR has been depleted by a maximal response to IP3R stimulation, a substantial 
response to caffeine persists, which has previously been interpreted as the 
arrangement of separate stores for both receptors (Yamazawa, lino et al. 1992; 
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Janiak, Wilson et al. 2001). Evidence to suggest a heterogeneous SR structure comes 
from studies in smooth muscle showing that the peripherally located SR may be 
depleted more readily than the SR located near the center of the cells (Devine, 
Somlyo et al. 1972). Calsequestrin was shown to be clustered at sites within the 
peripheral SR, this location was also dense in IP3R (Villa, Podini et al. 1993). 
In contrast there is evidence to suggest the SR is a single luminally 
continuous structure containing both IP3R and RyR in which Ca2+ can freely diffuse 
throughout. A study using pancreatic acinar cells noted free diffusion of Ca2+ 
throughout the store by the refilling of Ca2+ in the apical region despite the Ca2+ 
being introduced at the opposite end of the cell (Mogami, Nakano et al. 1997). Using 
confocal microscopy to monitor the movement of Ca2+ and small fluorescent probes 
in the ER lumen of pancreatic acinar cells, diffusion in to small apical ER extensions 
was observed suggesting Ca2+ release from the apical ER is replenished from the 
bulk of the rough ER at the base (Park, Petersen et al. 2000). Studies in ventricular 
myocytes using fluorescent recovery after photo bleaching (FRAP) observed dye re-
equilibration in the SR, also suggesting a continuous structure (Wu and Bers 2006). 
Studies in cultured cell types using photo bleaching of a Ca2+ store located green 
florescent protein (GFP) also noted that the GFP was able to move freely throughout 
(Montero, Alvarez et al. 1997; Subramanian and Meyer 1997; Dayel, Hom et al. 
1999). These studies suggest sensitivity differences may arise by regulation of IPJR 
and RyR opening by agonist concentration acting on the cytoplasmic portion of the 
receptor. As SR [Ca2l declines, the receptors sensitivity to their cytoplasmic ligand 
is reduced perhaps more so for one receptor than the other creating the appearance of 
functional differences; this could then be interpreted as structurally different stores. 
Furthermore, regions with higher densities of channels, pumps or luminal Ca2+ 
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binding proteins in the SR may result in sites with differing sensitivities to 
agonistslinhibitors (McCarron and Olson 2008); giving the impression of store 
subcompartments existing. 
Conflicting theories in the literature have lead to contradicting 
interpretations. The data presented here do not provide a conclusive answer 
regarding the identity of these compartments in ASM. Two possibilities still exist, 
namely the existence of two spatially separate but partly coupled stores (figure 3.32), 
or incomplete emptying of a single store following either RyR or ACh stimulation. 
Differences between mouse and pig in response to the same protocols may reflect 
species differences in receptor densities at sites on the SR; influencing signaling for 
channels! pumps for refilling and Ca2+ release. A time matched control showing the 
behaviour of the airways with prolonged OmM extracellular Ca2+ prior to agonist 
stimulation should have been included to interpret whether the exhaustion of the 
response is due to depletion of intracellular stores via separate stores or simply 
global depletion of stores due to prolonged 0mM Ca2+ exposure. Such controls will 
be included in future studies. 
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Figure 3.32 The relationship for ctl+ stores within the SR supplying the RyR and 
IPjR pathways remains unclear. Further investigation is required to determine 
whether i) the SR is luminously continuous or ii) made up of separate Ca2+ stores 
which separately supply the RyR and IP3R pathways or iii) consists of stores that 
partially share a common supply of Ca2+ for release via the RyR and IP3R. ER: 
endoplasmic reticulum; PM· plasma membrane; M2 R: muscarinic cholinergic 
receptor type 2; M3R: muscarinic cholinergic receptor type 3; MLCK: myosin light 
chain kinase; MLCP: myosin light chain phosphatase; myosin-P: phosphorylated 
myosin light chains; RyR: ryanodine receptor, SERCA: sarcoplasmic/endoplasmic 
reticulum Cif+-ATPase, IP3: inositol triphosphate, IP3R: IP3 receptor, PLC-P: 
phospholipase C, DAG: diacylglycerol, PIP2: phosphatidylinositol 4,5-bisphosphate. 
p2 R: Pradrenergic receptor; AC: Adenyl cyclase; cAMP: cyclic adenosine 
monophosphate; PDE: phosphodiesterase; PKA: protein kinase A. Adapted from 
(Dietrich, Chubanov et al. 2006; Pelaia, Renda et al. 2008). 
3.4.6 Role of Voltage Operated Calcium Channels (VOCC) in peripheral airway 
contraction 
The data shown here demonstrate that the L-type VOCC antagonist 
nifedipine did not significantly reduce contractile responses to ACh in peripheral 
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mouse or pig airways. The L-type VOCC has remained the best characterised 
pathway of Ca2+ entry, however, varied results have been produced in mouse, rat, 
guinea pig and human for experiments attempting to inhibit agonist induced 
contraction. Using a mouse bronchial ring preparation, when pretreated with 
nifedipine, the maximal contractile response to MCh was lowered by 51.5% (ECso 
0.9 J,lM), suggesting VOCC may play a role at the bronchial level in mouse (Liu, 
Yang et al. 2006). The results of the data shown here suggest that nifedipine does not 
induce relaxation at the peripheral airway level; this is supported by other lung slice 
models (perez and Sanderson 2005). Clinical studies using nifedipine and other L-
VOCCs blockers found overall insignificant effects on contraction (Ferrari, Olivieri 
et al. 1989); suggesting that voltage gated Ca2+ entry pathways are not important in 
asthma bronchoconstriction (Barnes 1985). A likely explanation for the lack of 
inhibition by L-VOCCs inhibitors in the peripheral airway level is the presence of 
alternative Ca2+ entry pathways such as T-type-VOCC, store operated (SOCC) 
(discussed in 3.4.7) and receptor operated calcium channels (ROCC) on the plasma 
membrane. 
3.4.7 Airway contraction inhibited by selected Ca1+ binding agents and Store 
Operated Calcium Channel (SOCC) inhibitors 
Given the previous results showing a lack of VOCC contribution to airway 
contraction/relaxation; the next set of experiments were designed to determine 
whether agonist induced maintenance of contraction is dependent on store refilling 
via the SOCC (1.2.3). 
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The results presented here showed that 2-APB provided some relaxation at 
concentrations above 10 J.1M, although more so for mouse (l mM, 81 % relaxation) 
than pig (1 mM, 34% relaxation). 2-APB within a range of 1 - 100 J.1M has been 
shown to exhibit Ca2+ signal inhibition in numerous cell types acting via the IP3R 
(Bootman, Collins et al. 2002). However, studies using permeabilised cells, cell 
membranes and intact cells suggest that 2-APB may be an inconsistent IP3R inhibitor 
and that the dose used is important (Maruyama, Kanaji et al. 1997). Its variable 
effects are also suggested to be due to the differential action of different IP3R 
isoforms. Hence whilst isoform type 2 IP3R is insensitive to 2-APB effects, for type 1 
and 3 IP3R obvious effects are shown. For these experiments the choice of IP3 
antagonist was limited. Other tools have been used to study Ca2+ signalling but again 
have non specific actions. Heparin is commonly used however, its multiple actions 
include uncoupling G-protein signalling and activating RyR (Ehrlich, Kaftan et al. 
1994; Jonas, Sugimori et al. 1997; Taylor and Broad 1998). Xestospongin has been 
described as a slow acting membrane permeant IP3R antagonist to inhibit Ca2+ 
signalling (Gafni, Munsch et al. 1997); however its mechanism is not clear. In 
addition to decreasing the release of internal Ca2+ stores, 2-APB may also inhibit the 
SOCC that replenish Ca2+ stores (Bootman, Collins et al. 2002), in the high J.LM 
range (> 100 J.1M 2-APB) (Dobrydneva and Blackmore 2001; Flemming, Xu et al. 
2003). 
In mouse nickel (Ni2l (an inhibitor of Ca2+ influx through SOCC) provided 
relaxation at concentrations> 100 J.1M (1 mM, 36% relaxation). In pig relaxation was 
only shown at maximum concentration (1 mM, 12 % relaxation). A study in bovine 
trachea cells loaded with Fura-2 AM noted that Ni2+ (2 mM) maximally decreased 
resting [Ca2ii but had no significant effect on refilling; it was further suggested that 
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the channels through which Ca2+ passed to the inner cytosol to maintain resting 
[Ca2+]i levels had a different sensitivity to Ni2+ than the channels reserved for 
refilling or agonist sensitive stores (Madison, Ethier et al. 1998). 
Lanthanum provided relaxation in mouse (l mM, 68% relaxation). However, in 
pig very little relaxation was seen (1 mM, 5% relaxation). The lanthanides, 
lanthanum ( L a 3 ~ ~ and gadolinium (Gd3+) inhibit Ca2+ permeable cation channels and 
have been used for the characterisation of Transient Receptor Potential (TRP) 
channels (Halaszovich, Zitt et al. 2000). Lanthanum's charge provides a high affinity 
for surface membrane anionic sites such as those normally occupied by Ca2+ and its' 
large hydrated ionic radius prevents cell entry, creating a specific Ca2+ channel 
inhibitor, although at higher concentrations it has been shown to inhibit plasma 
membrane Ca2+ pumping (Kwan, Takemura et a1. 1990; Putney, 2001). 
One explanation for SOCC diversity in different cell types may be attributed to 
the differential expression of various TRPC channel subunits. TRPC 1 is known to be 
sensitive to blocking by 0.02 - 1 mM Gd3+ or 0.01 - 1 mM La3+ (Zitt, Zobel et al. 
1996; Sinkins, Estacion et al. 1998; Liu, Wang et al. 2000). TRPC4 and TRPC5 have 
been shown to be stimulated by La3+ and Gd3+ (Schaefer, Plant et al. 2000; Strubing, 
Krapivinsky et al. 2001; Allakhverdi, Smith et al. 2007). A possible TRPC, 25 pS 
non selective cation channel was previously identified with sensitivity to 1 mM La3+, 
Gd3+ and 100 IlM SKF-96365 and activated by leukotrienes in human bronchial 
smooth muscle (Snetkov, Hapgood et al. 2001). A 25 pS non selective cation 
channel in bovine TSM was also identified that contributed to Ca2+ store refilling 
and cytosolic Ca2+ concentrations (Helli and Janssen 2008), with CP A induced Ca2+ 
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entry that was resistant to nifedipine. Previous work by our group suggests that 
human ASM expresses TRPC1,3,4 & 6. 
I next explored the effects of Icrac inhibition on ASM tone. Initial inhibitory 
dose responses for JS (GSK1349571A) and Nl17 (N11764-14-1) in the presence of 
ACh suggested that in physiological conditions SOCC do not contribute to airway 
contraction maintenance. Therefore I measured airway contractile behaviour in 
conditions designed to favour SOCC activity; using one hour pre-treatment with the 
Icrac inhibitors, which were also maintained throughout the experiment with a 
change from 0 mM Ca2+ (10 J.lM CPA present) to 2 mM extracellular Ca2+. 
Treatment with NIl 7 did appear to reduce the contractile response (albeit not 
significantly). Given the ineffectiveness of the majority of the SOCC inhibitors used 
in this study, it appears that the contribution of SOCC entry for ASM contraction in 
physiological conditions is low although in conditions of store depletion or abnormal 
[Ca2+], SOCC appear to contribute to SR refilling and release for maintenance of 
contraction. Taken together these data argue for a role for SOCC in regulating the 
intracellular Ca2+ store, but argue against short term regulatory effects on ACh 
contractile response, under normal physiological conditions. 
There is limited data to suggest a major role for SOCC in contributing to 
skeletal and smooth muscle tone based on abnormal regulation resulting in 
functional consequences; although SOCC co-existing with non-store operated Ca2+ 
influx pathways may compensate for a lack of functional STIMl and Orait. Defects 
in Ca2+ handling in vascular smooth muscle cells are among the candidate 
mechanisms leading to hypertension. Studies on aortic rings from stroke-prone 
spontaneously hypertensive rats noted increased expression of STIMl and Orail, 
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which contributed to abnormal vascular function (Giachini, 2009) such as increased 
force development after depletion of Ca2+ stores (Kanagy, Ansari et al. 1994). In 
human, further normoxic contraction of the ductus arteriosus at birth is related to 
Ca2+ entry through SOCC and the ability to increase Ca2+ sensitisation (based on 
experiments inhibiting Rho kinase activity with Y -27632, which removed the 
normoxic contraction). Such findings have therapeutic implications for the treatment 
of congenital heart disease (Hong, Hong et al. 2006). Regarding the inclusion of 
TRPC channels as SOCC; there is evidence for SOCC involvement in Duchenne 
Dystrophy, displaying TRPC related abnormal Ca2+ homeostasis in skeletal muscle 
(Vandebrouck, Martin et al. 2002). TRPC6 channels play a role in contractility of 
aortic and vascular smooth muscle (Targos, Baranska et al. 2005). They are 
expressed in cells responding to hydrostatic pressure changes and suggested to 
mediate pressure induced responses. TRPC6 channels are implicated in smooth 
muscle proliferation in patients with idiopathic pulmonary arterial hypertension (Yu, 
Fantozzi et al. 2004) and suggested to generate myogenic tone in arteries (Welsh, 
Morielli et al. 2002; Beech, Muraki et al. 2004). TRPC6 knockout mice show 
increased arterial blood pressure, increased arterial tone and enhanced agonist and 
DAG induced current in smooth muscle (the unexpected increased Ca2+ mediated 
response resulted from a compensated increase in the expression of TRPC3) 
(Freichel, Vennekens et al. 2004; Dietrich, Mederos y Schnitzler et al. 2005; 
Dietrich, Mederos et al. 2005). Mouse models globally targeting STIMl and Orail 
result in early death postnatally (Feske, Gwack et al. 2006; Feske 2009; Picard, 
McCarl et al. 2009). Although, studies investigating the outcome of individual 
deletions in mouse models typically focus on T cells, mast cells and implications for 
the immune system rather than resulting skeletal or smooth muscle development. 
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Mutations in STIM and Orai result in rare human hereditary immunodeficiency 
syndromes. Patients display a loss of T cell cytokine expression, store operated Ca2+ 
entry and CRAC current (Partiseti, Le Deist et al. 1994; Le Deist, Hivroz et al. 1995; 
Le Deist, Hivroz et al. 1995; Feske, Draeger et al. 2000; Feske, Draeger et al. 2000; 
Feske, Prakriya et al. 2005; Feske, Gwack et al. 2006; Feske 2009; McCarl, Picard et 
al. 2009; Picard, McCarl et al. 2009). Evidence suggests that STIMI and Orail are 
the predominant family members responsible for store operated Ca2+ entry in human 
T cells. The predominant clinical phenotype consists of severe T -cell 
immunodeficiency, recurrent viral, fungal and bacterial infections, enamel 
calcification defects and in specific STIMI deficiency, auto immunity is seen (Feske 
2009). Congenital myopathy is also associated; consistent with the roles of STIMl 
and Orail in SOCC in skeletal muscle (Rosenberg 2009; Dirksen, 2009) and STIMI 
in myoblast differentiation (Feske 2009). This myopathy eventually leads to severe 
chronic pulmonary disease with increased mucus retention in the airways (McCarl, 
Picard et al. 2009). 
The data presented in this chapter demonstrates that precision cut mouse and 
pig lung slices provide a robust model to study mechanisms underlying contraction 
and relaxation of airway smooth muscle. Results highlight interesting species 
differences in agonist and inhibitor sensitivity, with the porcine system sharing 
similar pharmacology to human airways. The next chapter describes the application 
of this technique to a sensitised mouse model of airway inflammation. 
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4. CHAPTER FOUR 
4.1 INTRODUCTION 
Asthma is associated with airway hyper-responsiveness, airway remodelling, 
eosinophilic airway inflammation and mucus hyper-secretion. The response has been 
linked in many model systems to up regulation of the T H2 cytokines, IL-4, IL-5, IL-9 
and IL-13 (Robinson, Hamid et al. 1992) (discussed in 1.1). The best approach to 
gain understanding of the pathways involved in asthma and potential drug therapies 
would be to perform experiments on human patients with asthma; such studies 
provide practical difficulties. Animal models provide an alternative to gain 
understanding of the progression of the mechanisms involved in allergic airway 
disease. However, because asthma is a complex multifactorial disease, it is not 
possible to develop a single animal model that can replicate chronic human asthma 
(Nials and Uddin 2008); therefore the animal models developed aim to mimic 
specific features of the disease. Many models of acute and chronic airway 
inflammation have now been established. Due to accumulated knowledge of mouse 
immunology, access to the full genomic sequence and gene targeted mice, mouse 
models have proved particularly useful and seemed an obvious direction for 
experiments with our peLS technique already set up for murine lungs. 
The process for induction of airway inflammation in sensitised models 
involves systemic priming of the immune system against an antigen, followed by 
challenge, a triggering of the allergic reaction by a second application of the antigen 
in the airways. Variations in dose of antigen and form of administration used can 
influence the manifestation. The most natural allergen models involve challenge with 
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house dust mite, pollen or cockroach extracts by intranasal or inhaled administration. 
Previously we had explored differences in airway contractile behaviour using an 
acute mouse model of house dust mite extract exposure via intranasal administration 
(data not shown) and found no major differences in airway sensitivity to 5-HT or 
MCh using the lung slice technique; difficulties in the allergen reaching the distal 
airways were debated. For our studies, ovalbumin (OVA) derived from chicken egg 
white protein was our choice of allergen, given its well established use and ability to 
induce robust, allergic inflammation in many animals (Nials and Uddin 2008). Initial 
sensitisation involved intraperitoneal injection with OV A (in combination with an 
adjuvant, aluminium hydroxide), further challenges required aerosolised OV A 
(described in 2.1). In these experiments the BALB/c strain of mouse was chosen for 
antigen challenge, as this strain develops a strong T H2 biased response (Boyce and 
Austen 2005). C57IBL and AlJ strains have also been used successfully (Kumar, 
Herbert et al. 2008). 
Using OV A challenge in BALB/c mice, we aimed to create a model of 
airway disease with such specific features as AHR and chronic exposure induced 
airway remodelling; to replicate these aspects of human asthma. In this chapter, the 
distal airway structural changes observed and contractile behaviour measured using 
the PCLS technique provided a fascinating insight into the ramifications of such 
allergen exposure for this mouse model. 
The pathway involving the T H2 inflammatory response is the particular focus 
in this chapter. After initial allergen encounter naive T cells are reported to undergo 
differentiation leading to the production of T H2 cytokines, further challenges result 
in inflammatory cell recruitment to the airways and progression of the disease. Table 
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4.1 provides a list some of the cytokines involved in this inflammatory process that 
were considered for investigation in this chapter. 
Table 4.1 Cytokines involved in the airway inflammatory process. All cytokines 
listed were initially used individually for treatment of naive WT mouse lung slices, to 
identify any specific influences of these cytokines on airway contraction behaviour. 
IL-4 
IL-5 
IL-9 
1112 ( ,tokilll" "11111111:11"' 
Drives differentiation of naive T HO cells to T H2 cells, which 
secrete IL-4, IL-5, IL-9, IL-13 but not interferon (O'Garra 
and Arai 2000; Murphy and Reiner 2002). Antigen induced 
allergic inflammation was shown to be decreased in IL-4 
deficient mice (Brusselle, Kips et al. 1994). Anti-IL-4 Ab 
prior to antigen immunisation prevented the development of 
antigen induced airway inflammation, however the same 
administration after immunisation and prior to antigen 
inhalation was not effective in preventing the inflammatory 
response (Coyle, Le Gros et al. 1995). 
Originally identified as a T cell derived cytokine that 
triggers activated B cells for terminal differentiation into 
immunoglobulin producing cells (Takatsu, Takaki et al. 
1994). Major maturation and differentiation mediator for 
eosinophils, which are involved in fibrosis by producing a 
fibrogenic factor ( T G F - ~ ~ 1) (Koike and Takatsu 1994; 
Rothenberg and Hogan 2006). Studies have shown 
increased expression of IL-5 mRNA in bronchial biopsies of 
asthmatic patients (from CD4+ T cells) (Robinson, Hamid 
et al. 1992). Forced expression ofIL-5 in transgenic mice 
leads to eosinophil infiltration (Lee, McGarry et al. 1997). 
Anti-IL-5 mAb was shown to inhibit antigen induced AHR 
and eosinophil infiltration in mice and guinea pig airways 
(Akutsu, Kojima et al. 1995). Antigen sensitised IL-5 
deficient mice show lack of bronchial hyper-reactivity and 
eosinophilia (Foster, Hogan et al. 1996). Anti-IL-5 Ab 
treatment did not reduce asthmatic symptoms and airway 
reactivity in patients with mild asthma (Leckie, ten Brinke 
et al. 2000). Although, anti-IL-5 treatment in mild atopic 
asthmatics has been shown to reduce ECM deposition in the 
bronchial subepithelial basement membrane. Fibrosis is 
abolished in sensitised and allergen exposed IL-5 receptor 
null mice, but increased in IL-5 transgenic mice. Treatment 
with anti-IL-5 Ab in WT mice almost completely abolished 
subepithelial and peribronchial fibrosis in sensitised mice 
(Tanaka, Komai et al. 2004). 
Expression of IL-9 mRNA was increased in bronchial 
biopsy samples of asthmatics (Shimbara, 
Christodoulopoulos et al. 2000). Possible genetic linkage to 
Required for 
initial 
differentiation 
of antigen 
specific T H2 
cells. 
Possible role 
in the late 
asthmatic 
response. Key 
mediator for 
eosinophils, 
involved in 
fibrosis. 
Role in 
inflammatory 
process via 
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AHR (Nicolaides, Holroyd et al. 1997). Suggested that IL-9 
may play a role in goblet cell hyperplasia and mast cell 
development based on experiments using IL-9 deficient 
mice (Townsend, Fallon et al. 2000). Primary ASM cells 
express a functional IL-9R in vitro, further more ASM 
bundles from atopic asthmatics showed increased 
expression ofIL-9R (Gounni, Hamid et aI. 2004). 
Stimulation of IL-9R on ASM showed increased expression 
ofCCL11 via STAT3 signalling, showing a role for 
enhanced eosinophil chemotaxis (Yamasaki, Saleh et al.). 
Antigen challenge in IL-13 deficient mice failed to show 
AHR and mucus production despite the presence of IL-4, 
IL-5 and airway inflammation (Waiter, McIntire et al. 
2001). IL-13 is consistently over expressed in the lungs of 
asthmatic patients (Wills-Karp 2004) and is reported to 
contribute to the T H2 mediated inflammatory response via 
its ability to stimulate gene expression of adhesion 
molecules, chemokines and metalloproteinases. Inhibition 
ofIL-13 in vivo by administration of the soluble IL-13Ra2-
Ig or through IL-13 gene targeting in mice either prevents or 
reverses established mucus cell changes (Grunig, Warnock 
et al. 1998; Wills-Karp, Luyimbazi et aI. 1998; Walter, 
McIntire et al. 2001). IL-13 signalling pathway members 
IL-4Ra and STAT6 have been shown to be involved in 
mucus cell changes (Kuperman, Schofield et al. 1998). IL-
4Ra chain polymorphisms may play a role in asthma 
susceptibility (IL-33 was also linked) (Hoffjan and Ober 
2002). 
chemotaxis. 
Acts on 
epithelial and 
smooth. 
muscle cells. 
Role may be 
independent 
of other TH2 
cytokines. 
Role inAHR.. 
", iI ,"11.11""1.11411' ( \ 14I"IIH" ""111111.11, 
Expressed in a subpopulation of CD4+ T cells, namely T H 17 
cells, involved in autoimmune disease (Weaver, Harrington 
et al. 2006). Induce expression of cytokines and chemokines 
including IL-6, granulocyte macrophage colony stimulating 
factor and induce IL-8 from fibroblasts (Linden 2001; 
Moseley, Haudenschild et al. 2003; Kawaguchi, Adachi et 
al. 2004). Mediate migration of neutrophils, but not 
eosinophils, maybe involved in severe asthma, as 
neutrophils are a hallmark (Jatakanon, Uasuf et al. 1999). 
Produced by activated TH2 cells (Fort, Cheung et al. 2001) 
and mast cells (Jkeda, Nakajima et al. 2003). Systemic 
administration of protein (Fort, Cheung et al. 2001), or 
expression by transgene (Pan, French et al. 2001) induces 
IL-4,IL-5 and IL-13 production from undefined non-T, 
non-B cells, resulting in blood eosinophilia, increased serum 
19B levels and pathological changes in lung and other 
tissues (Tamachi, Maezawa et al. 2006). IL-25 mRNA was 
expressed in lung after antigen inhalation, neutralisation of 
11-25 by IL-25R decreased antigen-induced eosinophil and 
POSSible link 
between 
activation of 
Tcells and 
recruitment of 
neutrophils. 
May play a 
role in 
amplifying! 
prolonging 
T H2 mediated 
inflammation 
in asthma. 
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CD4+ T cell recruitment into the airways. Enhanced 
expression in asthmatic patient airways (Letuve, Lajoie-
Kadoch et al. 2006). 
Tumour 
necrosis 
f a c t o r ~ ~
(TNF-a) 
Leukocyte recruitment through up regulation of adhesion 
molecules on endothelial cells (Babu, Davies et al. 2004). 
Induction of cytokines, chemokines involved in asthma 
(Babu, Davies et al. 2004). Increased levels found in BAL 
and biopsy samples in asthmatic patients (Thomas, Yates et 
al. 1995; Keatings, Collins et al. 1996). Inhalation ofTNF-a 
causes AHR and increased sputum neutrophils (Thomas, 
Yates et al. 1995). Anti-TNF-a Ab reduce endotoxin and IL-
18-induced changes in airways in rodent models (Kips, 
Tavernier et al. 1992; Kumano, Nakao et al. 1999). 
Treatment with the TNF-a antagonist 'etanercept' is shown 
to reduce AHR and asthma symptoms (Berry, Hargadon et 
al. 2006). 
Role in 
pathogenesis 
of severe 
asthma. 
IL-33 IL-1like cytokine (Schmitz, Owyang et al. 2005). IL-33's receptor, 
ST2 is an IL-1R- related protein expressed on T cells and mast cells 
(Trajkovic, Sweet et al. 2004). ST2 may have a possible role in T H2 
responses in asthma (Lohning, Stroehmann et al. 1998). Produced 
by smooth muscle cells, epithelial and dendritic cells, IL-33 drives 
production of IL-5 and IL-13 from T -cells (Schmitz, Owyang et al. 
2005). Stimulates primary human mast cells to produce 
proinflammatory cytokines and chemokines (Allakhverdi, Smith et 
al. 2007). Acts with TSLP to accelerate maturation of CD34+ mast 
cell precursors and induce secretion of T H2 cytokines and T H2-
attracting chemokines (Allakhverdi, Smith et al. 2007). Treatment 
of mice with IL-33 induces expression of high levels ofIL-4, IL-5 
and IL-I3 in various tissues, with eosinophilia and increased IgE 
and IgA. IL-33 treated mice show severe inflammatory lesions of 
the lungs and digestive tract with eosinophilic infiltrates, epithelial 
cell hyperplasia and increased production of mucus (Schmitz, 
Owyang et al. 2005). Human IL-33 mRNA is expressed in airway 
epithelial cells, bronchial smooth muscles and smooth muscle of the 
and ulmo arteries Schmitz, 0 an et al. 2005 . 
4.1.1 AIMS 
The IL-33/ 
ST2 
interaction 
may a play 
role in 
induction of 
airway 
inflammation 
involving 
mast cells. 
This chapter aimed to explore the pathogenesis of hyper-reactivity implicated 
in airway inflammatory disease by studying mechanisms involved in inflammatory 
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mediated increased airway smooth muscle contraction in a murine model of airway 
inflammation. 
4.2 METHODS 
Detailed methods for the preparation of lung slices, use of an oscillating 
tissue slicer, measuring contractile response and staining of slices are provided in the 
materials and methods in 2.1.3. Use of the cryostat slicer for mouse lung tissue 
slicing and H&E staining is described in 2.1.4. Protocols for cytokine incubation and 
ovalbumin sensitisation are also outlined in 2.1. 
4.2.1 Perfusion timing protocols specific to Chapter Four Results 
For image capture of the airway contraction, the lung slices were held in 
place on a microscope slide attached to a chemical perfusion system. For most 
experiments shown, differences in magnitude of contraction were measured to a 
maximum concentration of 10 J.1M methacholine (MCh) for five minutes followed by 
a ten minute wash with buffer (table 4.2). A dose response to MCh was included to 
view changes in airway sensitivity (table 4.3). All chemicals were perfused at a 
constant flow rate (2 ml/minute) over the lung slice during real time video image 
capturing of the airway contraction. 
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Table 4.2 Perfusion timings for contraction to 1 OpM methacholine (MCh) with wash 
timings for airway relaxation measurement. 
10 Jl-M methacholine (MCh) for measurement of airway 
contraction ~ ~ - - - - - - ~ ~ ~ ~ - - - - - - - - - - - - - - - - - - -Time Perfusion 
(minutes) 
o 
1 
6 
11 
16 
2 mM Ca2+ buffer 
10 IlMMCh 
buffer wash out 
measurement of relaxation (five 
minutes) 
end point: measurement of 
relaxation (ten minutes) 
Table 4.3 Methacholine (MCh) dose response perfusion timings for buffer and 
increasing agonist concentrations until relaxation of the airway with wash buffer. 
Contractile agonist dose response 
Time (minutes) [MCh] 
o 2 mM Ca2+ buffer 
1 0.001 IlM 
6 O.OIIlM 
11 0.1 IlM 
16 0.51lM 
21 1 IlM 
26 10 IlM 
31 IOOIlM 
36 
46 
4.2.2 Statistical Analysis 
buffer wash out 
end point 
For all results shown in this chapter, graphed values are derived from the 
initial airway lumen area measurements for individual mice (n= nwnber). Values 
were then expressed as percentage contraction from the initial baseline values (at 
buffer perfusion) when the airway is relaxed. For all figures shown in this chapter, 
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statistical significance was assessed using the Mann Whitney test; used to 
acknowledge median values (rather than mean) and rank distribution of the values 
between control and treatment groups. For all scatter dot plot graphs each dot 
represents an individual airway contraction measurement from an individual mouse, 
red lines indicate median values in each group. Dose response experiments were 
analysed with the PRISM software Graphpad 5.02 using analysis tools for dose 
response for the log of the agonist against the response for variable data. In this 
chapter ECso measurements with confidence intervals (Cl) were calculated to 
provide a measure of differences in airway sensitivity between control and sensitised 
mice or treated slices, when exposed to the same drug concentration protocols (MCh 
dose response). 
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4.3 RESULTS 
4.3.1 Structural remodelling, inflammatory cell infiltration and responsiveness 
of the airways is increased with repeated ovalbumin allergen exposure 
Cardiac lobes from either PBS or chronic OVA sensitised airways were 
frozen in liquid nitrogen and cut to 20 ~ m m thick slices using a cryostat tissue slicer. 
Staining revealed increased eosinophils in the OVA sensitised airways compared to 
PBS treated groups (figure 4.1). 
a) b) 
Figure 4.1 Airway remodelling with increased eosinophils in OVA sensitised lung 
tissue. Representative H & E staining of 20 Jlm thick a) PBS control (n = ten 
airways from ten mice) and b) OVA chronic sensitised mouse lung slices (n = ten 
airways from ten mice), taken at 200x magnification using a Nikon DIAPHOT 300 
microscope. Increased eosinophils and structural changes to the airway wall 
(arrows), particularly basement membrane thickening are visible by eye. 
Previous results from the MRC laboratory, Cambridge, had revealed 
significantly increased airways resistance to MCh in DV A chronic sensitised airways 
compared to PBS treated airways (data not shown, experiment by Jillian Barlow). I 
then designed experiments to directly measure the influence of OVA sensitisation on 
airway sensitivity at the distal airway level using the PCLS technique. In contraction 
experiments shown 'n' equates to number of airways from individual mice, i.e. n = 
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15 equates to 15 airways from 15 mice. I initially designed dose response 
experiments to MCh and 5-HT for chronic OV A sensitised and matched non-
sensitised mice in view of highlighting increased airway sensitivity in the allergen 
exposed mice. Concentration curve experiments to MCh were run 24 hours after 
mouse sacrifice and lung excavation; during experiments an increase in airway 
sensitivity was obvious by eye (figure 4.3). However, 48 hours later during 5-HT 
induced dose response contraction experiments (data not shown), this hyper-
reactivity in the OV A exposed lungs was not obvious and % airway contraction had 
receded to similar levels to that in the non-sensitised airways. Excluding the 
potential for agonist pathway targeted differences in contractile response, the most 
obvious explanation was the influence of the inflammatory environment in retaining 
this increased airway responsiveness. Therefore to show AHR at its peak, the 
following experiments were designed to be achieved within 24 hours of mouse 
sacrifice and lung slice preparation; for each non-sensitised and matched OVA 
exposed model (acute, mid-chronic, chronic). The following results (figure 4.2) show 
% airway contraction from initial dilated airways to contraction to 10 J.lM MCh 
perfusion for five minutes, for non-sensitised and OV A exposed mice. 
Corresponding representative images of airways are shown above. 
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Figure 4.2 Responsiveness of the airways to MCIt is increased with repeated allergen exposure. i) Above microscope images for a) acute, b) 
mid-chronic & c) chronic OVA allergen exposed mice, showing progressive inflammatory cell infiltration and increased airway wall thickness 
corresponding with repeated allergen exposure (130 pm slices, 200x magnification, P = PBS control mouse, 0 = OVA sensitised mouse). ii) 
Airway contractions to a maximum concentration of 1 0 pM MCh perfusion for five minutes in airways from mice that received either P BS or a) 
acute, b) mid-chronic & c) chronic OVA albumin allergen exposure. All experiments were performed within 24 hours of lung excavation. 'n ' 
equates to number of airways from individual mice, i.e n = 15 equates to 15 airways from 15 mice. % contraction was compared to the initial 
area of the fully relaxed airway. Statistical significance was assessed by the Mann Whitney test. Data are shown as scatter dot plot for 
individual mice, red lines indicate median. Airway responsiveness was significantly increased after mid-chronic and chronic sensitisation. P = 
0.0168 for mid-chronic sensitisation (median = 62.2% contraction) vs. matched PBS (median = 39.2%). P = 0.0032 after OVA chronic 
sensitisation (median = 72.7% contraction) vs. matched PBS (median = 40.8%). 
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Figure 4.3 OVA allergen exposure increases airway sensitivity to MCh. 
Measurement of % airway contraction to an MCh dose response in BALB/C mice 
following OVA chronic sensitisation (n = five mice), compared with time point 
matched PBS controls (n = five mice). Experiments were perf ormed within 24 hours 
of lung removal. % contraction is compared to the initial area of the fully relaxed 
airway. EC50 measurements were calculated by graphing the log of the agonist 
against the response for variable slope data. Data points represent median values, 
error bars show inter quartile range. The EC 50 measurement to MCh in P BS airways 
was 206.2 nM (Cl, 66.8 nM - 636.9 nM) compared with 84.7 nM (CL 53.2 nM -
135.3 nM) in OVA airways. ** indicate statistical significance assessed using the 
Mann Whitney test for PBS vs. OVA sensitised groups for individual MCh 
concentrations. Differences in contractile response between P BS and OVA airways 
were significant at MCh concentrations above 0.5 pM (p = 0.0079). 
The above data indicate enhanced airway responsiveness in vitro following in 
vivo sensitisation. I therefore proceeded to investigate how long these enhanced 
contractile responses persist in prolonged culture. Airway contraction in PBS and 
OVA chronic model sensitised airways was measured to 10 I!M MCh within 24, 48 
and 72 hours after lung removal. Experiments revealed that while there was a 
significant difference in airway reactivity between PBS and sensitised airways within 
the first 24 hours; this significance was lost 48 hours after lung removal (figure 4.4). 
At three days post lung removal, magnitude of contraction between PBS and OV A 
airways were similar (data not shown). 
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Figure 4.4 Airway hyper-responsiveness is reduced 48 hours after lung removal. i) 
representative bright field images of airways from chronically OVA sensitised mice 
ai) 24 hours after lung removal and aii) 48 hours after lung removal; both airways 
show airway remodelling with inflammatory cell infiltration and basement 
membrane thickening. ii) Airway contraction in airways from mice that received 
either PBS or chronic OVA allergen exposure in aii) airways measured 24 hours & 
bii) airways measured 48 hours after sacrifice and tissue removal. Airway 
contractions are shown to a maximum concentration of 10 JlM MCh. % contraction 
is compared to the initial area of the fully relaxed airway. Statistical significance 
was assessed by the Mann Whitney test, data are shown as scatter dot plot, red lines 
indicate median values for each group. At 24 hours there is a significant difference 
in airway sensitivity between PBS and OVA sensitised airways (p = 0.0032) (OVA 
sensitised median = 72. 7% airway contraction vs. matched PBS median = 40.8%). 
This significance was lost 48 hours after lung removal (p = 0.056) (OVA sensitised 
median = 57.4% airway contraction vs. matched PBS median = 35.1% airway 
contraction). 
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4.3.2 IL-33 plays a key role in mediating ainvay hyper-responsiveness 
Despite obvious airway structural remodelling in the sensitised airways, 
hyper-responsiveness was diminished 48 hours after lung removal (figure 4.4), 
suggesting the inflammatory environment may play a role in this enhanced airway 
response. The following experiment was designed to study the effects of pre-
treatment with selected inflammatory mediators on magnitude of agonist induced 
airway contraction in the slices. Cytokines known to play a role in the T H2 
inflammatory response were included (lL-4, IL-5, IL-9, IL-13 , IL-17A, IL-25, lNF-
a. and IL-33), refer to table 4.1. Slices were cut from BALB/c wild type (WT) lung 
lobes within 24 hours of sacrifice and incubated overnight with 100 ng/ml of the 
chosen cytokine, contraction experiments were run the following day. 
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Figure 4.5 Overnight exposure to IL-33 increases airway response to MCh. 
Results show % airway contraction to 10 pM MCh following overnight treatment 
with a range of cytokines (lOO ng/ml) in WT BALB/C mice; contraction in OVA 
chronic sensitised airways is also shown. % contraction was compared to the initial 
area of the fully relaxed airway. Statistical significance was assessed by the Mann 
Whitney test, comparing all data to P BS values. Data are shown as scatter plot for 
individual mice, lines indicate median values within each cytokine treatment group. 
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PBS control median = 34.2% airway contraction. Of the cytokines selected, only 1L-
33 significantly increased airway responsiveness to MCh (p = 0.0007, median = 
57.1% airway contraction). Data for OVA chronic sensitised mice is included for 
comparison (p = 0.0001, median = 72.7% airway contraction). 
Given the increased maximal response to MCh seen following IL-33 
exposure, I next investigated the effects of IL-33 on a range of doses to MCh (figure 
4.6). 
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Figure 4. 6 Exposure to lL-33 (l OO nglml) increases airway sensitivity to Melt. 
Measurement of% airway contraction to an MCh dose response in WT BALBlc mice 
following overnight incubation with 1L-33 (lOO nglml) (n = nine mice), compared 
with matched P BS controls (n = nine mice). % contraction is compared to the initial 
area of the fully relaxed airway. The EC50measurement to MCh in PBS airways was 
108.6 nM (CL 52.4 nM - 223.4 nM) compared with 85.3 nM (CL 40.3 nM - 180.5 
nM) in 1L-33 exposed airways. Measurements were calculated using the log of the 
agonist vs. the response for variable sloped data. Data points indicate median, error 
bars indicate inter quartile range. Although a trend towards increased sensitivity 
and magnitude of contraction was seen the difference in the EC50 of the contractile 
response between PBS and JL-33 treated airways was not statistically significant. 
IL-33, a recently named IL- l family member (Baekkevold, Roussigne et al. 
2003; Schmitz, Owyang et al. 2005; Cayrol and Girard 2009), signals via the IL- l 
receptor related protein ST2 (Schmitz, Owyang et al. 2005), which may mediate 
production of cytokines and chemokines in mast cells (Allakhverdi, Smith et al. 
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2007), TH2 lymphocytes (Smithgall, Comeau et al. 2008), NK cells (Bourgeois, Van 
et al. 2009), basophils and neutrophils (Cherry, Y oon et al. 2008). I therefore 
proceeded to investigate responses to IL-33 in an ST2 receptor (also named T1 /ST2) 
KO mouse model, to show that this IL-33/ST2 receptor interaction was required for 
airway hyper-responsiveness. Experiments involved overnight incubation of lung 
slices with IL-33 (100 ng/ml) or PBS equivalent, airway contractions to 10 /lM MCh 
were measured the following day in the slices (figure 4.7a). 
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Figure 4.7a IL-33 induced airway hyper-responsiveness is notfound in the IL-33 
receptor KO modeL Results show % airway contraction to 10 pM MCh following 
overnight treatment with 1L-33 (100 ng/ml) or equivalent P BS controls. 130 pm thick 
slices were cut from either WT or ST2 receptor KO BALB/C mice. % contraction is 
compared to the initial area of the fully relaxed airway. Statistical significance was 
assessed by the Mann Whitney test, data points represent individual mice, red lines 
indicate median for each group. For WT + PBS exposed mice the median = 34.2% 
airway contraction, for ST2-/- + PBS exposed mice the median = 31.9% airway 
contraction. JL-33 exposure induced significantly increased airway sensitivity to 
MCh in WT mice (median = 55.2% airway contraction, p = 0.0003). This increased 
responsiveness to 1L-33 was lost in the ST2 receptor KO mice (median = 30.1% 
airway contraction). 
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Lower degrees of inflammation would be expected to be associated with 
lower concentrations of IL-33; experiments were therefore repeated using 10 nglml 
ofIL-33 (figure 4.7b). Although there was a trend towards increased responses in the 
WT mice, this no longer remained significant. As expected responses in the ST2 KO 
mice were similar to control. 
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Figure 4. 7b Airway hyper-responsiveness after IL-33 (1 0 ng/ml) exposure in WT 
and ST2 KO murine lung slices. Results show % airway contraction to 10 pM MCh 
following overnight treatment with lL-33 (10 nglml) or equivalent P BS controls. 
Slices were cut from either WT or ST2 receptor KO BALBlc mice. % contraction is 
compared to the initial area of the fully relaxed airway. Data points indicate values 
for individual mice, lines indicate medians for each group. Statistical significance 
was assessed by the Mann Whitney test. Although there is a trend towards increased 
contraction in WT mice after IL-33 exposure, this was no longer significant. No 
increase in responsiveness to IL-33 was seen in the ST2 receptor KO mice. 
Previous studies have reported that such cytokines as IL-1 3 may directly 
induce contraction of ASM (Venkayya, Lam et al. 2002). To investigate whether IL-
33 alone induced airway contraction directly, I exposed lung slices to IL-33 (100 
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ng/ml) on a glass cover slip for image capture over 60 minute and eight hour time 
frames (figure 4.8). 
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Figure 4.8 IL-33 alone does not induce immediate airway contraction. Time course 
of% contraction/or airways exposed to 100 ng/ml 1L-33 over a) 60 minutes and b) 
eight hours. Lung slices were kept at 31 C, 5% C02 for the duration of the 
experiments and were removed from these conditions only to acquire data at the 
appropriate time points. Data show median values, error bars indicate inter quartile 
range; n = seven airways (three mice). 
These results demonstrate that IL-33 by itself does not cause a contractile 
response of murine airways. All experiments shown so far in this chapter were 
conducted in BALB/c mice. As previous studies have indicated that BALB/c mice 
are genetically skewed towards a T H2 type response (Nishimura, Santa et al. 1997), 
experiments were repeated in C57BLl6 mice to see if this IL-33 induced AHR is 
strain specific (figure 4.9). 
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Figure 4.9 Airway cOlltraction increased by IL-33 exposure is shown in C57BU6 
mice. Airway contractile response for C57BLI6 mouse lung slices (n = three mice) 
incubated overnight with IL-33 (100 nglml) (11 airways), or PBS (ten airways) prior 
to experiments. Statistical significance was assessed by the Mann Whitney test, data 
show values for individual airways, red lines indicate medians. 1L-33 exposure lead 
to increased airway responsiveness to MCh in C57BLI6 mice (p = 0.0448, median = 
43. 7% airway contraction after 1L-33 exposure vs. median = 28.8% airway 
contraction in PBS group). 
These results suggest that the effects of IL-33 are not strain specific. Whilst 
the initial results of experiments examining a range of cytokines (figure 4.5) did not 
show agonist induced enhanced responses after treatment, previous work has 
suggested enhanced Ca2+ responses in ASM preparations exposed to TNF-a. One 
possible explanation for this difference might be altered sensitivity to agonists such 
as MCh without an enhanced maximum response. I therefore studied the response of 
murine lung slices to a range of concentrations of MCh after pre-exposure to TNF-a 
(figure 4.10). 
211 
c 
o 
;: 
u 
ca 
L.. 
-C o 
u 
~ ~
100 
90 
80 
70 
60 
50 
40 
30 
20 
10 
Chapter Four: Airway hyper-responsiveness in a murine model of airway inflammation 
TNF-alpha (100ng/ml , 24h) 
..... TNF-a: (1 00ng/ml, 24h) (n=4) 
.... PBS (n=6) 
O+-__ - - . . ~ ~ ~ - - - r - - , - - - , - -
·10 
Figure 4.10 Overnight exposure to TNF-a does not alter airway sensitivity to 
MCh. % airway contraction to MCh dose response following overnight treatment 
with TNF-a (100 ng/ml) (n = four mice) or equivalent P BS control (n = six mice). % 
contraction is compared to the initial area of the fully relaxed airway. No difference 
in airway sensitivity is shown between slices treated with TNF-a and PBS controls. 
The EC50measurement to MCh in PBS airways was 150.7 nM (CL 63.9 nM to 355.1 
nM) compared with 213 nM (CL 86.4 nM to 525 nM) in TNF-a exposed airways. 
Data was calculated by graphing the log of the agonist vs. the response for variable 
sloped data, data points are shown as median, error bars indicate inter quartile 
range. 
Cytokine blocking antibodies (Ab) were also considered to be administered 
on the OV A sensitised slices in the hopes of revealing a key mediator involved in 
AHR (figure 4.11). 
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Figure 4.11 Overnight treatment with anti-IL-25 Ab reduces OVA exposure 
induced airway responsiveness to MCh. % airway contraction to 10 pM MCh in 
PBS and OVA chronic sensitised airways from BALBIc mouse lung slices, also 
showing contraction in OVA sensitised airways after overnight treatment with anti-
JL-25 antibody (Ab) (l0 ng/ml) and Ab isotype control. % contraction is compared 
to the initial area of the fu lly relaxed airway. Statistical significance was assessed by 
the Mann Whitney test, data represent individual mice, red lines indicate median 
values within each group. In comparison to PBS control airways (median = 28.3% 
airway contraction), OVA chronic sensitisation induced significant AHR to MCh (p 
= 0.01 47, median = 54. 7%), treatment with the anti-IL-25 Ab reduced this 
significance in the OVA sensitised airways (median = 41.7% contraction, not 
significant); the isotype control Ab did not reduce this significance (median = 
51.9%, p = 0.022). 
Rapidly accumulating literature suggests the T H2 cytokines IL-13 , IL-4, IL-5 
and IL-9 play a role in the inflammatory response and AHR. One possibility is that 
the enhanced response seen to IL-33 is mediated by a range of the TH2 cytokines, but 
that exposure to a single cytokine such as IL-4 or IL-5 is insufficient to cause 
sensitisation. To address this issue I repeated IL-33 exposure of lung slices in slices 
from a T H2 KO mouse model, in which IL-4, IL-5, IL-9 and IL-13 are deleted (figure 
4.1 2). 
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Figure 4.12 % airway contraction to 10 flM MChfollowing overnight treatment with 
1L-33 (100 ng/ml) or equivalent PBS control in airways from a) 1L-25 KO and b) 1L-
4, -5, -9 & -13 KO mice. % contraction is compared to the inilial area of the fully 
relaxed airway. Data points represent individual mice; lines indicate median values 
within each group. Using the Mann Whitney test to assess differences in contraction 
between PBS WT and KO treated airways, no significant difference in contraction 
was found. Although increased airway contraction is observed in IL-25-1- mice 
incubated with 1L-33 (median = 53.9% airway contraction vs. median = 32.6% in 
PBS mice). Note: in the IL-4, 1L-5, 1L-9, 1L-13 KO experiments, contractile 
responses were generally much smaller in WT mice. 
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4.4 DISCUSSION 
In this chapter I aimed to explore mechanisms involved in the pathogenesis 
of airway inflammation and AHR; by applying the PCLS technique to a mouse 
model of allergen exposure induced airway disease. OV A sensitisation led to 
progressive structural remodelling and AHR to I 0 ~ M M methacholine (MCh). 
However, this hyper-responsiveness was decreased 48 hours post lung removal. 
Based on initial results indicating that the inflammatory environment influences 
sensitivity of the airways (due to decline in AHR after 48 hours), lung slices were 
incubated with selected cytokines to investigate differences in contractile response. 
Of the inflammatory mediators assessed for lung slice incubation, IL-33 significantly 
increased AHR to MCh. In lung slices prepared from ST2 (IL-33 receptor) KO mice, 
IL-33 was unable to sensitise the contractile response. Results from this chapter 
suggest that the inflammatory environment promotes AHR and disassociates this 
airway sensitivity from structural remodelling. Importantly, this study implicates a 
role for IL-33 in mediating AHR in this murine model of allergic airway disease. 
4.4.1 Structural remodelling and hyper-responsiveness is induced by repeated 
allergen exposure 
In this study, an allergic inflammatory response was induced in murine lungs 
by sensitisation with ovalbumin. Mice were sacrificed after varying lengths of 
allergen challenge (refer to 2.1, acute, mid-chronic and chronic protocols). 
Progressive structural remodelling and inflammatory cell infiltration from blood 
vessels was seen with increasing allergen exposure. After chronic sensitisation, 
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significant airway remodelling was observed (figure 4.1, 4.2). These results are in 
keeping with previous studies which have noted correlations between length of 
allergen exposure and presence of extracellular matrix deposition (Leigh, Ellis et al. 
2002), also suggesting that repeated allergen exposure may influence the degree of 
remodelling and hyper-responsiveness (Temelkovski, Hogan et al. 1998; Palmans, 
Kips et al. 2000; Trifilieff, EI-Hashim et al. 2000). 
Increasing lengths of allergen challenge corresponded to statistically 
significant increases in agonist induced AHR in lung slices between control and mid-
chronic and chronic sensitised mice. After acute sensitisation, there was a trend 
towards an increase in airway contraction in OVA sensitised mouse lungs compared 
to PBS controls; however this increase was not significant. A dose response to MCh 
was conducted within 24 hours of sacrifice for the OV A chronically sensitised and 
PBS lung slices. Results showed a curve shift left and significant increase in 
magnitude of contraction at MCh concentrations above 0.5 IlM, reflective of 
increased airway sensitivity in the OV A sensitised airways. The ECso measurement 
to MCh in PBS airways was 206.2 nM compared with 84.7 nM in OV A airways. 
Taken together these results show that the AHR which can be measured following in 
vivo exposure to agents such as MCh can be recapitulated in vitro in accurately 
prepared lung slices. No available ECso values for PCLS models from untreated mice 
are present in the literature for comparison. A study using human PCLS « 1.5 mm 
outer diameter) found an ECso of 0.4 IlM to MCh in healthy airways (Wohlsen, 
Martin et al. 2003). 
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4.4.2 Inflammatory environment influences hyper-responsiveness 
Using lung slices from mice exposed to chronic OVA sensitisation, airway 
contractions were induced by a maximum concentration of MCh within 24 and 48 
hours of sacrifice. Hyper-responsiveness was observed in the OVA sensitised mice 
within 24 hours. However, by 48 hours, this reactivity was less significant, despite 
the airway structural remodelling present. This experiment was continued for 72 
hours after sacrifice and again the increased reactivity initially measured in the OV A 
sensitised mice appeared to decline further, to similar levels of contractile response 
measured in the control mice. This suggests that the inflammatory environment 
influences sensitivity of the airways and dissociates AHR from structural 
remodelling as inspection of the airways at 72 hours, as expected did not show any 
reduction in the extent of airway remodelling. Using a different protocol, a previous 
paper measuring constriction six weeks after challenge noted no difference between 
sensitised and control mice (Chew, Hirota et al. 2008), supporting these findings that 
persistent inflammatory mediators are required for sensitisation. This prompted 
further investigation of inflammatory mediator candidates. 
4.4.3 Manipulation of lung slice inflammatory environment suggests IL-33 plays 
a role inAHR 
Animal models of airway inflammation are progressively implicating 
inflammatory mediators which may be involved in initiating this process. Previous 
studies have shown that specific allergens may divert the immune response towards a 
TH2 phenotype (Schulz, Sewell et al. 1998) with induction of cytokines (Seder, Paul 
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et al. 1992), although the precise mechanisms by which T H2 cytokines mediate 
inflammatory infiltration and AHR are still unclear. 
Experiments were designed to explore the influence of overnight cytokine 
incubation of the naive mouse slice on their contractile behaviour. Key inflammatory 
mediator candidates chosen were i) IL-4 for its possible role in initial differentiation 
of the TH2 cells (Brusselle, Kips et al. 1994; Coyle, Le Gros et al. 1995; O'Garra and 
Arai 2000; Murphy and Reiner 2002). ii) IL-5 for its link to eosinophil infiltration 
and possible fibrosis (Robinson, Hamid et al. 1992; Koike and Takatsu 1994; 
Takatsu, Takaki et al. 1994; Akutsu, Kojima et al. 1995; Foster, Hogan et al. 1996; 
Lee, McGarry et al. 1997; Leckie, ten Brinke et al. 2000; Tanaka, Komai et al. 2004; 
Rothenberg and Hogan 2006). Hi) IL-9 which has been suggested to have a genetic 
link to AHR and mast cell development (Nicolaides, Holroyd et al. 1997; Shimbara, 
Christodoulopoulos et al. 2000; Townsend, Fallon et al. 2000). iv) IL-13, which is 
shown to influence epithelial and smooth muscle cell inflammation (Walter, 
McIntire et al. 2001). v) IL-17 A for its link between activation of T cells and 
recruitment of neutrophils (Jatakanon, Uasuf et al. 1999; Fort, Cheung et al. 2001; 
Linden 2001; Moseley, Haudenschild et al. 2003; Kawaguchi, Adachi et al. 2004; 
Weaver, Harrington et al. 2006). vi) IL-25 for its possible role in amplifying the TH2 
response (Jatakanon, Uasuf et al. 1999; Fort, Cheung et al. 2001; Pan, French et al. 
2001; Ikeda, Nakajima et al. 2003; Babu, Davies et al. 2004; Tamachi, Maezawa et 
al. 2006). vii) 1NF-a for its induction of cytokines and chemokines involved in 
asthma (Kips, Tavernier et al. 1992; Thomas, Yates et al. 1995; Keatings, CoIlins et 
al. 1996; Babu, Davies et al. 2004; Berry, Hargadon et al. 2006). viii) Finally, IL-33 
as IL-33/ST2 interaction may play a role in induction of airway inflammation 
through mast cell mediated inflammation (Lohning, Stroehmann et al. 1998; 
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Trajkovic, Sweet et al. 2004; Schmitz, Owyang et al. 2005; Allakhverdi, Smith et al. 
2007) (refer to table 4.1). 
Of the inflammatory mediating candidates chosen, overnight incubation with 
IL-33 (100 nglml) was shown to significantly increase the contraction of the mouse 
peripheral airways (figure 4.5) to contraction levels comparable to the chronic OVA 
sensitised mice, where as none of the other mediators recapitulated the effect of 
OVA. 
4.4.4 IL-33 influences airway hyper-responsiveness 
Further attempts to explore the role of IL-33 in influencing mechanisms 
involved in AHR involved an IL-33 receptor (ST2) KO mouse model. Results in 
figure 4.7a, show that wild type BALBc mice incubated with IL-33 (lOO ng/ml) 
overnight, showed significantly increased contractile responses in comparison to 
controls (p = 0.003). However, in the IL-33 receptor (ST2) knockout mice, no hyper-
responsiveness was observed after incubation with IL-33. 
IL-33's ability to stimulate contraction directly was considered, given that 
such cytokines as IL-13 have been reported to directly act on ASM CV enkayya, Lam 
et al. 2002). To show that IL-33 itself did not induce a contraction, a time course was 
set up with IL-33 incubation of the slices (figure 4.8). No contraction was observed 
within an hour, or over an eight hour period with exposure to 100nglml IL-33, 
indicating that IL-33 does not act directly on the ASM and cannot modulate 
contraction without an agonist present. 
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Previous experiments in this chapter involved the use of BALB/c mice, 
selected for sensitised models due to their preferential T H2 response (Nishimura, 
Santa et al. 1997). However, it was necessary to show that IL-33's effects on AHR 
were not strain selective; therefore these experiments were repeated in C57BLl6 
mice. Again IL-33 (100 ng/ml) was able to sensitise airways inducing an increased 
response to MCh in comparison to controls. 
From previous literature there is evidence to suggest TNF -a. may play a role 
in hyper-reactivity. Treatment with the TNF-a. antagonist 'etanercept' was shown to 
reduce airway hyper-reactivity in patients with refractory asthma (Berry, Hargadon 
et al. 2006). Using inhaled recombinant human TNF-a on normal patients, hyper-
responsiveness and increased sputum neutrophils were noted (Thomas, Yates et al. 
1995). Experiments in this chapter, designed to study the effects of recombinant 
mouse TNF-a on AHR, showed that slice incubation with TNF-a 100 ng/ml did not 
significantly increase airway contraction to a maximum concentration of MCh, 10 
f..I.M (figure 4.5). Additionally, no differences in airway sensitivity between TNF-a 
exposed and PBS airways were seen with a MCh dose response (0.001 - 100 f..I.M) 
(figure 4.l0). 
The activities ofTNF-a. are mediated by two distinct receptors, p55 (TNFR1) 
and p75 (TNFR2). A study in mouse tracheal rings treated with TNF-a, 
demonstrated that carbachol induced isometric force was significantly increased after 
treatment compared with controls. However, this enhanced response was abolished 
in p55R deficient mice and in control rings treated with a TNF-a mutant that only 
activates the p75R (Chen et al. 2003). A study by Kanehiro and colleagues, 1992, 
sensitising p55 and p75 KO mice with ovalbumin revealed that p75 deficient mice 
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developed AHR with similar levels to control mice. However, sensitised p55 KO 
mice failed to develop AHR (Kanehiro, Lahn et al. 2002). Furthermore in p55 
deficient mice IL-5, IL-13, IFN-y and IL-12 were significantly reduced compared to 
controls, with greater reduction than in p75 deficient mice; suggesting a dominant 
role for the p55 receptor pathway in THl and TH2 cytokine production and eosinophil 
recruitment to the lung. In human, TNF -a also induces trachea smooth muscle cell 
proliferation by activation of the p55 receptor (Amrani, Aubier et al. 1996). Given 
the independent cell expression (Ryffel and Mihatsch 1993) and lack of homology of 
the intracellular domains (Dembic, Loetscher et al. 1990), these receptors are likely 
to have different functions. p75 has greater specificity and affinity for TNF-a 
interactions than does p55 (Medvedev, Espevik et al. 1996), with the suggestion that 
p75 functions in transmitting activating signals for apoptosis (Bazzoni and Beutler 
1996; Hsu, Shu et al. 1996) and also to bind TNF-a and deliver it to the p55 receptor 
(Tartaglia and Goeddel 1992). Most interestingly, the murine p55 receptor binds 
both murine and human TNF-a, however, the murine p75 receptor only binds murine 
TNF-a and not the human protein (Lewis, Tartaglia et al. 1991). Taking into account 
these findings, my results suggesting that recombinant murine TNF -a exposure did 
not sensitise airways may actually be reflecting conflicting actions of the murine p55 
and p75 receptors. Using recombinant human TNF-a on the mouse lung slices, with 
an affinity for the p55 receptor only, I would expect increased sensitivity of the 
mouse airways. Furthermore the specific differences in binding affinity of the mouse 
p55 and p75 receptors present an opportunity for dissecting the distinct receptor roles 
in the inflammatory response and AHR. 
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The work summarised above had established that IL-33 was an upstream 
mediator of AHR; however, the downstream targets responsible for altered 
contraction in the ASM remained unclear. In an attempt to unravel the major players 
involved, experiments involving blocking Ab and KO mice were conducted. IL-25 
was considered based on previous literature documenting its role in inducing IL-4, 
IL-5 and IL-13 production from undefined non-T, non-B cells, resulting in blood 
eosinophilia, increased serum IgE levels and pathological changes in lung and other 
tissues (Tamachi, Maezawa et al. 2006). Experiments involved treating OVA 
chronically sensitised lung slices with an anti-IL-25 Ab, overnight. OVA chronic 
sensitised airways showed significant AHR to MCh. Treatment with the anti-IL-25 
Ab reduced this significance in the OV A sensitised airways; the isotype control Ab 
did not reduce this significance. These results indicate a potential role for IL-25 in 
the inflammatory pathway leading to altered airway sensitivity. 
These experiments were trialled on a larger scale using KO mice: for IL-25-1-
and for the combination: IL-4-1-, IL-S-I-, IL-9-1- and IL-13-I- (figure 4.3.2.8). These 
KO lung slices were incubated over night with IL-33 for contractile experiments to 
MCh. In IL-25 KO lung slices treated with IL-33, airway reactivity was increased 
but not significant compared to PBS treated controls. In the IL-4, IL-5, IL-9 and IL-
13 KO lung slices both PBS control and IL-33 treated airways gave similar yet small 
contractions « 30%). Without a reliable contraction in control mice, results could 
not be confidently interpreted. However, a general trend suggested that the IL-4, IL-
5, IL-9 and IL-I3 KO airways showed a reduced response and that exposure to IL-33 
by itself did not reinstate this increased reactivity. These experiments should have 
been repeated, however, with the availability of tissue and difficulty in breeding such 
KO mice, the opportunity only arose once. Despite the disappointing outcome for 
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this experiment, use of such KO mice and blocking Ab provides an exciting 
approach to further unravelling the mediators of AHR in this lung slice model. 
4.4.5 Does IL-33 have relevance for the treatment of human asthma? 
IL-33 has been reported to act intracellularly as a transcription factor and 
extracellularly as a NF-KB inducing cytokine (Carriere, Roussel et al. 2007). The 
membrane bound form of the mouse IL-33 receptor (TlIST2) forms a complex with 
IL-33 to activate NF-KB and MAP kinases and drive production of TH2 cytokines 
(IL-4, IL-5 and IL-13) (Schmitz, Owyang et al. 2005). The detailed mechanisms are 
discussed further in Chapter Five. In murine models administration of exogenous IL-
33 has produced splenomegaly, increased mucous production and hypertrophy in the 
respiratory and digestive tract (Schmitz, Owyang et al. 2005), IL-33 's role has also 
been suggested in the immune response in the CNS (Hudson, Christophi et al. 2008). 
Previous studies have shown that TlIST2 is preferentially expressed on murine TH2 
cells (Coyle, Lloyd et al. 1999). Antigen specific TH2 cytokine responses and 
effector function were impaired in TlIST2 deficient mice (Townsend, Fallon et al. 
2000). Administration of a TlIST2 mAb or a TlIST2 fusion protein reduced the 
induction of a T H2 immune response in lung mucosa (Lohning, Stroehmann et al. 
1998). Studies in a murine model of airway inflammation showed induced 
expression of IL-33 and the soluble and membrane bound forms of SU. The soluble 
form ofSU is suggested to act as an inhibitor ofIL-33/ST2 signalling as its addition 
reportedly blocked the induction of TH2 cytokines (IL-4, IL-5, IL-l3) from IL-33 
stimulated splenocytes and suppressed activation of NF-KB (Hayakawa, Hayakawa 
et al. 2007). Rapidly accumulating evidence suggests a critical role for IL-33 in 
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allergic airway inflammation in animal models; however, the clinical relevance for 
human airways remains unclear. 
Only recently studies have explored expression of IL-33 in human tissue and 
its role in the TH2 response in diseased states. Use of cDNA libraries suggests human 
IL-33 is predominantly expressed by structural cells including fibroblasts and 
endothelial cells (Schmitz, Owyang et al. 2005; Carriere, Roussel et al. 2007). 
Recently IL-33 expression has been shown at the mRNA and protein level on ASM 
(prefontaine, Lajoie-Kadoch et al. 2009). IL-33 expression was shown to be 
increased in bronchial biopsies from patients with asthma in comparison to controls. 
These data suggest IL-33 plays a role in the inflammatory response and AHR 
in animal models, with potential translation to the allergic inflammatory response in 
human. Future studies will involve contractile experiments after treatment of naive 
mouse lung slices with bronchoalveolar lavage fluid taken from OV A sensitised 
mice and supernatants taken from OVA sensitised mouse lung slices. These 
experiments will attempt to demonstrate the essential requirement of the cytokines 
identified in these studies; that are present in the inflammatory environment to 
initiate and maintain AHR. The next chapter explores the mechanisms involved in 
IL-33 mediated AHR with particular emphasis on the downstream inflammatory 
mediators and cells targeted by IL-33. 
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5. CHAPTER FIVE 
5.1 INTRODUCTION 
In the previous chapter a potential key role for IL-33 in mediating enhanced 
airway contractile responses to MCh was identified using an av A sensitised mouse 
model. OV A sensitisation resulted in structural changes, increased eosinophil 
infiltration around the airways and increased reactivity to MCh in ex vivo lung slices. 
This hyper-responsiveness was decreased 48 hours after lung removal despite airway 
remodelling. Of the cytokines chosen to study which might influence airway 
sensitivity, IL-33 significantly increased AHR to MCh in naive lung slices. This 
increased airway contractile response induced by IL-33 exposure in naive, WT 
BALB/c and C57BLl6 mouse lung slices suggests that IL-33 was able to produce 
AHR in the absence of previous sensitisation in vivo. As demonstrated using the ST2 
receptor KO mice, this AHR pathway requires an interaction between IL-33 and the 
ST2 membrane receptor. Most significantly, these results reflect the influence of the 
inflammatory environment on ASM function, independent of structural remodelling. 
Although IL-33 is a recently discovered IL-l family member (Baekkevold. 
Roussigne et al. 2003; Schmitz, Owyang et al. 2005; Cayrol and Girard 2009), 
rapidly accumulating studies have supported the role for IL-33 in airway 
inflammation; further attempts are now being made to unravel the mechanisms 
involved. Before designing the experiments for this chapter, previous literature was 
reviewed to summarise the known role of IL-33 in various cell types (table 5.1), to 
identify common pathways in inflammatory cells and structural cells. Published data 
for expression profiling of IL-33 and the ST2 full length transmembrane receptor 
(ST2L) are summarised in table 5.2. 
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In this chapter the regulation of the IL-33/ST2 receptor axis was further 
explored to detennine if increased IL-33 and ST2 receptor expression were shown in 
sensitised lung slices. This regulatory axis was also investigated in the human system 
to detennine whether IL-33 targets the ASM directly. 
In addition, given the possibility that enhanced contractile responses of ASM 
could be due to altered Ca2+handling (as has previously been demonstrated by IL-13 
induced upregulation of the RhoA protein, involved in Ca2+ sensitivity (Chiba, 
Nakazawa et al. 2009»; I also explored the possible regulation by IL-33 of key 
proteins involved in Ca2+ homeostasis, namely STIMl and OraB. Dr S. Peel 
(Therapeutics and Molecular Medicine Department) had previously shown that 
STIMl and Orail play a role in SOCC activation following store depletion in human 
ASM (Peel, Liu et al. 2008). The depletion of Ca2+ results in dissociation of Ca2+ 
from STIMl, which causes STIMl to relocate within the ER to areas near Orail 
channels located in the plasma membrane. STIMl is then proposed to activate Ca2+ 
selective Drail channels (Smyth, Dehaven et al. 2006; Putney 2007). IL-33 mediated 
regulation of STIMI-Orail activity was considered as a potential pathway for 
increased ASM cell Ca2+ entry and resulting increased airway contraction; therefore 
experiments were designed to investigate differences in expression of STIMl and 
Orai 1 between OV A sensitised and matched non-sensitised mouse lung tissue. 
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Table 5.1 Evidellce to support the role of lL-J3 in selected ceU types promoting the airway inflammatory response. 
Cardiac 
muscle 
ASM 
Endothelial 
Epithelial 
Mast cells 
Macrophage 
Expression in cardiac myocytes, soluble ST2 release in response to myocardial infarction (Weinberg, Shimpo et al. 2002). 
Higher levels ofIL-33 were detected in biopsies from asthmatic patients compared to controls. IL-33 was shown to be 
at both Drotein and mRNA levels in ASM cells lPrefontaine. Laioie-Kadoch et al. 
IL-33 was initially discovered as a nuclear factor expressed in high endothelial venules (NF-HEV), specialised blood vessels 
which mediate lymphocyte recruitment into lymphoid organs. This spawned theories that IL-33 may act as both a cytokine and 
nuclear factor, similarly to IL-la and chromatin-associated cytokine HMGBl. IL-33 is suggested to play a role as an 
endogenous danger signal to alert the immune system after endothelial or epithelial cell damage (Moussion, Ortega et al. 
2008). IL-33 is constitutively expressed in large and small blood vessels in most tissues (> 50) and is expressed in endothelial 
cells from lymphoid tissues, rheumatoid arthritis and Crohn's disease. IL-33 was also expressed in the nucleus of endothelial 
cells in specific human tumours, suggesting IL-33 is a marker of tumour blood vessels. These data suggest that IL-33 is a 
nuclear marker of the endothelium in normal and chronicallv inflamed human tissues (Moussion. Ortel!a et al. 
Using immunostaining for IL-33 in endobronchial tissue sections from patients with mild, severe asthma and controls; the 
bronchial epithelium of patients with severe asthma showed elevated IL-33 levels over those with mild asthma and controls 
(Prefontaine, Nadigel et al. 2009). In a recent study S1'2 showed expression in epithelial and endothelial cells (not fibroblasts 
or smooth muscle), in this study IL-33 mediated the production ofIL-6, IL-8 and MCP-l from epithelial cells and 
microvascular endothelial cells (Orihara. Yal!ami et al. 
In naive murine bone marrow-derived, cultured mast cells IL-33 promoted IL-13 and IL-6 production. IL-33 promoted 
cytokine production via a MYD88-dependent pathway (Ho, Ohno et al. 2007). Administration of IL-33 to WT mice 
exacerbated collagen-induced arthritis and increased production of proinflammatory cytokines and anti-collagen Ab. Mast cells 
expressed high levels of STIL and after IL-33 stimulation produced inflammatory cytokines and chemokines (IL-5, IL-13 but 
not IL-4) lXu. Jianl! et al. 
IL-33 changed the phenotype of alveolar macrophages toward an alternatively activated macrophage (AAM) phenotype that 
expressed the mannose receptor, IL-4Ra and produced IL-13 dependent high levels ofCCL24 and CCL17. IL-33 increased IL-
13 induced polarization of alveolar and bone marrow derived macrophages towards an AAM phenotype, through IL-13/ IL-
4Ra si2Ilallinl! for inducinl! eXDression of ST2L. Increased exoression of IL-33 in lunl! eoithelial cells of asthmatic .. 
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Eosinophil 
Basophil 
compared to healthy controls was also shown (Kurowska-Stolarska, StolarskLeLal. 2002}. 
IL-33 increased eosinophil survival and increased cell surface expression of the intercellular adhesion molecule (ICAMI) on 
eosinophils (Chow, Wong et al.). IL-33-mediated increased survival of adhesion molecules and release of cytokines and 
chemokines were differentially regulated through activation of the nuclear factor (NF)-kB, p38 mitogen activated protein 
kinase (MAPK) and extracellular signal-regulated kinase (ERK) pathway. Aside from basophils, eosinophils are the only other 
leukocyte-type directly activated by IL-33, shown by screening of p38 activation in peripheral blood cells (Pecaric-Petkovic, 
Didichenko et al. 2009). 
Using mouse bone marrow derived cultured basophils, IL-18 and IL-33 stimulation lead to production ofIL-4, IL-13. IL-I8 
and IL-33 activation ofTH2 cytokine production occurs through MYD88 and p38a. signalling proteins (Kroeger, Sullivan et al. 
2009). Human basophils express IL-18 receptors, ST2 surface expression is inducible by IL-3. IL-33 promotes IL-4, IL-13 and 
IL-8 secretion with IL-3 and/or Fc€RI-activation and enhances Fc€RI-induced mediator release. IL-33 activates NF-KB and 
shows a preference for p38 MAP kinase, while IL-3 acts through JAKlSTAT and preferentially activates ERK (Pecaric-
Petkovic, Didichenko et al. 2009). 
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Table 5.2 Published data on the expression of IL-33 and the ST2L (membrane 
bound) receptor in a range of cell types in human tissues. 
1 \JlIT"ioll 11 -."n "121. I ~ ~ l'll'IT" l'l' 
ASMcells RNA (Prefontaine, Lajoie-Kadoch et al. 2009), 
this study 
Endothelial RNA, RNA (Moussion, Ortega et al. 2008; Prefontaine, 
cells (vascular, protein Lajoie-Kadoch et al. 2009) 
lung) 
Epithelial cells RNA, RNA (Prefontaine, Nadigel et al. ; Schmitz, 
(lung) protein Owyang et al. 2005; Moussion, Ortega et 
al. 2008). this study 
Mast cells RNA (Allakhverdi, Smith et al. 2007). this study 
Macrophages RNA (Schmitz, Owyang et al. 2005) 
Fibroblasts Protein RNA (Moussion, Ortega et al. 2008) 
Dendritic cells RNA (Schmitz, Owyang et al. 2005; Tumquist, 
Sumpter et al. 2008) 
T lymphocytes RNA, (Oshikawa, Yanagisawa et al. 2002) 
protein 
Eosinophils, Protein (Chow, Wong et al. ; Pecaric-Petkovic, 
Basophils Didichenko et al. 2009; Valent 2009) 
5.1.1 AIMS 
The aims of the work described in this chapter were i) to investigate 
regulation of expression of IL-33 and ST2 soluble and membrane bound receptor 
mRNA in OVA sensitised mouse lung tissue using quantitative PCR and ii) to 
examine expression in these samples of the key proteins STIMI and Orail, involved 
in ASM Ca2+ homeostasis and store operated Ca2+ entry. 
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5.2 METHODS 
All relevant methods for cell culture, RNA isolation, cDNA synthesis, 
protocols for quantitative peR, Affymetrix microarray data and analysis are 
described in section 2.3. 
5.2.1 Statistical analysis 
Using PRISM software Graphpad 5.02, statistical significance was assed by 
the Mann Whitney test, which ranked the data and compared medians. For all scatter 
plots, each dot represents an individual mouse, red lines indicate median values ('n' 
refers to number of mice). 
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5.3 RESULTS 
Quantitative PCR (Q-PCR) experiments were designed to investigate altered 
expression of STIM1, Drail, IL-33 and the ST2 soluble (ST2s) and membrane 
bound (ST2L) receptors in OVA sensitised mouse lung tissue. Initial experiments 
were performed to examine the efficiency of Q-PCR reactions for the target genes. 
Figure 5.1 shows standard curves for murine IL-33, ST2L, ST2s and the potential 
housekeeping genes, 18S and p-actin. Initial results suggested little difference in 
terms of performance of murine 18S and p-actin as housekeeping genes and the 
results for murine experiments shown in this chapter were all standardised to p-actin. 
Figure 5.4 shows standard curves for Q-PCR reactions for murine STIM1, Orail and 
p-actin. Primer efficiencies were determined by plotting a cDNA standard curve. 
Although primer efficiencies were not 100%, they were all similar in value to each 
other; therefore for comparative analysis the 20MCt equation was used (see methods, 
2.3.6). For results shown, reactions for PBS and OV A cDNA samples were repeated 
in triplicate for all genes examined. The 'n' number equates to the number of 
individual mice used, individual scatter points represent the mean of the three values 
found for individual cDNA samples, from individual mice. Data were analysed using 
the Mann Whitney test, with mRNA expression measured relative to the p-actin 
house keeping gene. 
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5.3.1 Increased expression of IL-33, ST2s and ST2L in ovalbumin sensitised 
lung tissue 
Prior to Q-PCR experiments targeting IL-33, ST2 soluble (ST2s) and ST2 
membrane bound (ST2L) primer efficiencies were calculated for the assays (figure 
5.1) from cDNA standard curves using cultured naIve WT mouse trachea smooth 
muscle cells (see methods, 2.2.1). 
mou •• ST2. 
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Figure 5.1 Standard curves for Q-PCR reactions for murine ST2s, ST2L, IL-33, 188 
and p-actin. In each case the amplification of two fold serial dilutions of narve WT 
mouse trachea smooth muscle cDNA (three repeats within experiment) was 
performed. The slope of each graph and peR amplification ejJiciencies are shown. 
Initial Q-PCR experiments were designed to reveal differences in IL-33 
expression in whole lung tissue from the OV A sensitised mice compared to controls 
(figure 5.2). 
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Figure 5.2 IL-33 mRNA expression is increased in OVA sensitised lung tisSlle. Quantitative peR results showing mRNA expression of JL-33 in 
acute, mid-chronic and chronic OVA sensitised BALB/C mouse lung tissue compared with PBS controls. Data were analysed using the Mann 
Whitney test, with IL-33 mRNA expression measured relative to the fJ-actin house keeping gene. Results showed significantly increased 
expression of IL-33 in all OVA sensitised models (acute, mid-chronic, chronic) compared to matched non-sensitised mice. 
Given this up regulated expression of IL-33 in the sensitised lung tissue, further Q-PCR experiments were designed to investigate 
whether ST2 receptor transcription was also increased in these samples. Results showed increased expression of the alternatively spliced 
secreted soluble form of the ST2 receptor (ST2s) and the full length transmembrane form (ST2L) in mid-chronic and chronic sensitised models 
(figure 5.3). 
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Figure 5.3 ST2s and ST2L mRNA expression is increased in OVA sensitised lung tissue. Quantitative peR results showing mRNA expression 
of a) ST2s and b) ST2L in acute, mid-chronic and chronic OVA sensitised BALB/C mouse lung tissue compared with PBS controls. Data were 
analysed using the Mann Whitney test, mRNA expression is measured relative to the fJ-actin house keeping gene. Significantly increased 
expression of the ST2s and ST2L receptors are shown after mid-chronic and chronic OVA sensitisation of the lung tissue compared to matched 
non-sensitised tissue. 
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Results for quantitative PCR experiments comparing expression of IL-33 and 
the ST2 soluble (ST2s) and membrane bound (ST2L) receptors in OVA sensitised 
and control mouse lung tissue suggest significantly increased expression of IL-33 in 
all samples and increased expression of ST2s (soluble) and ST2L (full length 
transmembrane) in the mid-chronic and chronic OV A sensitised lung tissue 
compared with controls. To better understand the regulation of the IL-33/ST2 axis, 
further Q-PCR assays were designed for human protein targets (shown in 5.3.3). 
5.3.2 STIMll Orait: a potential role in ovalbumin sensitised airway hyper-
responsiveness? 
Studies on SOCC suggest a key interaction involving STIM I (ER Ca2+ 
sensor) and Orail (CRAC channel pore forming subunit) (Liou, Kim et al. 2005; 
Roos, DiGregorio et al. 2005; Soboloff, Spassova et al. 2006). Given the data shown 
in 5.3.1 demonstrated upregulation of the IL-33/ST2 axis in sensitised murine lung 
tissue; I next investigated whether or not this resulted in altered regulation of 
components of the Ca2+ signalling pathway in the tissue, in particular STIMl and 
Orail. The potential role of SOCC and disregulated Ca2+ entry in attenuating airway 
contraction leading to AHR was considered; given that IL-33 expressed in damaged 
tissue has been shown to induce other cytokines such as IL-13 (Mahn, Ojo et al. ; 
Chiba, Nakazawa et al. 2009) which play a role in altered Ca2+ handling in ASM. 
Using quantitative PCR, altered mRNA expression of STIM 1 and Orai 1 was 
investigated in the OV A sensitised mouse lung tissue. Prior to Q-PCR experiments 
primerefficiencies were calculated for STIMl and Orail assays (figure 5.4). 
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Figure 5.4 Standard curves for Q-PCR reactions for murine STIM1, Orail and {3-
actin. For each, the amplification of two fold serial dilutions of naive WT mouse 
trachea smooth muscle cDNA (three repeats within experiment) was performed. The 
slope of each graph and PCR amplification efficiencies are shown. 
The following results for Q-PCR experiments show differences in expression 
of STIMl and Orai! in the OVA sensitised lung tissue and non-sensitised mouse 
lung tissue (figure 5.5, 5.6). 
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Figure 5.5 STIM1 mRNA expression is decreased in OVA sensitised lung tissue. Quantitative peR results showing mRNA expression of 
STIMJ in acute, mid-chronic and chronic OVA sensitised BALB/C mouse lung tissue compared with PBS controls. Data were analysed using the 
'ann Whitney test, with mRNA expression measured relative to the p-actin house keeping gene. Expression of STlM1 was significantly 
decreased in chronically sensitised lung tissue (44 + 1.8% decrease compared with PBS). 
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Figure 5.6 No difference in Orail mRNA expression between PBS and OVA sensitised lung tissue. Quantitative peR results showing mRNA 
expression of Orail in acute, mid-chronic and chronic OVA sensitised BALB/C mouse lung tissue compared with PBS controls. Data were 
analysed using the Mann Whitney test, with mRNA expression measured relative to the fJ-actin house keeping gene. 
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Results for quantitative PCR experiments comparing expre ion of TIMl 
and Orail in OVA sensitised and non sensiti sed mou e lung ti ue ugge t TIMl 
was significantly decreased in the chronic lung ti u c mpared with controls. 
Results for Orai 1 expression were of particular intere t a rai I i thought to form 
the CRAC channel for Ca2+ influx for store refilling; h w ver, re ult indicated no 
difference in Orai1 expression between ensiti ed and c ntrol lung ti ue, therefore 
this work was not pursued further in the human y tern . T IM 1 and Orail have 
previously been demonstrated to play a role in human immunodeficienc (Feske 
2009) and are known to be expressed in the A M (Peel Liu et a!. 200 ). 
5.3.3 Expression of IL-33 and the T2 receptor in human ainvay mooth muscle 
Given the previous results indicating altered expre i n f IL-33 and T2 in 
sensitised murine lung tissue (5.3.1)' Q-P Ra ays were de ign d fi r human IL-33 
and ST2, to determine whether 1L-33 could act dire tly n human airwa smooth 
muscle (HASM) to induce hyper-respon iv n f IL-33 and the ST2 
membrane receptor was investigated in primary ultur d HA M and human 
bronchial epithelial cells (HB C) cultured fr m lung bi pi . h human mast cell 
line (HMC-1) was used as a control for 2 xpr i n. Initial P R amplification of 
the ST2 soluble fonn ( T2s) (designed t h v ex n th T2s and 
ST2L) and the T2L membrane rec pt r fail ed t 
with non quantitative visuali ati n u ing gel ele tr fi gur 5.7. 
240 

Chapter Five Results: Mechanisms ofIL-33 mediated airway hyper-responsiveness 
S2 
human ST2s, HMC-1 
log (IDIIII RNA inpuQ ng 
1Iope. -3.47 ± 0.07 
eIIk:Iency • 93.94% 
human HPRT, HMC-1 
log [IDIIII RNA inpuQ ng 
IIope • -3.45 ± 0.08 
ellk:iency • 94.73% 
hUlllln 1..-33, .. EC 
4.0 -u -1.0 .u 0.0 U 
log 1'* ~ ~ Input) ng 
IIopt • -5.54 t 0.21 
IIIIc:Iency • 51.46'16 
32 
30 
21 
20 
18 
(j 
1. 
14 
human STZL, HMC-1 
log [toIIiI RNA Input) ng 
IIope • -3.54 ± 0.06 
emclency • 91.82% 
human 188, HMC-1 
12+---,------,r---""T"""---, 
-2.0 -1.1 -1.0 -cu 0.0 
log [toIIiI RNA Input) ng 
IIope • -3.87 ± 0.05 
etfIclency • 81.38% 
hUlllln 188, HBEC 
1.4+--.....----.--....-""T"""----. 
-1.0 -1.1 -1.0 -0.. 0.0 U 
log [1otII RNA Input] ng 
1Iope. -4.405 t 0.16 
elllclency • 1 1 8 . ~ ~
hUlllln GAPOH, IlJEC 
-1.0 -1.1 -1.0 .u 0.0 ILl 
log ]ICIII RNA I ~ ~ ng 
1Iopt. -4.91 ± 0.37 
IIIIcienCy • 58. n" 
Figure 5.8 Standard curves for Q-PCR reactions for human ST2S, ST2L, IL-33, 
HP RT, 18S and GAP DH for the amplification of two fold serial dilutions of either 
human mast cell (HMC-1) or human bronchial epithelial cell (HBEC) cDNA (three 
repeats within each experiment were performed). The slope of each graph and PCR 
amplification efficiencies are shown. 
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Q-PCR experiments were designed to determine if the ST2 receptor is 
expressed on HASM, suggesting that IL-33 could target ASM directly and regulate 
through this pathway. For all Q-PCR results shown in figure 5.9 for expression of 
IL-33, ST2s and ST2L in HMC-l, HBEC and HASM, Ct values were normalised to 
the HPRT house keeping gene. All ST2 data was normalised to expression of ST2 in 
HMC-l, given the consistent expression in these samples. However, as HMC-l did 
not express IL-33, all data for IL-33 is compared to mean HBEC expression (figure 
5.9). 
These Q-PCR results shown in figure 5.9 suggested potential cell passage 
related decreases in expression of IL-33 and the ST2 receptors. To support these 
results, previous data from within our department was searched for IL-33 and the 
human ST2 receptor (lL-lRL-l) in an Affymetrix Genechip Human Gene 1.0 ST 
array data set designed for 28,869 well annotated genes with 764,885 distinct probes 
(Singh, Billington et al. 2010). Raw data was extracted from the scanned images to 
generate normalised probe-level intensity measurements for the Affymetrix gene 
chips termed robust multi-array average (RMA). Raw RMA values for the target 
genes were compared relative to the HPRT housekeeping gene to reflect expression 
levels in low and high passage HASM and lung fibroblasts (passage four) (figure 
5.10). In addition to IL-33 and ST2 receptor (IL-IRL-l), STIMl and Orail were 
included in the search, as was myosin light chain kinase (MLCK) which served for 
comparison as it is known to be expressed at high levels in ASM. 
243 
Chapter Five Results: Mechanisms ofIL-33 mediated airway hyper-responsiveness 
100 100% 
90 
80 
70 
60 
ISO 
40 
30 
20 
10 
20.02% 
a) 
0.38% 
O ~ ~ ~ ~ F L ~ ~ ~ - T ~ ~ ~ - - - r r
_ ~ ~ ~ q"J q"J q" ~ ~ qf) qf) qf) q" 
~ . . !'J ... 'P # ~ ~ "J# sP'" ~ . . . . ~ t § t t ~ ~ ~ ~ , . . , ,, , ~ ~ ,,<c ,,<c ~ ~q tI' ~ ~; q .... <fJ tI' <JS $ ~ C J J ~ 4 ' V V ~ ~ ~ v v ~ ~ ~ # # ' ~ . t p p # 
100 100% 
90 
80 
70 
60 
ISO 
40 
30 
20 
10 
b) 
FigUl'e 5.9 QUIl1JtitatWe expression of ST2s, ST2L and IL-33 in HMC-l, HBEC 
and HASM. All Q-PCR Ct values were normalised to the HPRT house keeping gene 
(n = two experiments for each target gene, three repeats within each experiment). 
ST2s (a) and ST2L (b) expression was compared relative to HMC-l (shown as 
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100%). ST2s and ST2L were clearly expressed in HMC-l and expressed at low 
levels in HBEC. There was very low expression of ST2s in one HASM donor. 
Expression of ST2L in HASM was undetectable. c) As IL-33 was expressed at very 
low levels in HMC-l, mean values for HBEC expression served as a standard (100% 
expression) to compare samples. IL-33 expression was detected in HBEC and in 
HASM, often at very high levels. It is noted that the low passage (HASM D0401 P2) 
sample showed expression of ST2s (Ct 37) and significantly high expression of IL-
33; suggesting donor/passage number variability. P = cell passage number. 
245 
~ ~ ~
:.:;Q.. 
~ : J : :
C) C) 
L.e) 
- cv cv th 
C th 
. ~ ~ cv 
thQ. 
~ ~ ~
:EO 0::-o 
-
11001 1050 1000 
650
1 525.45% r;wa 600 550 500 
100 100% 
20 
o 
Low passage HASM (P3) 
Chapter Five Results: Mechanisms of fL-33 mediated airway hyper-responsiveness 
1088.99% 
El 
631 .06% 
m m 
High I)assage HASM (P9) Lung fibroblast (P4) 
_ HPRT 
_ IL-33 
c::J 812 (IL-1 RL-1) 
B!I MLCK 
_ 8TIM1 
c::J Orai1 
Figure 5.10 Probe level intensity measurements generated from Affymetrix data chips searched for expression of HPRT, 1L-33 and the ST2 
receptor (IL-1RL-1), MLCK, STIM1 and Orail in low and high passage HASM and lungfibroblasts. Results are shown relative to the HPRT 
housekeeping gene in low passage HASM. Results of interest indicate very low expression of the ST2 receptor in low and high passage HASM 
and decreased expression of lL-33 in higher passage HASM. HPRT: Hypoxanthine phosphoribosyltransferase (housekeeper); MLCK: Myosin 
light chain kinase; 1L-1 RL-l: 1L-1 r eceptor like 1; ST1Ml: Stromal 
Interaction molecule 1. P = cell passage number. 
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5.4 DISCUSSION 
Given the results in the previous chapter suggesting that the IL-33/ST2 
interaction plays a role in the development of AHR in a mouse model of allergic 
airway disease; in this chapter Q-PCR experiments were designed to investigate 
alterations in expression level of IL-33 and the ST2 soluble (ST2s) and membrane 
(ST2L) forms of receptor in acute, mid-chronic and chronic OVA sensitised murine 
lung tissue. As previous studies have found IL-l3 mediated dysregulation of the Ca2+ 
sensitive pathway in ASM leads to AHR (Chiba, Nakazawa et al. 2009); additional 
Q-PCR experiments were designed to investigate alterations in mRNA expression of 
STIMl and Orail (key store operated calcium channel components involved in Ca2+ 
influx in ASM). Q-PCR results revealed increased mRNA expression of IL-33, the 
ST2 soluble and ST2 membrane receptor in acute, mid-chronic and chronic OVA 
sensitised BALB/c mouse lung tissue. There was no significant difference in Orail 
mRNA expression between control and OV A sensitised mice. However, after 
chronic sensitisation STIMl expression was significantly decreased; as experiments 
were not followed further, no explanation was reached for these results. 
Q-PCR experiments were also performed to look for expression ofIL-33 and 
the soluble and membrane forms of the ST2 receptor (also named IL-IRL-l in 
human) in human airway smooth muscle (HASM), human airway epithelial cells 
(HBEC) and a human mast cell line (HMC-l). Results indicate that IL-33 is 
expressed at very low levels in HMC-l and clearly expressed in HASM (passage two 
- seven) and HBEC (passage three - four). The ST2 soluble receptor (SUs) was 
highly expressed in HMC-l, expressed at very low levels in HBEC and was virtually 
undetectable in HASM. The ST2L membrane receptor was expressed at high levels 
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in HMC-1, detectable at low levels in HBEC, but absent in HASM. These targets 
were also searched for in our departmental data set for Affymetrix Gene chip 
analysis of - 30,000 genes for expression in low and high passage HASM and lung 
fibroblasts (Singh, Billington et al. 2010). Results confirmed the very low expression 
of the ST2 receptor in low and high passage HASM and decreased expression of IL-
33 in higher passage HASM. 
5.4.1 Altered IL-33 and ST2 mRNA expression in ovalbumin sensitised mouse 
lung tissue 
Quantitative PCR results showed significantly increased expression of IL-33, 
the ST2s and ST2L membrane bound receptor in the OV A sensitised lung tissue. 
These results are consistent with recent papers finding increased IL-33 expression in 
bronchial biopsies of asthmatic patients (Prefontaine, Nadigel et al. 2010; 
Prefontaine, Lajoie-Kadoch et al. 2009) and increased serum ST2 levels that 
correlate with asthma severity (Oshikawa, Kuroiwa et al. 2001). The IL-33/ST2 
receptor's role in development, maintenance of the allergic response and AHR is 
also supported in a study by Kearley and colleagues, 2009, using OVA sensitised 
BALB/c and C57BLl6 mice and ST2, IL-4 and IL-13 blocking Ab to confirm the 
role of TH2 cells, particularly IL-33 in maintaining AHR (Kearley, Buckland et al. 
2009). 
Quantitative peR to investigate altered mRNA expression of STIMl and 
Orai 1 in the samples revealed interesting results. My initial hypothesis was that 
increased expression of these proteins might result in increased Ca2+ pools for 
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maintenance of contraction to support AHR. However, the results obtained suggested 
no difference in Orai 1 expression between control and OV A sensitised mice from the 
acute, mid-chronic and chronic models. There was no difference in STIMl 
expression between control and sensitised mice after acute and mid-chronic 
sensitisation, however, STIMl mRNA expression was significantly decreased after 
chronic sensitisation. Whilst this might reflect the relatively small number of 
samples available for study, it is also possible that STIMI expression is reduced 
following long term sensitisation on a negative feedback homeostasis mechanism. 
This requires further study. 
In this thesis, the role of SOCC has been investigated within the context of 
ASM homeostasis and contraction pathways. However, there is evidence for STIMl 
and Orail playing a role in immunodeficiency, inflammation and infection (Feske 
2009) through T cell activation. SOCC activated prolonged Ca2+ entry through 
CRAC channels activates Ca2+ sensitive transcription factor NFAT, responsible for 
directing T cell proliferation and gene expression (Macian 2005; Di Sabatino, 
Rovedatti et al. 2009). Altered Ca2+ responses in T cells have been associated with 
such auto immune and inflammatory conditions as systemic lupus erythematosus 
(Tenbrock, Juang et al. 2007), rheumatoid arthritis (Feske 2007), inflammatory 
bowel disease (Di Sabatino, Rovedatti et al. 2009) and most notably severe 
combined immunodeficiency syndrome in patients lacking CRAC (Feske, Prakriya 
et al. 2005). Perhaps the inhibition of SOCC in the T cell inflammatory response 
may present another direction for therapeutic intervention in airway inflammation. 
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5.4.2 IL-33 sources and targets in human airway inflammation 
Having demonstrated the importance of the IL-33/ST2 axis in murine lung 
inflammation following av A sensitisation, I proceeded to investigate the axis in 
primary human airway cells relevant to human lung disease. Quantitative PCR 
experiments revealed that HBEC and HASM were a source of IL-33, however the 
ST2L membrane receptor was undetectable on HASM (five patient donors) and 
detected at very low levels on HBEC (three patient donors). Given that these studies 
were conducted in cultured cells from passage two - seven, the potential for receptor 
expression to disappear in culture was considered (ST2s expression was noted in the 
HASM passage two sample, but not seen in higher passage cells). Without access to 
fresh HASM, ST2L membrane receptor expression on ASM could not be studied 
further. No other studies have confmned expression of ST2L protein on ASM 
(summarised in table 5.2). These results were further supported by results generated 
from the Affymetrix gene array analysis data; the ST2 receptor was barely detectable 
in low and high passage HASM and lung fibroblasts. IL-33 was detectable in low 
passage HASM and expression was decreased in high passage HASM, IL-33 was 
also expressed at very low levels in lung fibroblasts. 
During these experiments it became increasingly apparent that such structural 
cells as airway smooth muscle and endothelial cells may serve as a source of IL-33 
and in turn target the ST2L receptor expressed on inflammatory cells leading to 
further production of cytokines known to act directly on the ASM. In human, IL-33 
is predominantly expressed by epithelial cells, endothelial cells (Moussion, Ortega et 
al. 2008) and fibroblasts (Sanada, Halruno et al. 2007) at the protein level. IL-33 
targets cells expressing the ST2 membrane receptor, notably T H2 cells rather than 
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TH1 (Xu, Chan et al. 1998). IL-33 is shown to induce such proinfiamrnatory 
cytokines and chemokines as IL-5, IL-13, IL-1, IL-6, TNF-a, CCL2 and eCL3 (Ali, 
Huber et al. 2007; Allakhverdi, Smith et al. 2007; Iikura, Suto et al. 2007; Moulin, 
Donze et al. 2007; Kurowska-Stolarska, Kewin et al. 2008). In addition IL-33 
induces degranulation of mast cells and enhances mast cell maturation and survival. 
Quantitative PCR studies in this chapter suggested an absence of the ST2L 
membrane receptor on ASM from cultured HASM; no previous literature suggesting 
ST2L expression in ASM cells was found. This suggests that the effects of IL-33 
may be indirect and secondary cytokines may be produced after cell stimulation with 
IL-33; for potential cytokine candidates shown to alter ASM Ca2+ homeostasis and 
induce AHR see table 5.3. In work using a neutralising Ab targeted against the 
human ST2 receptor which would be effective both against ST2 on the ASM cell 
surface or in soluble form in the culture media, IL-33 ELISA on the supernatants 
collected from cells suggested the ST2 receptor did not play a significant role in IL-
33 release on ASM cells (Prefontaine, Lajoie-Kadoch et al. 2009). These data could 
also support the notion that IL-33 may play an intracellular role in altering gene 
transcription, like other IL-1 type cytokines (Gadina and Jefferies 2007). 
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Table 5.3 Cytokines implicaJed in the induction of altered airway smooth muscle ctl+ homeostasis and induced airway hyper-responsiveness. 
IL-S 
TNF-a 
IL-lP 
IL-4 
In ASM IL-13 modulates the CD3S/cADPR-dependent pathway influencing C a ~ ' " " signalling. SERCA 
expression was decreased after cytokine exposure and rate of fall of [Ca2+]i transients was slowed. IL-
13 produced as aT lymphocyte product was shown to act directly on ASM to induce hyper-
responsiveness. IL-l3 was also shown to induce upregulation of the RhoA protein in human bronchial 
ASM and contributed to AHR throwm the RhoA Dathwav in mice. 
IL-S expression is increased in patients with cystic fibrosis and asthma, and is a CXC chemokine and 
chemo attractant for neutrophils by CXCRl and CXCR2 G protein coupled receptors. Constitutive 
expression of CXCRt and CXCR2 was shown in HASM, IL-S mediated Ca2+ release, contraction and 
ASM I'nntNIl'hnn 
TNF-a stimulates expression of intercellular adhesion molecule 1 (ICAMl) by activating NF-KB. TNF-
a induced expression of ICAMl on ASM cells involves a thapsigargin sensitive pathway. SERCA 
expression was decreased after cytokine exposure and rate of fall of [Ca2+]i transients was slowed. 
Results s u ~ e s t t that inflammation maintains [Ca2li levels by decreasing SERCA expression and 
InmlnA Ca + reuDtake (SERCA resrulation involves 
Reported to desensitise histamine HIR, involving activation ofp38 MAPK and NF-KB, inducing 
expression ofCOX-2 and PGE2 synthesis. PGE2 increased intracellular cAMP leading to PKA 
activation which phosphorylated and subsequently functionally uncoupled histamine HIR. Results 
from this study suggest that bronchial hyper-responsiveness to histamine is not associated with 
enhancement in HJR 
IL-4 produced as a T lymphocyte product was shown to act directly on mouse ASM to induce hyper-
(Venkayya, Lam et al. 2002; 
Deshpande, Dogan et al. 2004; 
Chiba, Nakazawa et al. 2009; 
Sathish, Thompson et al. 2009) 
(Govindaraju, Michoud et al. 
2006) 
(Amrani, Lazaar et al. 2000; 
Sathish, Thompson et al. 2009) 
(Pype, Xu et al. 2001) 
(Venkayya, Lam et al. 2002) 
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5.4.3 IL-33: mechanisms of action 
In the absence of pro inflammatory stimuli IL-33 localises to the nucleus 
(Baekkevold, Roussigne et al. 2003; Carriere, Roussel et al. 2007). Cellular necrosis 
leads to release of full-length functional IL-33 (Cayrol and Girard 2009; Luthi, 
Cullen et al. 2009). IL-33 binds a heterodimeric receptor complex involving ST2 and 
an IL-lR accessory protein (lL-lR AP) (Chackerian, Oldham et al. 2007). Signalling 
requires the TIR domain and recruitment of myeloid differentiation primary-
response protein 88 (MYD88) (Ali, Huber et a1. 2007). IL-lR associated kinase 
(IRAKl) and IRAK4 (Schmitz, Owyang et al. 2005) are recruited and induce 
activation of nuclear factor KB (NF-KB) and inhibitor of NF-KB-a (IkBa). Various 
studies have noted cell specific differences in the signalling pathways. The pathway 
activated by IL-33 in mast cells are shown in figure 5.11. 
In mast cells, IL-33 activates phospholipase D and sphingosine kinase and 
through Ca2+ mobilisation, targets NF -KB. This pathway is required for the 
production ofIL-IP, IL-3, IL-6, TNF-a, CXC chemokine ligand 2 (CXCL2), CCL2, 
CCL3, prostaglandin D2 and leukotriene B4 (Allakhverdi, Smith et al. 2007; Moulin, 
Donze et al. 2007; Pushparaj, Tay et a1. 2009). An alternative pathway involves 
mitogen activated protein kinase (MAPK) , through extracellular signal-related 
kinase 1 (ERKl), p38 and JUNN-terminal kinase-l (JNK-l) (pushparaj, Tay et al. 
2009), leading to production of IL-5, IL-13, CCL5, CCL17 and CCL24 (Kurowska-
Stolarska, Kewin et al. 2008). Studies involving IgE priming show increased cell 
surface expression of STIL and induction of mast cell degranulation (Pushparaj, Tay 
et al. 2009). Interestingly, the soluble isofonn ST2s receptor acts as a decoy receptor 
253 
Chapter Five Results: Mechanisms ofIL-33 mediated airway hyper-responsiveness 
to bind excess IL-33 and inhibit binding to the ST2L membrane receptor (Hayakawa, 
Hayakawa et al. 2007). 
~ ~ 11RAK1.11W41-.......,. 
I ~ P l - o o-SPH--K] I MAPKK 1,,-
Ca" 1 r-"[ E-RK,-p3-a,-JN-K--
[ lkB, pSO, p6s] 
I NF-"B] 
\ ------... Mast cell dqr.nul.tlon, 
Il·11I. TNF, Il·6, 
CCU, CCll, CXC12, 
PGO"LTB. 
\ 
Figure 5.11 IL-33 signalling in mast cells. lL-33 signals through an ST2L receptor 
and lL-1 receptor accessory protein (IL-1RAP) complex, recruiting MYD88. 
Through a pathway involving phospholipase D (PLD)I sphingosine kinase (SPHK) 
activated ecl+ mobilisation, nuclear factor K B (NF-KB) is activated leading to 
further mast cell degranulation, cytokine and chemokine production. An alternative 
pathway involving mitogen activated protein kinase (MAP K) also leads to 
production of lL-13, lL-5 and other chemokines. MYD88: Myeloid differentiation 
primary-response protein 88; lRAK1, lRAK4: lL-1R associated kinase; 1kBa: 
inhibitor of NF-KB-a; ERK1: extracellular signal-related kinase 1; JNK-1: JUNN-
terminal kinase-1; eeL, cc, eXCL, exc: chemokine ligand; TNF: tumour necrosis 
factor; PGD2: prostaglandin D2; LTB4: leukotrine B4, Adapted from (Dew, Pitman et 
al.). 
IL-33 targets a range of immune cells and may play a role in a wide variety 
of disease states such as arthritis (Xu, Jiang et al. 2008), cardiovascular disease 
(Weinberg, Shimpo et al. 2002), allergy and anaphylaxis (Pushparaj , Tay et al. 
2009), Alzheimer's disease (Chapuis, Hot et al. 2009) and respiratory syncytial virus 
infection (Walzl, Matthews et al. 2001). Given that IL-33 is released from structural 
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cells like the respiratory epithelium, it may serve as an initial defence against 
pathogens or may play a role in sensing damage by infection or inflammation. 
Studies in Chapter Four indicated that treatment of na'ive mouse lung slices 
with IL-33 (lOOng/ml, over night exposure) lead to AHR to MCh despite a non 
inflammatory environment present; through a pathway that required interaction with 
the ST2R. Experiments in this chapter were designed to determine whether IL-33 
acts directly on the ASM via targeting of the ST2R. Results indicate that HASM 
does not express the ST2R. Therefore, IL-33 may act on other non inflammatory cell 
types present that express the ST2R which inturn produce cytokines that target the 
ASM directly to alter airway responsiveness. Alternatively, IL-33 is shown to be 
expressed on ASM and may act internally by translocating to the nucleus and 
altering transcription of other cytokines that influence the contractile pathway. 
Future experiments to investigate key cytokine candidates involved in AHR 
include quantitative PCR experiments performed on OVA sensitised and cytokine 
treated mouse lung tissue to investigate alterations in mRNA expression of key 
signaling pathway members involved in the contractile pathway in ASM. Further 
investigation is required to identify the unknown cell types present expressing the 
ST2R which IL-33 may act on to produce further cytokine production for down 
stream AHR of ASM (refer to 6.2). 
In summary, this chapter aimed to explore some of the mechanisms involved 
in IL-33 mediated AHR. The results obtained showed increased mRNA expression 
ofIL-33, the ST2 soluble and membrane receptor in OVA sensitised BALB/c mouse 
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lung tissue; indicating a role for IL-33/ST2 receptor in tissue damage and airway 
inflammation. Investigation of IL-33, the ST2 soluble and membrane bound receptor 
expression in human airway smooth muscle (HASM), human bronchial epithelial 
cells (HBEC) and mast cells revealed that epithelial and ASM are a source of IL-33. 
However, ST2 receptor expression was virtually undetectable in these cell types, yet 
highly expressed in mast cells. Together these results support previous literature 
suggesting the possible role for IL-33 as a sensor of tissue damage and driver of the 
T H2 inflammatory response through inflammatory cell activation. While the role, 
release and downstream pathways activated by IL-33 in asthma and various 
inflammatory states require further studies; these data indicate the potential for 
therapeutic intervention by targeting ofIL-33 and the ST2 receptors. 
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6. CHAPTER SIX 
The aims of the work described in this thesis were: 
• To optimise the use of the precision cut lung slice model for the study of 
airway contraction and relaxation. 
• To examine key pathways involved in contractile signalling via Ca2+ influx. 
• To investigate altered contractile responses in a murine model of OVA-
induced allergic airway sensitisation using precision cut lung slices. 
• To define key mediators involved in sensitisation of airway smooth muscle in 
sensitised airways. 
• To develop the use of porcine precision cut lung slices as a bridging model to 
help develop human studies. 
6.1 Summary of results 
In this thesis my experiments were initially designed to establish the lung slice 
technique in mouse and in pig to provide a bridging model for future human studies. 
Selected pharmacological agents were used to target specific channels involved in 
the Ca2+ signalling pathway required for contraction induction and maintenance. The 
results obtained demonstrated the significance of extracellular Ca2+ for internal Ca2+ 
store refilling and release to repeatedly induce and maintain a contraction and 
showed interesting species differences in agonist and inhibitor sensitivity; with the 
porcine system sharing similar pharmacology to that reported in human airways. 
These results highlight the necessity for regulated Ca2+ handling in ASM for correct 
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tone maintenance. Although the results in this thesis suggest that under normal 
physiological conditions, short term, SOCC do not contribute to regulation of 
intracellular Ca2+ stores; an alternative approach in the future would be to explore 
the importance of SOCC long term for maintenance of intracellular Ca2+ stores. The 
species differences shown in ASM Ca2+ handling and pharmacological response 
suggest that conservative assumptions need to be made for human airway behaviour 
based on findings in animal models and demonstrate the need for human studies at 
the peripheral airway level. 
The lung slice technique was next applied to a sensitised mouse model of 
airway inflammation; experiments were designed to investigate the key 
inflammatory mediators involved in AHR and the T H2 inflammatory process. 
Results revealed that OVA sensitisation led to progressive structural remodelling and 
AHR to MCh. However, this hyper-responsiveness was decreased 48 hours post lung 
removal despite persistent airway remodelling. In WT nalve mice, IL-33 exposure 
significantly increased AHR to MCh. However, in lung slices prepared from ST2 
KO mice IL-33 was unable to sensitise the contractile response in vitro. These results 
illustrate a key role for IL-33 in the induction of hyper-responsiveness in this murine 
model and demonstrate the contribution of the inflammatory environment to 
persisting increased airway sensitivity, independent of structural remodelling. 
Experiments designed to further investigate the mechanisms involved in IL-33 
mediated AHR revealed increased mRNA expression of IL-33 and also the ST2 
soluble and membrane receptor in the OV A sensitised mouse lung tissue. 
Investigation in a cultured human airway system for IL-33, ST2 soluble and 
membrane bound receptor expression showed that epithelial and ASM cells are a 
source of IL-33. However, ST2 receptor expression was undetectable in these cell 
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types, yet highly expressed in mast cells. These results support the notion that IL-33 
may function as an initiator of the inflammatory response in tissue injury (discussed 
further in 6.2) and also highlight the need to explore the effects of endogenous IL-33 
administration on human lung slices and the potential therapeutic role of the soluble 
form of the ST2 receptor in preventing T H2 cytokine induction. 
6.2 IL-33 initiates the pathway for AHR 
Experiments in Chapter Four demonstrated that overnight treatment with IL-
33 (lOOng/ml) induced AHR in naive WT type mouse lung slices, yet this increased 
response was abolished in ST2R -r mice indicating that the ST2R is required for the 
signaling pathway leading to AHR. Results in Chapter Five indicated that human 
ASM does not express the ST2R suggesting that the pathway to AHR is not via 
direct activation of the ASM but may involve activation of inflammatory cells 
present or other helper cells that lead to production of cytokines that inturn act 
directly on the ASM to alter the signaling pathway leading to AHR (figure 6.1). 
Alternatively, these results may suggest that IL-33, which is shown to be expressed 
on ASM, may act locally to alter transcription, promoting production of other 
cytokines which influence the contractile response. 
Studies using the recently generated IL-33 -r mouse model indicate that IL-
33 plays a role in innate inflammation in the lung and gastrointestinal tract. 
However, is not necessary for further acquired immunity (Oboki, 2011). Further 
support of the key role of IL-33 in the initial induction of the innate response, was 
shown in a mouse model of influenza infection induced AHR that was independent 
ofTH2 cells and adaptive immunity, through a pathway that required IL-33 acting on 
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cells of non T, non B cell origin, namely natural helper cells (NHC) (Chang, Kim et 
al. 2011). Further more the study demonstrated that natural helper cells were present 
prior to infection. Natural helper cells express IL-7R (TSLPR), ST2R, IL-17RB (lL-
25R), express C-kit (mast cell growth factor), have high levels of MHC class 11, can 
function as antigen presenting cells and have the ability to differentiate into 
macrophage, mast cells, eosinophils and basophils (Chang, Kim et al. 2011; Cormier 
and Kolls 2011; Kim, DeKruyff et al. 2010; Moro, Yamada et al. 2009; Neill, Wong 
et al. 2010; Saenz, Siracusa et al. 2010). Studies suggest that IL-33 may act on NHC 
to produce such cytokines as IL-13 which plays a role in ASM hyper-reativity. Both 
IL-33 and IL-25 act on NHC to produce IL-13 during helminth infection (Price, 
Liang et al. 2010). ASM is shown to express the IL-13R complex (IL-13Ral and IL-
4Ra) (Moynihan, Tolloczko et al. 2008). IL-13 has also been shown to alter the 
calcium sensitivity pathway in ASM (Chiba, Nakazawa et al. 2009). Furthermore, in 
IL-13-r mice that were sensitised and challenged, despite airway inflammation and 
eosinophilia present, AHR does not develop (Walter, McIntire et al. 2001). 
Collectively these studies may implicate IL-33 as a critical initiator of the innate 
response, with the ability to act on non inflammatory natural helper cells to inturn 
produce key cytokines such as IL-13 which acts on the ASM to influence airway 
contractility (figure 6.1). 
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Figure 6.1 Possible IL-33 induced pathways in airway hyper-responsiveness. a) 
Allergen exposure (via OVA sensitisation) or tissue injury to such structural barriers 
as epithelial cells leads to release of JL-33. 1L-33 drives the TH2 inflammatory 
response by targeting the ST2L receptor on T H2 and mast cells to up regulate 
transcription of cytokines and chemokines that contribute to airway remodelling and 
airway hyper-responsiveness. However, in these studies b) AHR was also shown in 
naive mouse lung slices, independent of inflammatory cells or TH2 cells suggesting 
that 1L-33 (lOOng/ml, 24 hour treatment) must act on other cell types present in the 
local environment to induce AHR. As ASM does not express the ST2R, 1L-33 may act 
on a non inflammatory cell present such as a natural helper cell (NHC) or act 
directly on ASM to alter transcription of other cytokines such as 1L-13, 1L-1 RAP: IL-
l receptor accessory protein. 
6.3 IL-33: a danger signal? 
Recent theories surrounding the activation of the immune response by a 
'danger signal' (also termed 'alarrnin') are supported by the discovery of receptors 
for pathogen associated molecular patterns (PAMP), such as toll-like receptors 
(TLR), nucleotide-binding oligomerization domain (NOD)-like receptors and C-type 
lectin receptors and further supported by genetic mutations in these pathways being 
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related to chronic non infectious inflammatory diseases (Brydges and Kastner 2006; 
Fritz, Ferrero et al. 2006; Petrilli, Dostert et al. 2007). Germ line encoded pattern 
recognition receptors and recognition of highly conserved P AMP provides an 
intrinsic system to identify pathogen types and generate the required immune 
response (Akira, Uematsu et al. 2006). IL-33 has been suggested as an 'alarmin' 
(Moussion, Ortega et al. 2008) due to its ability to recruit and activate immune cells, 
nuclear expression profile and its secretion by necrotic cells; all similarities between 
IL-33 and such other 'alarmins' as high mobility group box I (HMGBI) and IL-Ia 
(Oppenheim and Yang 2005; Bianchi 2007) (discussed below). 
IL-33 expreSSlOn was initially observed in endothelial cells of high 
endothelial venules (HEV), specialised blood vessels for the recruitment of 
lymphocytes to lymphoid organs (Baekkevold, Roussigne et al. 2003; Carriere, 
Roussel et al. 2007). IL-33 is now the most recent addition to the IL-I family of 
cytokines; known to play a major role in inflammatory, infectious and auto immune 
disease (Dinarello 1996). Predominantly clustered on human chromosome two 
(Sims, Nicklin et al. 2001), family members include IL-Ia, IL-IP, IL-lRa (IL-I 
receptor antagonist) and IL-18. The expression of these cytokines is tightly regulated 
by alternatively spliced forms of ligands and receptors, soluble receptors (IL-I 
receptor type 2) and natural antagonist proteins (IL-Ra, IL-18 binding protein) 
(Dunne and O'Neill 2003). IL-l cytokines act through the toll-like receptor-IL-I 
receptor super family, characterised by the presence of an intracellular toll-IL-IR 
(TIR) module. IL-I ligands typically bind to a receptor complex consisting of two 
IL-I receptor family members (e.g the receptor complex for IL-Ia and IL-IP 
involves IL-IRI and IL-lRAP (receptor accessory protein, the same receptor 
required for the IL-33/ST2 membrane bound complex» (Dunne, Ejdeback et al. 
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2003). IL-l receptor signalling pathways typically involve activation of NF-KB and 
the mitogen activated protein kinases (MAP) p38, JNK and ERK, as described for 
IL-33 (Schrnitz, Owyang et al. 2005). 
IL-33 is suggested to play a role in response to tissue injury and infection 
based on its expression in the nucleus of endothelial and epithelial cells from tissues 
where pathogens and allergens may be encountered. Nuclear localisation occurs via 
an amino-terminal homeodomain-like DNA binding motif (Baekkevold, Roussigne 
et al. 2003) where IL-33 shows transcriptional regulator properties and associates 
with chromatin; initially demonstrated in the nucleus of HEV in vivo (Carriere, 
Roussel et al. 2007; Roussel, Erard et al. 2008). Studies suggest dual roles for IL-33 
as a cytokine and intracellular nuclear factor similar to the cytokines IL-l a and 
chromatin associated cytokine HMGB 1. IL-l a exerts proinflammatory cytokine 
activation through IL-1Rl and IL-1RAP (Dinarello 1996) and also translocates to the 
nucleus to regulate transcription (Werman, Werman-Venkert et al. 2004). HMGBl 
acts as a proinflarnrnatory cytokine secreted by macrophages during inflammation 
(Bonaldi, Talarno et al. 2003), after tissue injury and cell necrosis (Scaffidi, Misteli 
et al. 2002; Lotze and Tracey 2005) and also regulates transcription, chromatin 
structure and function in the nucleus (Agresti, Lupo et al. 2003). 
Although the role of IL-33 activation of the ST2 receptor on TH2 and mast 
cells is well documented, the nuclear function ofproIL-33 and how IL-33 is released 
from the nucleus for secretion remains unclear. IL-33 is produced as a 31KDa 
propeptide, similar to IL-l p and IL-I8 and is cleaved to generate the mature l8KDa 
form (Carriere, Roussel et al. 2007; Moulin, Donze et al. 2007). In vitro studies have 
reported cleavage of proIL-33 through mechanisms involving either the nucleotide 
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binding domain and leucine rich repeat containing gene family (NRL) P3 or NLRC4 
inflammasomes, possibly involving caspase-l (Schmitz, Owyang et al. 2005). 
However, the caspase-l cleavage site on proIL-33 is not conserved amongst species 
(Carriere, Roussel et al. 2007). It is also noted that a significant portion of secreted 
IL-33 is full length proIL-33 (Li, Willingham et al. 2008). Recently IL-33 was 
shown to be released from macrophages induced to undergo necrotic cell death 
(Luthi, Cullen et al. 2009). Similar to IL-Ia and HMGBI, IL-33 is released by 
necrotic cells but kept intracellular during apoptosis, reinforcing a possible role as an 
'alarmin'. 
The IL-33/ST2 axis is an attractive therapeutic target given the ability of IL-
33 alone to induce asthma like features independent of the adaptive immune system; 
as demonstrated in this thesis by the increased airway sensitivity shown to IL-33 
administration in vitro. Studies using recently generated IL-33 KO mouse models 
have confinned the role of IL-33 in the innate response for T cell independent 
allergen induced inflammation and OVA sensitisation (Oboki, Ohno et al. 2010; 
Oboki, Ohno et al. 2010) and demonstrated that IL-33 contributes to production of 
T H2 associated cytokines and is linked to eosinophil infiltration and histopathologic 
changes in the lung (Louten, Rankin et al. 2011). Previous studies have shown that 
administration of IL-33 results in AHR independent of CD4+ T cells (Kondo, 
Y oshimoto et al. 2008), shown in RAG-2 KO mice lacking both T and B cells, in 
which IL-33 administration also induced globlet cell hyperplasia and eosinophilic 
infiltration. Other studies have shown IL-33-driven activation, degranulation, 
enhanced adhesion and survival of eosinophils (Cherry, Yoon et al. 2008; Suzukawa, 
Iikura et al. 2008). IL-33 stimulates other innate immune cells such as basophils for 
migration (Cherry, Yoon et al. 2008) and production of IL-13, IL-4 and IL-5 in the 
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absence of allergen or IgE (Smithgall, Comeau et al. 2008; Pecaric-Petkovic, 
Didichenko et al. 2009). IL-33 promotes maturation, survival, adhesion and cytokine 
production in mast cells and mast cell progenitors (Ali, Kay et al. 2007; Allakhverdi, 
Smith et al. 2007; Ho, Ohno et al. 2007; Iikura, Suto et al. 2007; Xu, Jiang et al. 
2008). IL-33 administration in vivo has also been shown to promote IgE production 
without infection or allergen present (Schmitz, Owyang et al. 2005). 
Further more IL-33 plays a role in amplifying the inflammatory response to 
such infectious agents as parasites, bacteria and virus which can lead to exacerbation 
of atopic disorders (Schwarze, Hamelmann et al. 1997; Herz, Lacy et al. 2000; 
Holtzman, Morton et al. 2002; Lemanske 2004; Marone, Spadaro et al. 2006). IL-33 
is produced from epithelial cells in the respiratory tract or gastrointestinal tract that 
have been activated through pattern recognition receptors which recognise P AMP 
(previously described) associated with these invading pathogens. IL-33/ST2 
signalling plays a role in the local induction of the innate response which can further 
exacerbate airway inflammation; through increasing levels of eosinophils, 
lymphocytes, macrophages, IL-13, TOF-P, CCL3, CCL17 and CCL24 in the lung 
(Stolarski, Kurowska-Stolarska et al. 2011). These findings may provide explanation 
for the allergen independent inflammation seen in non-atopic asthmatics (Smith 
2010) and contribute to the diverse phenotypes exhibited in patients with asthma. 
This suggests an obvious opportunity for therapeutic intervention, although 
further studies are required to determine the safest way to interrupt the IL-33/ST2 
receptor down stream pathway with out impairing innate immune function; perhaps 
through targeting of the ST2 receptor. The soluble form of the ST2 receptor acts as a 
decoy receptor for IL-33 (Oshikawa, Kuroiwa et al. 2001; Hayakawa, Hayakawa et 
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al. 2007). Previously pretreatment with ST2s in a murine model of asthma resulted in 
decreased production of IL-4, IL-5, and IL-13 from IL-33 stimulated splenocytes 
(Hayakawa, Hayakawa et al. 2007). Disruption of IL-33/ST2L signalling has also 
been shown through use of both an anti-TlIST2 mAb and recombinant TlIST2 
fusion protein, preventing eosinophil infiltration and T H2 cytokine secretion 
(Lohning, Stroehmann et al. 1998). 
Incorporating the genetic susceptibility and environmental factors that serve 
as a predictor for disease risk, recent genome wide association studies aimed at 
identifying susceptibility signals for asthma have consistently identified both IL-33 
(location 9q24) and IL-IRL-l (the ST2 receptor in human, 2q12) as asthma 
candidate genes (Kabesch, 2010). The largest and most recent genome wide 
association study ( G WAS) of asthma included ~ ~10,000 case subjects and ~ ~16,000 
controls. Strong associations included single nucleotide polymorphisms (SNP) 
within IL-33 and IL-1RL-l (Moffatt, Gut et a1. 2011). A GWAS had previously 
identified a SNP at IL-l RL-l that showed significant association with asthma, 
prompted by a substudy scanning eosinophil count in blood from > 9000 Icelanders 
(Gudbjartsson, Bjornsdottir et al. 2009). Additionally, similar significance for 
association with asthma was observed in 10 different populations (7996 cases, 44890 
controls). SNPs within the genes encoding WDR36, MYB and IL-33 also suggested 
association with eosinophil counts and atopic asthma in these populations. A GW AS 
investigating SNPs associated with eosinophilia for contribution to susceptibility for 
nasal polyposis also identified IL-33 (Buysschaert, Grulois et al. 2010). 
Polymorphisms in IL-l RL-l have now been associated with asthma and atopy 
(Reijmerink 2008). Polymorphisms in the IL-IRL-l gene are also associated with 
chronic rhino sinusitis (Castano, Bosse et al. 2009) and polymorphisms in the IL-
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lRL-1 promoter region occurred more frequently in children with acute asthma, 
serum levels were also increased in children with acute asthma (Ali, Zhang et al. 
2009). Additionally supported by a study showing that polymorphisms in IL-IRL-l 
were associated with increased serum soluble IL-l RL-l, levels of blood eosinophils 
and asthma prevalence in children (Savenije, Kerkhof et a1. 2011). In patients with 
atopic dermatitis a significant genetic association was shown with SNPs in the distal 
promoter region of IL-l RL-1, regulating expression and influencing activation of the 
TH2 response (Shimizu, Matsuda et a1. 2005). Interestingly, a study attempting to 
identify new candidate genes for Alzeheimer's disease (AD) found decreased IL-33 
expression in brain from AD cases compared to controls; selected polymorphisms 
within IL-33 were associated with a decrease in AD risk possibly through 
modulation of cerebral amyloid angiopathy formation (Chapuis, Hot et al. 2009). 
These fmdings taken together with the role of IL-33 in inflammation and 
AHR demonstrated in this study support IL-33's potential as an 'alarmin' and 
inflammatory marker of asthma and raise the potential for therapeutic intervention 
by targeting of the ST2 receptor (IL-IRL-l). Future approaches involve determining 
the influence of these polymorphisms within IL-33 and the ST2 receptor for 
initiation, maintenance of the inflammatory response and implications for 
exacerbation of further disease. 
6.4 Animal models of bronchial asthma 
Progression of our understanding of asthma in human is reliant on animal 
models that reflect the manifested disease state. Diseases baring any resemblance to 
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asthma rarely occur naturally in other animals, the closest being allergic syndrome in 
cats (Padrid, Snook et al. 1995) and heaves in horses (Couetil, Hoffinan et al. 2007); 
forcing a need for sensitised animal models of airway inflammation. In humans 
asthma diagnosis is reliant on phenotype (given the poorly understood underlying 
pathology); yet clarifying such a phenotype in animal models is difficult. Revelation 
of the complex interplay between the innate immune system and adaptive response 
has also led to disagreement over whether the inflammatory environment or the 
altered ASM is more influential for severity of the disease; impacting on the design 
of sensitisation models. Due to knowledge of the genomic sequence, immunological 
tools available, low cost and short gestation period; mouse models are commonly 
used to gain understanding of the disease (Taube, Dakhama et al. 2004), with studies 
contributing to justification for pharmacotherapy. Many variations of the 
sensitisation protocol exist, including method of administration, length and timings 
of protocol and the foreign protein used for sensitisation. Ovalbumin (OV A) used in 
my studies for sensitisation of BALB/c mice, remains the most common antigenic 
protein to use (Bates, Rincon et a1. 2009). However, disagreement with the relevance 
of OV A to disease initiation in human has lead to use of such natural allergens as 
house dust mite extract (Fattouh, Pouladi et al. 2005). Another difficulty has been 
the formation of a chronic protocol in animal models to mimic the chronic disease 
with features of airway remodelling as in human. Extended exposure to aerosolised 
OV A is reported to result in tolerance in some mouse strains including BALB/c in 
which airway inflammation generally peaks at 24 - 72 hours after challenge and 
resolves within one - two weeks (Yiamouyiannis, Schramm et al. 1999; Kumar, 
Herbert et al. 2004; Lommatzsch, Julius et al. 2006; Bates, Cojocaru et al. 2008); 
while long term sensitisation by house dust mite shows greater success in retaining 
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chronic asthmatic features (Fattouh, Pouladi et a1. 2005). A novel approach emerging 
is the simultaneous exposure to multiple antigens, indicating success in the absence 
of an adjuvant and against tolerance in chronic protocols (persisting at least three 
weeks after allergen exposure) (Goplen, Karim et al. 2009). Believed to be due to the 
effect of multiple allergens on stimulation of p38 MAPK phosphorylation in 
dendritic cells and resulting maintained T cell activation. Development of such 
tolerance in mouse models provides a major hurdle for the understanding of 
maintained inflammation in asthma, particularly given the therapeutic implications 
for targeting this chronic disease in human. 
6.5 The Precision Cut Lung Slice technique 
In ASM Ca2+ plays a central role in contractility, secretion of inflammatory 
mediators, metabolism, cell differentiation and proliferation (Mahn, Ojo et al. ; 
Berridge 2008; Gerthoffer 2008; Lipskaia, Hulot et al. 2009); processes reported to 
be altered in patients with asthma. Previously the role of disregulated Ca2+ 
homeostasis in T cells associated with inflammatory and autoimmune diseases was 
discussed (section 5.4.1). This project was concerned with the influence of altered 
Ca2+ handling on contraction in ASM; assessed using the PCLS technique. 
Throughout this thesis the PCLS technique was used to measure peripheral airway 
contraction in mouse and pig, a sensitised mouse model of airway inflammation and 
KO mouse models and slices exposed to selected pharmacological agents and 
inflammatory mediators. Key advantages of the lung slice technique include many 
slices cut from each animal being used for multiple contractile experiments or frozen 
for RNA extraction and histology; preventing tissue wastage. 
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Difficulties with this technique include the delicate balance between lung 
inflation with air and agarose, given the risk for over inflation resulting in tearing or 
damage to airways. The influence of preparation and disruption to the nervous and 
circulatory system on airway behaviour in the lung slice has not been directly 
compared to the behaviour of the distal airways in intact lung via MRII quantitative 
CT assessment; comparisons are complicated by the variation in conditions, agonist 
and airway generation assessed in previous studies. In my experiments using slices 
from av A sensitised lung tissue, results indicated that removal from the 
inflammatory environment resulted in a decrease in allergen induced AHR after 24 -
48 hours post lung removal. This meant all sensitisation experiments had to be 
performed within 24 hours, with time constraints restricting repeats and length of 
protocol. Given the difficulties in acquiring tissue, it is not yet known whether 
removal from the inflammatory environment results in resolution of AHR in human 
PCLS from asthmatic patients. 
6.6 Future Studies 
The ability to study the functional properties of some ion channels and 
receptors and their influence on contraction in ASM has been limited due to a lack of 
pharmacological tools. RNA interference (RNAi) technology has become a rapidly 
expanding area of research to target set transcripts and silence genes (Elbashir, 
Martinez et al. 2001; Zhou, Tsai et al. 2003; Gurney and Hunter 2005). Short 
interference RNA (siRNA) provides a tool for characterisation of gene function, 
identification of signalling pathways and has applications for therapeutic 
intervention in virally infected cells and as drug targets. siRNA has previously been 
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applied to cells with success and recently attempted in isolated rat cerebral arteries 
(Corteling, Brett et al. 2007). An obvious area for future experiments would be to 
optimise conditions for the transfection of lung slices with siRNA targeting selected 
candidates playing a role in the Ca2+ signalling pathway (STIMI, Orai!) to study the 
effects of this gene silencing on airway contractile behaviour. Further aims include 
loading of slices with a Ca2+ sensitive dye (Fluo-4) to image capture and measure 
ASM Ca2+ oscillation frequency with exposure to various agents, extracellular Ca2+ 
conditions and inflammatory mediators. The studies could be extended to include 
investigation of the mechanisms regulating cilia beat frequency and its modulation 
(requiring image capture at higher magnification (630x), >200 time points/second 
(Bergner and Sanderson 2002»; potentially providing a model to assess the influence 
of allergen or epithelial damage on cilia beat frequency. Finally, the ultimate goal of 
this project is to apply the lung slice technique to human lung tissue, with 
contraction experiments designed for basic pharmacological characterisation and 
measurement of contraction after allergen exposure (IL-33); to better understand the 
link between the airway inflammatory response and altered Ca2+ homeostasis leading 
to AHR in human. 
In conclusion, the studies described in this thesis demonstrate the multiple 
applications of a novel lung slice technique used to study key signalling pathways 
leading to ASM contraction and to investigate the key mediators involved in the T H2 
inflammatory response resulting in airway inflammation and AHR. This work 
suggests a critical role for IL-33 as a mediator of airway inflammation and AHR. 
Future studies are required to gain an understanding of the nuclear function and 
272 
Chapter Six: Discussion 
release for secretion of IL-33. Discovering the identity of the key downstream 
cytokines targeted by IL-33/ST2 activation and resulting impact on altered ASM 
Ca2+ homeostasis leading to AHR has significant therapeutic implications for the 
treatment of airway hyper-sensitivity and interruption to the inflammatory response. 
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